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Atherosclerosis	 is	 a	 progressive	 inflammatory	 disease,	 characterized	 by	
accumulation	of	 fatty	deposits	and	degenerative	material	 in	the	wall	of	arteries	
forming	 a	 growing	 atheromatous	 plaque	 that	 upon	 rupture	 may	 cause	
thrombosis.	 An	 essential	 step	 in	 atherosclerosis	 progression	 is	 monocyte	
recruitment	to	the	inflamed	vessel	wall	and	subsequent	uptake	of	fats	that	upon	
apoptosis	contribute	to	further	inflammation.	Increased	levels	of	PEV	have	been	
reported	 to	 circulate	 in	 atherosclerosis	 patients,	 suggesting	 that	 they	 possibly	
contribute	to	disease	development.		
We	 demonstrated	 that	 PEV	 are	 released	 from	 platelets	 upon	 activation	
through	various	routes.	PEV	contain	adhesion	receptors	such	as	GPIb	and	GPIIb	
and	may	 also	 contain	 a	mitochondrion.	 In	vitro	 platelet	 activation	 in	 the	blood	
results	 in	 PEV	 release	 that	 preferentially	 form	 aggregates	 with	 monocytes.	
Monocytes	 can	 internalize	 PEV	 through	 various	 endocytic	 mechanisms.	 PEV	
aggregation	with	monocytes	was	 functional	 as	monocytes	 that	 had	 aggregated	
with	 PEV	 exhibited	 increased	 recruitment	 to	 the	 carotid	 endothelium	 in	 mice	
with	established	atherosclerosis	 in	vivo.	We	also	generated	and	characterized	a	
new	 mouse	 model,	 which	 is	 athero-prone	 and	 inducible	 of	 platelet	 clearance.	
This	mouse	will	help	elucidate	 the	acute	and	chronic	effects	of	 injected	PEV	 in	
atherosclerosis,	independently	of	platelets.	
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Healthy	 artery	 walls	 consist	 of	 three	 layers.	 The	 innermost	 layer,	 the	 tunica	
intima,	 is	 lined	 by	 a	monolayer	 of	 endothelial	 cells	 that	 is	 in	 direct	 contact	 with	 the	
blood	and	a	sheet	of	elastic	fibres,	the	internal	elastic	lamina	underneath	that	contains	
extracellular	 connective	 tissue	matrix.	 The	middle	 layer,	 the	 tunica	media,	 consists	 of	
smooth	muscle	cells	(SMCs)	in	a	complex	extracellular	matrix.	The	outermost	layer,	the	
adventitia,	contains	connective	tissue,	mast	cells,	nerve	ending	and	microvessels.	
Atherosclerosis	 is	 initiated	 by	 lipoprotein	 accumulation	 and	 aggregation	 with	
matrix	and	collagen	fibrils	 in	the	subendothelial	matrix	of	the	intima.	The	next	step	in	
atherosclerosis	progression	involves	monocyte	recruitment	at	the	inflammatory	site.		
Leukocyte	recruitment	 is	a	physiological	response	 in	 the	event	of	 infection	and	
inflammation.	 Leukocytes	 are	 recruited	 at	 the	 site	 of	 inflammation	 by	 traversing	 the	
endothelium	 (Fig.1.1).	 In	 atherosclerosis,	 the	 endothelial	 cells	 get	 activated	 and	
upregulate	 expression	 of	 L-,	 P-	 and	 E-selectins	 and	 intercellular	 adhesion	 molecules	
(ICAMs),	 such	as	 ICAM-1	 (Borregaard,	2010;	Galkina	and	Ley,	2007;	 Johnson-Tidey	et	
al.,	 1994).	 These	 adhesion	 molecules	 are	 recognised	 by	 the	 P-selectin	 glycoprotein	
ligand-1	(PSGL-1)	and	L-selectin	on	the	surface	of	leukocytes	that	mediate	capture	from	
flow.	 Sequential	 formation	 and	 dissolution	 of	 these	 bonds	 under	 the	 shear	 forces	
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generated	by	blood	flow	results	 in	rolling	adhesion	along	the	 luminal	endothelial	cells	
(Kansas	 1996;	 McEver	 and	 Cummings,	 1997).	 	 This	 initial	 interaction	 results	 in	 the	
activation	 of	 the	 β2	 integrins	 lymphocyte	 function-associated	 antigen	 1	 (LFA-1)	 and	
Macrophage-1	 antigen	 (Mac-1)	 on	 the	 leukocyte	 which	 then	 bind	 to	 the	 ICAM-1	
immunoglobulin	 receptors	 of	 the	 endothelium;	 leading	 to	 arrest	 of	 rolling	 and	 “firm	
adhesion”	(Woollard	and	Geissmann,	2010;	Yago	et	al.,	2010;	Mueller	et	al.,	2010;	Ley	et	
al.,	2007;	Campbell	et	al.,	1998).	After	firmly	adhering,	the	leukocyte	then	crawls	on	the	
endothelial	 surface	 until	 it	 finds	 an	 endothelial	 cell	 junction,	 which	 it	 uses	 to	
transmigrate	 in	 a	 process	 depending	 on	 β2	 integrins	 and	 ICAM	molecules	 (Ley	 et	 al.,	
2007;	 Phillipson	 et	 al.,	 2006).	 Having	 crossed	 the	 endothelial	 barrier,	 the	 leukocyte	
continues	its	journey	towards	invading	pathogens	by	following	chemotactic	gradients.		
Following	 recruitment	 in	 the	 artery	 wall,	 monocytes	 mature	 into	 macrophage	





cells	 further	 increasing	 the	 size	 of	 the	 lesion,	 which	 initially	 expands	 towards	 the	
adventitia	but	 as	 the	 lesion	advances	 it	 starts	 to	 expand	 into	 the	 lumen	of	 the	vessel,	
occluding	blood	flow	(Fig.	1.3).	Advanced	lesions	also	contain	cholesterol	crystals	and	
microvessels.	 Monocytes	 keep	 getting	 recruited	 in	 the	 vessel	 wall	 at	 all	 stages	 in	
atheroma	 formation	 in	order	 to	clear	 the	degenerative	material	but	 instead	 they	keep	







Leukocytes	 from	 blood	 are	 recruited	 at	 the	 sites	 of	 inflammation	 by	 traversing	 the	
endothelium	in	a	process	that	involves	tethering	to	the	endothelium,	followed	by	rolling	
along	 the	 surface,	 leukocyte	 firm	 adhesion	 and	 activation,	 mediated	 by	 different	
selectins	 and	 integrins	 such	 as	 p-selectin,	 PSGL-1,	 ICAM-1,	 Mac-1	 and	 LFA-1.	 Upon	







wall,	 the	 tunica	 intima,	 causing	 inflammation.	 The	 monocyte	 is	 recruited	 at	 the	













provide	 extra	 support	 to	 the	 vessel	 wall.	 With	 time,	 foam	 cells	 die	 bursting	 their	
contents	out,	 contributing	 to	 inflammation.	SMC	can	die	as	well,	 further	 inflaming	 the	
artery	 wall.	 Advancing	 lesions	 also	 contain	 crystalised	 cholesterol.	 The	 size	 of	 the	
plaque	increases	and	starts	to	extend	into	the	lumen	of	the	artery,	limiting	blood	flow.	
Once	blood	endothelial	cells	encounter	oscillatory	or	 low	shear	stress,	 they	up-
regulate	 expression	of	 cellular	 adhesion	molecules	on	 their	 surface	 such	as	monocyte	






arteries	where	 there	 is	sustained	 laminar	blood	 flow	and	high	shear	stress,	 the	above	
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Low	 endothelial	 shear	 stress	 results	 in	 the	 development	 and	 progression	 of	
atherosclerosis	 through	a	 variety	of	mechanisms;	 a)	by	 attenuating	nitric-oxide	 (NO)-
dependent	atheroprotection,	b)	by	promoting	LDL	uptake,	synthesis	and	permeability,	
c)	 by	 promoting	 oxidative	 stress,	 d)	 by	 promoting	 inflammation,	 e)	 by	 promoting	







major	 anti-atherosclerotic	 properties.	 It	 down-regulates	 expression	 of	 both	 the	
monocyte	chemoattractant	peptide-1	(MCP1)	and	the	vascular	cell	adhesion	molecule-1	
(VCAM1),	 inhibits	 lipid	 oxidation,	 inhibits	 vascular	 smooth	 muscle	 proliferation,	
prevents	 platelet	 aggregation	 and	 inhibits	 expression	 and	 action	 of	 matrix	
metalloproteinases	(MMPs)	(Cai	and	Harrison,	2000;	Wang	et	al.,	2005;	Chen	and	Wang,	
2004;	Upchurch	et	al.,	2001;	Akool	et	al.,	2003).	
Physiologic	 shear	 stress	 continuously	 stimulates	 NO	 production	 by	 the	 blood	
endothelial	cells	(Lam	et	al.,	2006;	Go	et	al.,	2001).	However,	in	conditions	of	disturbed	




Low	 shear	 stress	 results	 in	 sustained	 activation	 of	 sterol	 regulatory	 element-
binding	proteins	(SREBPs)	in	endothelial	cells	in	a	beta	(1)-integrin-dependent	manner.	












proteoglycans	 and	 undergo	 oxidative	modification	 (Ross,	 1999;	 Hansson,	 2005).	 Low	
shear	stress	results	in	reactive	oxygen	species	(ROS)	production	in	the	artery	wall	that	
then	 oxidise	 LDL,	 by	 endothelial	 upregulation	 of	 gene	 expression	 of	 major	 oxidative	
enzymes	such	as	NADPH	oxidase	(Harrison	et	al.,	2006;	Hwang	et	al.,	2003;	McNally	et	
al.,	 2003).	 In	 addition,	 animal	 studies	 have	 shown	 that	 the	 extracellular	 group	 IIa	







genes	 downstream	 of	 it.	 These	 genes	 encode	 adhesion	 proteins	 e.g.	 vascular	 cell	
adhesion	molecule	(VCAM-1),	intercellular	adhesion	molecule	(ICAM)-1	and	E-selectin;	
chemotactic	 proteins	 e.g.	 monocyte	 chemoattractant	 protein	 (MCP)-1,	 pro-
inflammatory	 cytokines	 e.g.	 tumor	 necrosis	 factor	 (TNF)-α,	 interleukin	 (IL)-1	 and	
interferon	(IFN)-γ	and	growth	factors	such	as	the	macrophage	colony-stimulating	factor	
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(M-CSF)	 that	 stimulates	 macrophage	 proliferation,	 differentiation	 and	 scavenger	
receptor	expression	(Watson	et	al.,	1997).		
Oxidised	LDL	also	modulates	inflammation	by	inhibiting	endothelial	synthesis	of	
nitric	 oxide	 (Wang	 et	 al.,	 2011).	Oxidized	LDL	 is	 rapidly	 taken	up	by	macrophages	 to	
form	 foam	 cells.	 LDL	 modified	 by	 myeloperoxidase	 binds	 to	 macrophage	 scavenger	
receptors	such	as	CD36	and	SR-A	(Podrez	et	al.,	2000;	Suzuki	et	al.,	1997;	Febbraio	et	al.,	
2000).	Absence	of	 these	 receptors	 results	 in	a	 reduction	 in	 the	 size	of	 atherosclerotic	
plaques.	Activity	of	these	receptors	is	controlled	by	the	transcription	factor	PPARγ	and	
by	various	cytokines	such	as	TNFα	and	IFNγ	(Tontonoz	et	al.,	1998).	Sphingomyelinase	
on	 the	 other	hand	hydrolyzes	 the	 sphingomyelin	 of	 LDL	 and	promotes	 LDL	 retention	
and	aggregation,	this	way	enhancing	macrophage	uptake	(Marathe	et	al.,	1999).		
Vascular	smooth	muscle	cell	(VSMC)	migration,	differentiation	and	proliferation	




1999).	 Once	 in	 the	 intima	 layer,	 VSMC	 start	 producing	 extracellular	 matrix	 (ECM)	
components,	 such	 as	 collagen	 (Ross,	 1999).	 By	 time,	 VSMC	 and	 fibroblasts	 produce	 a	
fibrous	cap	over	the	thrombogenic	lipid	core	to	keep	it	away	from	flowing	platelets.	The	











The	 fibrous	 cap	 is	maintained	 by	 continuous	matrix	 synthesis	 and	 breakdown	
that	are	regulated	by	inflammatory	cells.	T	lymphocytes	secrete	gamma	interferon	that	
inhibits	 matrix	 production	 by	 SMC	 (Armento	 et	 al.,	 1991).	 In	 addition,	 macrophages	





of	 cytokines,	 matrix	 metalloproteinases	 and	 adhesion	 molecules.	 Disruption	 of	 CD40	





with	 increased	 expression	 of	 TF	 that	 triggers	 coagulation	 by	 the	 endothelium	 and	
macrophages.	Synthesis	of	TF	is	promoted	by	the	CD40/CD40L	signalling	pathway	and	
the	 oxidization	 of	 LDL	 (Schonbeck	 et	 al.,	 2000).	 Furthermore,	 disturbed	 flow	 and	
underlying	 low	 shear	 stress	 downregulate	 the	 expression	 of	 anti-thrombotic	 agents	
such	as	eNOS	and	prostacyclin	(Ziegler	et	al.,	1998;	Qiu	and	Tarbell,	2000).	
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Severe	 atherosclerosis	 may	 lead	 to	 thrombosis	 and	 associated	 complications	
upon	plaque	rupture.	Whether	a	lesion	will	lead	to	the	formation	of	thrombus	depends	









1975).	They	originate	 from	fragmentation	of	 the	megakaryocytes	of	 the	bone	marrow	
and	 as	 a	 result	 they	 are	 anucleate	 (Machlus	 et	 al.,	 2014).	 They	 exist	 only	 in	 the	
mammalian	 blood	 and	 their	 life	 span	 in	 the	 human	 is	 up	 to	 10	 days	 (Leeksma	 and	
Cohen,	 1955).	 Platelet	 activation,	 coagulation	 and	 resulting	 thrombus	 formation	 are	
essential	 to	 prevent	 haemorrhage	 upon	 tissue	 injury,	 however;	 in	 pathological	




Any	 damage	 to	 the	 vascular	 endothelium	 that	 exposes	 the	 subendothelial	
extracellular	matrix	(ECM)	triggers	platelet	recruitment	at	 the	 injured	site.	Circulating	
platelets	 initially	 decelerate	 over	 the	 compromised	 site	 due	 to	 transient	 interactions	
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with	the	extracellular	matrix.	These	initial	interactions	trigger	platelet	activation,	which	
results	 in	 the	 expression	 of	 specialized	 integrins	 that	 then	 enable	 firm	 adhesion	 of	
platelets	 to	 the	 ECM.	 Activated	 platelets	 release	 agonists	 that	 activate	more	 platelets	




stress,	 platelets	 bind	 directly	 to	 exposed	 collagen,	 fibronectin	 and	 laminin.	 However	




al.,	 1986).	This	binding	has	a	 fast	dissociation	 rate;	hence	 it	 is	 incapable	of	mediating	
stable	adhesion	and	indeed	functions	in	the	same	manner	as	selectins	during	leukocyte	
recruitment,	 supporting	 platelet	 rolling.	 However,	 this	 interaction	 keeps	 platelets	 in	
close	proximity	with	the	vessel	surface,	with	rolling	along	the	VWF	in	the	direction	of	
blood	 flow.	 The	 resulting	 deceleration	 or	 “rolling”	 enables	 another	 platelet	 receptor,	
called	 glycoprotein-VI	 (GPVI),	 to	 interact	with	 exposed	 collagen.	GP	VI	 binds	 collagen	
with	low	affinity;	therefore	it	is	incapable	of	mediating	stable	adhesion	either.	However,	
it	 induces	 intracellular	 signaling	 that	 activates	 platelets	 and	 transforms	 platelet	
integrins	to	a	high-affinity	state.	Platelet	activation,	results	in	the	activation	of	integrin	





Platelets	 initially	bind	 to	 the	exposed	ECM	(collagen)	 indirectly,	 through	binding	with	
their	GPIb	to	VWF	adhered	to	collagen.	Next,	platelet	GPVI	binding	to	collagen	initiates	
platelet	 activation	 that	 causes	 platelet	 integrin	 shift	 to	 a	 high-affinity	 state.	 Platelet	
activation	also	 leads	 to	extracellular	release	of	soluble	agonists	such	as	ADP,	ATP	and	
TxA2	that	activate	additional	platelets.	Exposed	tissue	factor	stimulates	the	formation	of	
thrombin,	 which	 contributes	 to	 platelet	 activation.	 Finally,	 platelets	 adhere	 firmly	 to	
collagen	directly	 through	activated	α2β1	and	 indirectly	 through	αΙΙbβ3	binding	 to	VWF	
and	ensure	sustained	GPVI	signaling	and	initiation	of	thrombus	growth.	










factors	 bind	 and	 through	 which	 interaction	 their	 enzymatic	 activity	 is	 potentiated	
(Heemskerk	et	al.,	2005).	
Upon	coverage	of	the	total	injured	vessel	wall	area	with	a	monolayer	of	platelets,	
the	 next	 step	 in	 thrombus	 formation	 is	 the	 recruitment	 of	 additional	 platelets	which	
subsequently	 aggregate.	 The	 different	 soluble	 agonists	 that	 are	 produced	 or	 secreted	
from	activated	platelets	attached	to	collagen	(or	 to	VWF	attached	to	collagen)	such	as	





Platelet	 activation	 and	 aggregation	 (primary	 haemostasis)	 leading	 to	 clot	
formation	 is	 linked	 to	 activation	 of	 the	 coagulation	 cascade	 (secondary	 haemostasis)	









to	 suggest	 that	 platelets	 are	 also	 involved	 in	 the	 initial	 steps	 of	 atherosclerosis	 a)	 by	
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acting	 as	 an	 adhesive	 substrate	 that	 leads	 to	 the	 recruitment	 of	 monocytes	 to	 the	
surface	 of	 the	 vessel	 wall,	 and	 b)	 by	 releasing	 chemokines	 that	 stimulate	 monocyte	
activation	and	support	transendothelial	migration.	Some	examples	are	given	below.	




muscle	 cells	 (SMCs)	 were	 cocultured	 with	 endothelial	 cells,	 simulating	 inflammatory	
conditions,	 flowing	 platelets	 were	 able	 to	 bind	 to	 the	 activated	 endothelium	 and	 get	
activated	 themselves	 (platelets	 do	 not	 ordinarily	 bind	 to	 endothelium).	 P-selectin	
expression	 on	 the	 activated	 platelet	 was	 able	 to	 preferentially	 capture	 flowing	
monocytes,	 this	way	 recruiting	 them	 to	 the	 endothelium	 as	well.	 In	 addition,	 platelet	
factor	4	(CXCL4)	release	from	the	activated	platelet	supported	monocyte	activation	on	
the	 endothelial	 surface,	 followed	 by	 transendothelial	 migration	 (Kuckleburg	 et	 al.,	
2011).	
In	 the	 blood	 of	 healthy	 individuals,	 platelets	 naturally	 form	 aggregates	 with	
leukocytes	at	 low	levels	(Yip	et	al.,	2013).	However	in	different	inflammatory	diseases	
such	as	diabetes,	rheumatoid	arthritis,	inflammatory	bowel	disease,	atherosclerosis	and	
athero-thrombotic	 disease,	 the	 incidence	 of	 these	 aggregates	 is	 higher	 and	 correlates	
with	the	severity	of	disease	(Harding	et	al.,	2004;	Joseph	et	al.,	2001;	Tekelioglu	et	al.,	
2013;	Wrigley	et	al.,	2013;	Furman	et	al.,	1998).	 Indeed,	circulating	activated	platelets	
were	 found	 to	 preferentially	 bind	 monocytes	 in	 whole	 blood,	 forming	 heterotypic	
aggregates	 that	 exacerbate	 atherosclerosis	 in	 apolipoprotein-E-deficient	 mice.	 These	
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activated	 platelets	 secreted	 the	 chemokines	 CCL5	 (RANTES)	 and	 CXCL4	 that	 activate	
monocytes	and	endothelial	cells,	leading	to	monocyte	recruitment	(Huo	et	al.,	2003).			
1.1.2 The	role	of	Extracellular	Vesicles	
Extracellular	 vesicles	 are	 membranous	 vesicles	 released	 from	 activated	 cells.	
They	are	present	in	various	biological	fluids	such	as	blood	(Nieuwland	and	Sturk,	2007;	





EV	 have	 been	 reported	 in	 patients	 with	 cardiovascular	 risk	 factors	 and	 after	
cardiovascular	events	(Rautou	et	al.,	2011).	
EV	 are	 a	 heterogeneous	 population	 in	 terms	 of	 size,	 density,	 morphology,	 cell	
origin,	 organelle	 origin	 and	 composition.	 Taking	 these	 differential	 characteristics	 into	
account,	van	der	Pol	et	al.,	(2012)	divided	EV	into	three	main	types:	(a)	exosomes,	(b)	





Transmission	 electron	 micrographs	 of	 human	 plasma	 (A)	 exosomes,	 urine	 (B)	





et	 al.,	 1998;	 Heijnen	 et	 al.,	 1999;	 Raposo	 et	 al.,	 1996;	 Trams	 et	 al.,	 1981),	 a	 density	




with	 long	 and	 saturated	 fatty	 acyl-chains	 (Subra	 et	 al.,	 2007;	 Trajkovic	 et	 al.,	 2008;	
Wubbolts	 et	 al.,	 2003).	 Regarding	 their	 protein	 content,	 exosomes	 are	 enriched	 in	
proteins	 that	 have	 a	 role	 in	 membrane	 transport	 and	 fusion	 such	 as	 Rab,	 GTPases,	
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Annexins	 and	 flotillin,	 vesicular	 trafficking	 mediators	 such	 as	 Alix	 and	 tumour	
susceptibility	gene	101	(TSG101),	stress	proteins	(hsp70	and	hsp90),	integrins	(e.g.	α4)	
and	tetraspanins	such	as	CD9	and	CD63	(Simons	and	Raposo,	2009;	Thery	et	al.,	2009;	
Beyer	 and	 Pisetsky,	 2010;	Mathivanan	 et	 al.,	 2010;	 Bombrie	 et	 al.,	 2011;	 Chaput	 and	
Thery,	2011;	Record	et	al.,	2011;	Wubbolts	et	al.,	2003).	
	 Apoptotic	bodies	 Microvesicles	 Exosomes	
Size	 0.5-2	μm	 100-1000	nm	 20-100	nm	






















































membrane	 remodeling.	 When	 cells	 are	 at	 rest,	 lipids	 are	 unevenly	 distributed,	 with	
phosphatidylcholine	 and	 sphingomyelin	 concentrated	 on	 the	 outer	 leaflet	 of	 the	
membrane	and	PS	and	phosphatidylethanolamine	located	on	the	inner	leaflet	(Manno	et	
al.,	 2002;	 Seigneuret	 et	 al.,	 1984).	 This	 lipid	 order	 is	 maintained	 by	 the	 action	 of	
phospholipid	 transporters;	 flippases	 that	 transport	 lipids	 from	the	outer	 leaflet	 to	 the	
inner,	 and	 floppases	 that	 move	 PS	 from	 the	 interior	 to	 the	 exterior	 leaflet	 (Daleke,	
2003).	 When	 cells	 are	 activated,	 this	 lipid	 asymmetry	 is	 disrupted	 because	 PS	 is	
transferred	to	the	external	leaflet	due	to	increased	floppase	action	(Bevers	et	al.,	1999;	
van	 Helvoort,	 1996).	 In	 addition	 a	 bidirectional	 non-specific	 lipid	 transporter	 gets	
activated	 by	 an	 influx	 of	 Ca2+	 during	 cell	 activation	 and	 starts	 transporting	 all	
phospholipids	 down	 their	 concentration	 gradient,	 leading	 to	 random	 distribution		
(Bevers	 and	 Williamson,	 2010).	 	 Furthermore,	 the	 increase	 in	 calcium	 ions	 inhibits	







resting	 cell,	 by	 low	 cytoplasmic	 calcium	 concentration	 and	 active	 flippase	 enzymatic	
activity	(B)	Loss	of	the	asymmetric	distribution	of	phospholipids	in	the	cell	membrane	
due	to	cell	activation	and	associated	rise	in	cytoplasmic	calcium	level	that	activates	the	






membranes	 accummulate,	 they	 form	 multivesicular	 bodies	 that	 travel	 to	 the	 plasma	
membrane	where	 they	 fuse	with	and	 secrete	 the	exosomes	 to	 the	extracellular	 space.		
The	 transport,	 fusion	 and	 secretion	 of	 exosomes	 is	 facilitated	 by	 ESCRT	 and	 Rab	
proteins.	 MV	 on	 the	 other	 hand,	 are	 formed	 by	 structural	 rearrangement	 of	 the	
cytoskeleton,	 due	 to	 cleavage	 of	 actin	 filaments	 by	 enzymes	 activated	 by	 the	 rise	 in	

























































Various	 cells	 release	 EV	 that	 carry	 inflammatory	mediators	 such	 as	 IL-1β	 that	
cause	inflammation	directly.	They	may	also	carry	lipid	mediators	such	as	phospholipids	
and	 arachidonic	 acid	 that	 can	 activate	 cells	 and	 induce	 them	 to	 produce	 and	 release	
different	chemokines	and	cytokines	such	as	IL-6/8	and	MCPs	(Wang	et	al.,	2011;	Qu	et	
al.,	2007;	Pizzirani	et	al.,	2007;	Thomas	and	Salter,	2010;	Esser	et	al.,	2010;	Berckmans	


















EV	 shed	 from	 atherosclerotic	 plaques	 are	 highly	 pro-coagulant	 (Mallat	 et	 al.,	
1999).	EV-mediated	coagulation	is	usually	through	the	exposure	of	PS	or	TF	on	the	EV	
membrane	(Nomura	and	Shimizu,	2015,	Tesselaar	et	al.,	2007).	On	the	other	hand,	MV	
from	 EC	 and	 leukocytes	 can	 serve	 as	 a	 circulating	 source	 for	 fibrinolysis	 by	 the	





























Depending	 on	 the	 platelet	 activation	 pathway	 involved,	 PEV	 carry	 numerous	
proteins	(>500),	known	to	be	 involved	 in	various	cellular	responses,	 to	have	different	
molecular	functions	and	to	be	located	at	distinct	sites	within	the	platelet	(Garcia	et	al.,	
2005;	 Milioli	 et	 al.,	 2015).	 For	 example,	 activation	 of	 platelets	 by	 calcium	 ionophore	
A23187,	 leads	 to	 PEV	 formation	 that	 bear	many	proteins	 characteristic	 of	 α	 granules	
(such	as	thrombospondin,	platelet	factor	4	and	β-thromboglobulin)	(Horstman	and	Ahn,	
1999;	 Holme	 et	 al.,	 1998),	 whereas	 activation	 by	 thrombin	 results	 in	 PEV	 high	 in	





than	 40	 platelet	 membrane	 surface	 receptors	 such	 as	 glycoproteins	 Ib	 (CD42),	 IIb	
(CD41),	 IIIa,	 IV	 (CD36),	V	 (CD42d),	 IX	 (CD42a),	p-selectin	 (CD62),	 as	well	 as	different	
chemokines	such	as	CXCL4,	pro-platelet	basic	protein	(CXCL7)	and	CCL5	(Garcia	et	al.,	
2005;	Aatonen	et	al.,	2014).	PMV	and	platelet-derived	exosomes	express	largely	distinct	




nucleus,	 their	 RNA	 content	 derives	 from	 megakaryocytes	 during	 platelet	 biogenesis.	
Comparison	 of	 regulated	 miRNAs	 from	 PEV	 versus	 senescent	 platelets	 revealed	 70	
regulated	miRNAs	with	approximately	one	third	being	up-regulated.	Upregulated	PEV-
derived	miRNAs	are	known	to	target	mRNAs	that	have	roles	in	lipid	metabolism	(such	
as	 ABCB1),	 inflammation	 and	 vascular	 disease	 (such	 as	 complement	 factors	 and	
interleukins),	 platelet	 adhesion	 and	 activation	 (such	 as	 GPVI),	 coagulation	 (eg.	
fibrinogen	 and	 collagen),	 endocytosis	 and	 vesicle	 trafficking	 (e.g.	 Rab	 proteins),	
autophagy	 (e.g.	 ATG12),	 and	 generation	 and	 binding	 of	 small	 RNA	 (e.g.	 DICER1).	 The	
microRNA	profile	of	PEV	is	also	agonist	specific	(Ambrose	et	al.,	2018).	
The	life	span	of	PEV	in	the	human	circulation	is	unknown.	Mouse	studies	of	PEV	
injection	 into	 peripheral	 blood	 observed	 clearance	 within	 30	 minutes	 (unpublished	
observation	from	Flaumenhaft,	2006).	The	phosphatidylserine	(PS)	on	PEV	surface	can	





Increased	 levels	 of	 PEV	 have	 been	 reported	 to	 circulate	 in	 atherosclerosis	
patients	 (Michelsen	 et	 al.,	 2009),	 suggesting	 that	 they	 possibly	 contribute	 to	 disease	
development.	There	is	also	an	accumulation	of	studies	correlating	the	level	of	plasma	EV	
with	the	occurrence	of	a	number	of	cardiovascular	and	other	diseases	(Table	1.2.).	 In	
addition,	 studies	 on	 certain	 atherosclerosis	 medications,	 such	 as	 statins,	 have	
attributed,	at	 least	part	of	 their	cardioprotective	effect,	on	 the	associated	reduction	 in	
(P)EV	concentration	(Suades	et	al.,	2013).		Below	there	is	evidence	to	suggest	that	PEV	
are	also	 involved	 in	many	aspects	of	atherosclerosis,	 such	as,	 adhesion,	 inflammation,	
procoagulation,	angiogenesis	and	lipid	deposition.	
PEV	 contain	 various	 adhesion	 receptors	 on	 their	 surface	 as	 stated	 previously,	
such	 as	 glycoproteins	 Ia/Ib/IIa/IIb/IIIa	 (Aatonen	 et	 al.,	 2014;	 Garcia	 et	 al.,	 2005).	
Lukasik	et	al.	(2013),	found	a	correlation	between	increased	PEV	release	from	platelets	
and	 atherosclerotic	 thickening	 of	 carotid	 artery	 wall	 and	 plaque	 formation.	 These	




expression	 of	 lymphocyte	 function-associated	 antigen-1	 (CD11a)	 and	 macrophage	
antigen-1	(CD11b)	by	monocytes	(Chimen	et	al.,	unpublished;	Barry	et	al.,	1998).	PEV	
can	 also	 activate	 the	 intercellular	 adhesion	 molecule	 1	 (ICAM-1)	 that	 mediates	




(PKC)-	 dependent	 way	 (Barry	 et	 al.,	 1998).	 In	 addition,	 PEV	 were	 reported	 to	 have	
transferred	 CD41	 to	 cancer	 cells	 that	 enhanced	 their	 adhesion	 to	 fibrinogen	 and	
endothelium	 (Janowska-Wieczorek	 et	 al.,	 2004).	 Moreover,	 PMV	 may	 bind	





































PEV	 also	 induce	 SMC	 recruitment	 to	 the	 inflamed	 vessel	 wall.	 PEV	 release	
various	 mitogens	 such	 as	 platelet-derived	 growth	 factor	 (PDGF),	 platelet-derived	
	 31	
endothelial	 cell	 growth	 factor,	 endothelin,	 thrombospodin	 and	 endothelial	 growth	
factor	that	promote	recruitment	and	multiplication	of	SMC	in	the	arterial	walls	(Diehl	et	
al.,	2010).	
As	 already	 described	 in	 this	 chapter,	 the	 inner	 leaflet	 of	 the	 lipid	 bilayer	
membrane	 of	 platelets	 is	 composed	 of	 different	 aminophospholipids	 such	 as	
phosphatidylserine	(PS)	that	gets	exposed	to	the	extracellular	space	only	when	platelets	
get	activated	(Thiagarajan	and	Tait,	1991).	PS-expressing	platelet-derived	microvesicles	
(PMV)	 promote	 coagulation	 in	 the	 presence	 of	 calcium	 (Zwaal	 and	 Schroit,	 1997).	
Notably,	the	membrane	of	PMV	was	found	to	be	50-100	times	more	procoagulant	than	
the	surface	of	activated	platelets	(Sinauridze	et	al.,	2007)	and	EV-depleted	plasma	was	
found	 to	 be	 incapable	 of	 clotting	 (Nieuwland	 and	 Sturk,	 2007).	 The	 role	 of	 PMV	 in	
haemostasis	is	pathologically	confirmed	from	the	bleeding	phenotype	in	PMV	deficiency	





membrane	 of	 activated	 platelets.	 Factor	 Va	 combines	 with	 factor	 Xa	 and	 form	 the	
prothrombinase	complex.	Each	PMV	was	able	to	bind	as	much	factor	VIII	as	a	stimulated	
platelet	 (Gilbert	et	al.,	1991).	 	PEV	can	also	bind	 to	subendothelial	matrix	 (fibrinogen,	










platelets	 then	metabolize	 it	 to	 thromboxane	A2,	 resulting	 in	 their	activation	 (Barry	et	
al.,	 1997).	 	 PMV-released	 arachidonic	 acid	 also	 transactivates	 monocytes	 and	
endothelial	 cells	 leading	 to	 increased	monocyte	 adhesion	 to	 endothelial	 cells	 through	
intracellular	 cell	 adhesion	 molecule-1	 (ICAM-1)	 binding	 and	 elevated	 chemotaxis	 of	
monocytoid	 cells	 (Barry	 et	 al.,	 1998).	 The	 arachidonic	 acid	 also	 induces	 synthesis	 of	
cyclooxygenase-2	(COX-2)-derived	prostacyclin	(PGI2)	(Barry	et	al.,	1999;	Barry	et	al.,	
1997).	 PEV	 can	 also	 activate	 cells	 through	 exposure	 of	 platelet	 activating	 factor	
(Iwamoto	 et	 al.,	 1996).	 Furthermore,	 PEV	 can	 bind	 leukocytes	 through	 p-selectin	 –	





Notably,	 circulating	 microparticles	 from	 patients	 with	 myocardial	 infarction	
could	hinder	the	nitric	oxide-dependent	vasodilation	(Boulanger	et	al.,	2001)	and	PMV-
derived	 cyclooxygenase	 from	a	 rabbit	 artery	model	was	 found	 to	 convert	 arachidonic	
acid	 produced	 by	 endothelial	 cells	 into	 the	 vasoconstrictor	 thromboxane	 A2	 (Pfister,	
2004),	suggesting	that	PEV	can	mediate	vascular	tone.	
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Activated	 platelets	 release	 PEV	 containing	 mitochondria	 (Laffont	 et	 al.,	 2016)	
and	by	hydrolysis	of	 the	mitochondrial	membrane,	different	 inflammatory	stimuli	 are	
produced	 that	 activate	 neutrophils	 (Boudreau	 et	 al.,	 2014).	 	 These	 PEV-derived	




There	 is	 now	 sufficient	 evidence	 to	 suggest	 that	 PEV	 are	 important	mediators	
between	oxidative	stress	and	platelet	activation.	Oxidized	LDL	can	trigger	the	formation	
of	 PEV	 that	 then	 promote	 platelet	 activation.	 However,	 platelets	 that	 lacked	 the	








lipid	 growth	 factors	 (Kim	 et	 al.,	 2004)	 and	 by	 inducing	 phosphorylation	 of	 MAPK	
p42/44	and	serine/threonine	kinase	(Janowska-Wieczorek	et	al.,	2004).	PEV	were	also	
found	to	promote	angiogenesis	in	vivo	in	a	transplantation	model	of	ischaemia	(Brill	et	
al.,	 2005).	 PEV	 can	 also	 contribute	 to	 neovascularization	 by	 stimulation	 of	






angiogenesis	 and	 lipid	 deposition,	 might	 identify	 targets	 for	 development	 of	 future	
pharmacological	 agents	 in	 order	 to	 prevent	 and	 treat	 atherosclerotic	 cardiovascular	
diseases.	
1.2 Project	Hypothesis	and	Aims	




Hence,	 our	 overall	 aims	 are	 to	 investigate	 a)	 PEV-mediated	 recruitment	 of	
monocytes	 in	 atherosclerosis	 and	 b)	 potential	 adoption	 of	 PEV	 components	 such	 as	










Peripheral	 blood	was	 collected	 from	healthy	 volunteers	with	written	 informed	







C57BL/6	 mice	 and	 apolipoprotein	 E-null	 (ApoE-/-)	 mice	 on	 a	 C57BL/6	
background	 were	 obtained	 from	 Charles	 River	 UK	 and	 were	 further	 bred	 and	
maintained	at	the	Biomedical	Services	Unit.		
hiL4R/GPIbα-Τg+/+	mice	on	a	C57BL/6	background	were	generated	by	Ware	and	


























































































































the	 platelets,	 as	 detected	 by	 FACS	 (Accuri	 C6,	 BD	 Biosciences)	 (see	 Fig.	 2.2).	




Figure	 2.2.	 Representative	 FACS	 histogram	 showing	 hiL4Rα	 trace	 of	 ApoE	 KO-
hiL4Rα/GPIbα	Tg	mice	



















Blood	 was	 collected	 in	 1.6	 mg/ml	 ethylenediaminetetraacetic	 acid	 (EDTA)-
coated	tubes	(Sarstedt).	In	order	to	separate	the	different	components	of	the	blood,	2.5	
ml	of	Histopaque	1199	(Sigma)	was	added	to	10	ml	 tubes,	2.5	ml	of	Histopaque	1077	
(Sigma)	 was	 layered	 on	 top	 of	 Histopaque	 1199.	 Following	 addition	 of	 5	 ml	 anti-
coagulated	blood,	the	tubes	were	centrifuged	for	30	minutes	at	700	x	g.	The	top	cloudy	
layer	between	the	plasma	and	the	Histopaque	1199,	that	contains	the	mononuclear	cells	
(PBMCs),	was	collected	using	a	Pasteur	pipette	and	transferred	 to	a	 fresh	 falcon	 tube.	
The	cells	were	washed	twice	 in	10	ml	MACS	buffer	(2	mM	EDTA-Sigma,	0.5	%	bovine	
albumin	fraction	V	from	ThermoFisher	Scientific	in	PBS)	at	400	x	g	for	6	minutes.	The	
cells	were	 pelleted	 and	 resuspended	 in	 80	 μl	MACS	 buffer	 per	 1	 x	 107	 cells.	 20	 μl	 of	
CD14	 magnetic	 microbeads	 were	 added	 and	 the	 cells	 were	 incubated	 on	 ice	 for	 20	
minutes.	The	suspension	was	washed	in	MACS	buffer	by	centrifugation	at	400	x	g	for	6	
minutes.	 Pellet	 was	 resuspended	 in	 500	 μl	 MACS	 buffer.	 Suspensions	 were	 passed	
through	 an	 MS	 column	 (Miltenyi	 Biotec)	 that	 was	 attached	 to	 a	 MiniMACS	 magnetic	
separator	 (Miltenyi	 Biotec).	 	 The	 flow-through	 was	 discarded	 and	 the	 column	 was	







Whole	 blood	 was	 collected	 in	 10	 %	 citrate-phosphate-dextrose	 solution	 with	
adenine	(Sigma-Aldrich)	and	centrifuged	at	150	x	g	for	6	minutes	in	the	presence	of	10	
%	Theophylline	solution	(60mM	theophylline	anhydrous,	4.8mM	D-glucose	anhydrous,	
phosphate	 buffered	 saline	 without	 Ca2+/Mg2+)	 (0.2μm	 pore-filtered)	 (Sigma-Aldrich).	
Platelet-rich	 plasma	 and	 the	 top	 half	 of	 the	 red	 blood	 cell	 layer	was	 transferred	 to	 a	
fresh	 eppendorf.	 0.150	 ml	 of	 Theophylline	 solution	 was	 added	 to	 the	 remaining	 red	
blood	cell	 layer	and	100	μl	of	Theophylline	solution	was	added	to	the	tube	containing	
platelet-rich	plasma	(PRP)	and	the	top	half	of	the	red	blood	cell	layer	and	resuspended.	
Both	 tubes	 were	 centrifuged	 at	 200	 x	 g	 for	 6	minutes.	 PRP	was	 collected	 from	 both	
tubes	 and	pooled	 together	 in	 fresh	eppendorf.	 PRP	was	 centrifuged	at	1000	x	 g	 for	6	






filtered)	 and	 stimulated	with	 1	 μg/ml	 (for	 human)	 or	 10	 μg/ml	 (for	mouse)	 CRP-XL	
(Prof.	Farndale	Group,	Department	of	Biochemistry,	University	of	Cambridge)	or	0.5	U	
/ml	 thrombin	 (Sigma)	 at	 37	 ˚C	 for	 30	 minutes	 to	 generate	 extracellular	 vesicles.	





were	 transferred	 to	 fresh	 tubes	 leaving	 behind	 ~100	 μl	 in	 order	 to	 prevent	
contamination	with	the	pellet.		
2.6.2 PEV	Detection	









Platelet	 gating	 is	 determined	 by	 size	 and	
granularity.	The	PEV	gate	was	determined	by	
running	microspheres	of	<	1	μm	 in	 size	and	








Coulter	 Z2	 cell	 and	 particle	 counter	 according	 to	manufacturer’s	 instructions.	 Briefly,	
the	 counter	 was	 washed	 in ISOTON	 II	 Diluent	 (Beckman	 Coulter).	 	 The	 platelet	
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suspension	 was	 diluted	 by	 a	 factor	 of	 20	 in	 ISOTON	 II	 Diluent	 in	 Beckman	 Coulter	
counter	cuvettes.	
2.7.2 PBMC	and	Monocytes	
PBMCs	 and	 monocytes	 were	 counted	 using	 a	 Nexcelom	 Cellometer	 K2	 Image	
Cytometer	according	 to	manufacturer’s	 instructions.	Briefly,	PBMC	suspension	 (PBMC	
suspended	in	1ml	MACS	buffer)	was	diluted	by	a	factor	of	20	in	MACS	buffer,	whereas	
monocyte	 suspension	 (monocytes	 suspended	 in	100μl	MACS	buffer)	was	diluted	by	 a	





from	as	 small	 as	10	nm,	using	a	Nanosight	NS300	 (Malvern	Panalytical)	 (Pikramenou	
group,	 Chemistry	 Department,	 University	 of	 Birmingham)	 using	 NTA	 software	 3.0.	
Diluted	 samples	 (1:50	 in	 0.2	 μm	 pore-filtered	 milli	 Q	 water)	 were	 loaded	 into	 the	
counting	chamber	manually	using	1ml	plastic	syringes.	milli	Q	water	was	further	loaded	
through	 the	 syringe	 pump	 to	 ensure	 sample	 flow	 during	 imaging.	 Focus	 was	 set	
manually.	 Data	 acquisition	 was	 undertaken	 at	 ambient	 temperature	 (23.1	 –	 23.5°C).	
Settings	 for	 data	 acquisition	were:	 detect	 threshold	 50,	 15	 runs,	 FPS	 25.0,	 automatic	
camera	 level/	 slider	 shutter/	 slider	 gain,	 blur	 size/	max	 jump	 distance,	 viscosity	 0.9.	









3	x	108	platelets	were	 resuspended	 in	100μl	of	Theophylline-Albumin	 solution	
(6mM	 theophylline	 anhydrous,	 0.48mM	D-glucose	 anhydrous,	 0.15	%	bovine	 albumin	
fraction	V	solution,	phosphate	buffered	saline	without	Ca2+/Mg2+)	(0.2	μm	pore-filtered)	
and	 stained	 with	 APC	 anti-CD42b	 (GPIbα)	 antibody	 (BioLegend)	 (1:6);	 APC	 isotype	
(BioLegend)	(1:6);	FITC	anti-CD41a	(GPIIb)	(Dako)	(1:10);	FITC	 isotype	(Dako)	(1:10)	








minutes	with	 periodic	mixing.	 An	 equal	 volume	 of	 1.5	%	 Bovine	 Albumin	 Fraction	 V	
solution	 (7.5	%,	 Life	 Technologies)	 in	 diluted	 theophylline	 solution	was	 added	 to	 the	




Platelets	 were	 alternatively	 stained	 with	 MitoTracker	 Deep	 Red,	 Orange,	 or	
Green	to	label	their	mitochondria	as	follows:	3	x	108	platelets	were	resuspended	in	1	ml	
Theophylline-Albumin	 solution	 and	 stained	 with	 0.2	 μM	 /	 ml	 MitoTracker	 for	 15	
minutes	at	RT	in	the	dark.	Platelets	were	washed	twice	to	remove	excess	dye.	
Double	staining	of	platelets	for	their	mitochondria	and	membrane	was	achieved	









At	 the	 end	 of	 incubation,	 samples	 were	 fixed	 in	 1	 %	 formaldehyde	 solution	
(Sigma)	 at	 RT	 for	 10	 minutes.	 Following	 fixation,	 cells	 were	 washed	 in	 Dulbeco’s	
phosphate	buffered	saline	(PBS)	(Sigma)	without	Ca2+/Mg2+	by	centrifugation	at	400	x	g	
for	5	minutes.	Pellet	was	resuspended	in	200	μl	PBS	and	cells	were	stained	with	FITC	
anti-CD16;	 FITC	 isotype	 antibody	 (1:50)	 (BioLegend)	 or	 PE-Cy7	 anti-CD16;	 PE-Cy7	
isotype	 (1:50)	 (eBioscience)	and	PE	anti-CD14;	PE	 isotype	 (1:100)	 (ImmunoTools)	by	
30-minute	 incubation	 at	 4˚C.	 Following	 staining,	 cells	 were	 washed	 in	 PBS	 by	
centrifugation	 to	 remove	 excess	 antibody.	 Pellets	 were	 resuspended	 in	 ACK	 Lysing	
buffer	(Life	Technologies)	and	left	to	incubate	at	RT	for	10	minutes	in	order	to	lyse	red	
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blood	 cells.	 Lysing	 buffer	 was	 neutralised	 in	 10	 x	 by	 volume	 PBS	 and	 samples	 were	
centrifuged	 to	 remove	 lysed	 red	blood	 cells.	 Pellets	were	 resuspended	 in	300	μl	 PBS,	





60-minute	 time	 course.	 For	 endocytosis	 investigations,	 monocytes	 were	 pre-treated	
with	 various	 endocytosis	 inhibitors;	 10μM	 Cytochalasin	 D	 (Sigma-Aldrich),	 100	 μM	
Ly294002	 (Abcam),	 200μM	 EIPA	 (Sigma-Aldrich)	 or	 80	 μg/ml	 Dynasore	 (Abcam)	 diluted	 in	



















are	 listed	 in	 Table	 2.5).	 PKH67	 staining	 was	 observed	 in	 the	 FITC	 channel	 and	
Mitotracker	 deep	 red	was	 observed	 in	 the	APC	 channel.	 Since	 PEV	 are	 at	 least	 10-50	
times	smaller	than	leukocytes,	any	PEV	bound	to	leukocytes	cannot	be	distinguished	as	
individual	entities,	separate	from	leukocytes,	hence	the	machine	records	any	aggregates	
as	 being	 leukocytes	 (based	 on	 forward	 versus	 side	 scatter).	 In	 brief,	 leukocyte-PEV	
aggregates	are	identified	as	the	leukocytes	(identified	by	size/granularity/expression	of	
leukocyte	 markers)	 that	 also	 express	 PEV	 markers.	 (Gating	 strategy	 adapted	 from	










whereas	 high	 CD16	 expression	 and	 variable	 expression	 of	 CD14	 defines	
CD14+veCD16+ve	 monocytes	 (see	 Figure	 2.2.).	 	 CD14+veCD16-ve	 monocytes-PEV	
aggregates	are	defined	by	having	high	expression	of	CD14,	no	expression	of	CD16	and	















































l-lysine	solution	 (Sigma)	 for	5	minutes	at	RT,	washed	with	 tissue	culture	grade	water	
and	 left	 to	dry	 for	2-3	hours	before	 introducing	cells	and	medium.	Alternatively,	1.5	x	
105	 monocytes	 were	 plated	 in	 8-well	 μ-slides	 T/C	 treated	 (Thistle	 Scientific).	 Plated	
cells	were	 incubated	 at	 37°C	 for	 30	minutes	 or	 as	 indicated	 in	 a	 CO2	 incubator	 (NU-
5510,	NuAire).	The	cells	were	 then	 fixed	 in	2%	 formaldehyde	solution	 (Sigma)	 for	10	
minutes.	 Following	 fixation,	 the	 culture	 surface	 was	 blocked	 with	 Bovine	 Albumin	
Fraction	V	solution	6.7%	(Thermo	Fisher	Scientific),	10%	goat	 serum	(Sigma-Aldrich)	
and	FcR	blocking	reagent	 (1:100,	Miltenyi	Biotec)	 for	30	minutes.	The	culture	surface	
was	washed	with	 Dulbeco’s	 phosphate	 buffered	 saline	 (Sigma).	 Cells	 were	 incubated	
with	anti-CD14-alexa	 fluor	647	 (1:200,	abcam)	or	 rabbit	anti-LAMP-1	 (1:50)	 (abcam),	
and	 either	 GPIb	 alpha/	 IgG1	 isotype-alexa	 fluor	 488	 (1:200,	 Novus	 Biologicals)	 for	 1	
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hour	 at	 4°C.	 Wells	 were	 washed	 in	 Dulbeco’s	 phosphate	 buffered	 saline	 and	 further	
stained	 with	 goat	 anti-rabbit-alexa	 fluor	 647	 (secondary	 antibody	 for	 LAMP-1)	 for	 1	
hour.	Wells	 were	 washed	 in	 PBS	 and	 saved	 at	 4°C	 in	 Vectashield	 antifade	 mounting	
medium	with	DAPI	(Vector	Laboratories)	until	imaging.		




(Nikon)	 or	 an	 Axioscan	 780	 (Zeiss).	 Z-stacks	 of	 0.2μm	 depth	 (in	 all	 colour	 channels)	
were	produced	spanning	the	whole	monocytes	from	top	surface	to	bottom	surface	using	
the	100x	lens.	
Live	 mitotracker-stained	 monocytes	 were	 imaged	 in	 real	 time	 by	 STORM	
(Stochastic	 Optical	 Reconstruction	 Microscopy)	 using	 a	 Nikon	 N-Storm	 Super	
Resolution	Microscope.	The	same	monocytes	were	imaged	every	second	for	50	seconds	




ImageJ/FIJI	 software.	 Z-stacks	 produced,	were	used	 to	 create	 composite	 images	 (max	
projection	 for	 GPIb,	 DAPI,	 PKH67,	 PKH26,	 LAMP1	 and	 MitoTracker	 and	 average	
projection	for	CD14)	to	show	the	total	PEV	signal	by	 individual	monocytes.	Automatic	












Mouse	 aortas	were	 fixed	 in	2	%	PFA	 for	10	minutes	 and	washed	 in	PBS.	They	
were	stained	with	Oil	Red	O	according	to	manufacturer’s	guidelines	in	order	to	remove	
external	 fat	 and	 connective	 tissue.	Aortas	were	 cut	 longitudinally	 and	 re-stained	with	
Oil	Red	O	to	stain	atheromatous	plaques.	Aortas	were	mounted	flat	using	double-sided	




Mouse	 livers	 were	 fixed	 in	 2	%	 PFA	 immediately	 upon	 extraction.	 They	 were	
embedded	 in	 paraffin	 and	 sectioned	 using	 a	 microtome.	 Sections	 were	 stained	 with	





Peripheral	blood	was	 left	untreated	at	 room	temperature	 for	2-4	hours	 to	clot.	
Clotted	 blood	was	 centrifuged	 at	 15	 000	 x	 g	 for	 10	min	 to	 collect	 serum.	 Serum	was	
stored	 at	 -20°C.	 Serum	 triglycerides	 (Randox),	 total	 cholesterol,	 high-density	












expose	 the	 trachea.	 The	membrane	 tissue	 around	 the	 trachea	was	 cleared	 away.	 The	
trachea	was	 cannulated	 to	 aid	mouse	 breathing.	 The	 left	 common	 carotid	 artery	was	







PEV	 were	 generated	 from	 3	 x	 108	 purified	 mouse	 platelets	 as	 described	 in	
section	2.6.1.,	and	were	incubated	with	1.5	x	106		human	monocytes	for	30	minutes	at	
37°C.	The	cells	were	stained	with	25μM	cell	 tracker	orange	(Thermo	Fisher	Scientific)	
during	 the	 incubation	with	PEV.	Stained	monocytes	were	spun	twice	at	 	400	x	g	 for	6	
minutes	 to	 remove	 free	 dye	 and	 free	 PEV.	 Pelleted	 monocytes	 were	 resuspended	 in	
500μl	 PBS-Albumin	 solution	 (0.15%	 bovine	 albumin	 fraction	 V	 solution,	 phosphate	
buffered	 saline	 with	 Ca2+/Mg2+)	 and	 kept	 on	 ice	 until	 injection.	 Stained	 monocytes	
without	PEV	were	injected	as	a	control.	
2.13.3 Imaging	and	Imaging	Analysis	
Interaction	of	 injected	 cells	with	 the	 vessel	wall	was	monitored	by	 fluorescent	
video-microscopy	using	 an	Olympus	BX61WI	Upright	Confocal	microscope	 in	 the	561	
channel	using	a	4x	objective	in	the	right	common	carotid	artery	at	the	athero-prone	fork	
site	 for	 six	 minutes	 following	 cell	 introduction.	 The	 number	 of	 stable	 and	 unstable	
monocyte	adhesion	was	manually	counted	using	the	Slidebook	6	Reader	Software.	The	
speed	and	the	duration	of	the	adhesion	interactions	were	also	calculated	manually	using	
data	 from	 the	Slidebook	6	Reader	Software.	Briefly,	 rolling	velocity	was	 calculated	by	








Graphical	 and	 statistical	 analysis	was	 performed	 using	 the	 software	 GraphPad	
Prism	4.	Data	 are	 shown	as	mean	+/-	 standard	 error	 of	 the	mean.	The	 tests	 used	 for	








Platelets	 release	 PEV	 upon	 activation.	 Physiological	 platelet	 activation	 occurs	
upon	 vascular	 injury,	 when	 platelets	 attach	 to	 the	 exposed	 extracellular	 matrix.	 The	
most	 thrombogenic	 component	 of	 the	 exposed	 extracellular	 matrix	 is	 collagen	
(Baumgartner	and	Haudenschild,	1972).	Collagen,	apart	 from	acting	as	a	substrate	 for	
platelet	 adhesion,	 also	 induces	 platelet	 activation	 (Cowan	 et	 al.,	 1981;	 Morton	 et	 al.,	
1989;	 Poole	 and	Watson,	 1995).	 There	 are	 two	 platelet	 receptors	 that	 interact	 with	
collagen;	 firstly	 collagen	 binds	 integrin	 α2β1	 to	 anchor	 platelets	 on	 collagen,	 then	
enabling	binding	to	the	lower	affinity	receptor	glycoprotein	VI	(GPVI)	that	induces	the	
activation	of	platelets	(Morton	et	al.,	1989;	Santoro	et	al.,	1991).	
Activated	 platelets	 then	 release	 soluble	 agonists	 that	 induce	 activation	 of	 new	
platelets.	 Released	 thrombin	 activates	 platelets	 by	 binding	 and	 cleaving	 protease-
activated	receptors	PAR-1	and	PAR-4.	There	is	some	evidence	to	suggest	that	cleavage	
of	PAR-1	by	thrombin	is	facilitated	by	the	adherence	of	thrombin	to	receptor	GPIbα	of	
the	 GPIb/IX/V	 complex	 (Brass,	 2003).	 Adenine	 di-Phosphate	 (ADP)	 from	 the	 dense	
granules	 of	 platelets	 binds	 to	 purinergic	 receptors	 P2Y1	 and	 P2Y12,	 and	 the	 lipid	
mediator	 thromboxane	 A2	 (TxA2)	 binds	 to	 TxA2	 receptor	 (TP),	 both	 contribute	 to	
further	 platelet	 activation	 (George,	 2000;	 Grette,	 1962;	 Zucker	 and	 Borrelli,	 1962;	
Hovig,	 1963;	 Hugues	 and	 Lapiere,	 1964;	Mills	 et	 al.,	 1968;	Murugappan	 et	 al.,	 2004).	





that	 mimic	 thrombin	 and	 collagen	 respectively	 are	 also	 used	 to	 induce	 platelet	
activation	in	vitro.	
	







of	 proteins.	 These	 are	 known	 to	 be	 involved	 in	 various	 cellular	 responses,	 to	 have	
different	 molecular	 functions	 and	 to	 be	 located	 at	 distinct	 sites	 within	 the	 platelet	
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(Garcia	 et	 al.,	 2005).	 PEV	 express	more	 than	40	platelet	membrane	 surface	 receptors	
such	 as	 glycoproteins	GPIb	 (CD42),	 GPIIb	 (CD41),	 GPIIIa,	 GPIV	 (CD36),	 GPV	 (CD42d),	
GPIX	 (CD42a)	and	P-selectin	 (CD62)	 (Garcia	et	al.,	2005).	The	 identity	of	 the	proteins	









Platelets	 were	 isolated	 from	 CPDA-anticoagulated	 blood	 and	 were	 stimulated	
with	different	agonists	(1	μg/ml	CRP-XL	and	0.5	U/ml	thrombin)	in	the	presence	of	Ca2+	
for	30	minutes	at	37˚C	to	induce	the	formation	and	release	of	PEV.	Prior	to	generation	of	
PEV,	 platelets	 were	 labelled	 with	 antibodies	 against	 GPIbα	 or	 GPIIb	 coupled	 to	
fluorescent	 probes	 or	 with	 appropriate	 isotype	 controls,	 or	 with	 the	 lipophilic	 dye	
PKH67	 (cell	 membrane	 dye),	 or	 were	 left	 unstained.	 PEV	 were	 purified	 by	 two-step	
sequential	centrifugation;	2000	x	g	for	20	minutes	followed	by	13000	x	g	for	2	minutes	
to	pellet	 and	 remove	platelets.	 PEV	were	 stained	at	 the	platelet	 stage	 instead	at	 after	








resulting	 PEV	 suspension	 and	 to	 characterize	 them	 in	 terms	 of	 numbers,	 size,	
granularity	and	molecular	and	lipid	composition.	Two	potent	platelet	agonists	that	act	







generated	 in	response	 to	CRP-XL	stimulation	or	with	 thrombin	stimulation	using	 flow	
cytometric	 quantification	 was	 not	 significantly	 different;	 therefore	 both	 agonists	
generated	the	same	number	of	PEV	(Fig.	3.2A).	Next,	we	compared	the	number	of	PEV	
formed	 from	 CRP-XL	 stimulation,	 as	 detected	 by	 flow	 cytometry	 versus	 nanoparticle	
tracking	analysis	quantification.	The	number	of	PEV	detected	by	FACS	was	significantly	
smaller	 than	 the	 number	 of	 PEV	 detected	 by	 NanoSight	 (Fig.	 3.2B).	 Specifically,	 the	
number	of	particles	detected	by	NanoSight	was	>1000	times	greater	than	the	number	of	
particles	detected	by	Accuri.		
In	 order	 to	 determine	 whether	 PEV	 were	 effectively	 purified	 by	 the	 double	
centrifugation,	 stimulated	 platelets	 were	 run	 on	 the	 flow	 cytometer	 before	 and	 after	
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centrifugation	 and	 the	 percentage	 of	 events	 in	 the	 platelet	 gate	 was	 recorded	 (Fig.	





(A)	 Number	 of	 PEV	 produced	 from	 3	 x	 108	 platelets	 stimulated	 with	 CRP-XL	 or	
thrombin,	as	quantified	by	flow	cytometry.	Data	are	represented	as	mean	+/-	SEM	of	3-
10	 experiments.	 (B)	Number	 of	 PEV	produced	 from	3	 x	 108	platelets	 stimulated	with	




to	 determine	 their	 size	 and	 granularity	 characteristics.	 Unpurified	 PEV	 (with	 platelet	
contamination)	were	 analysed	 by	 flow	 cytometry	 and	 the	 trace	 of	 forward	 scatter	 (a	
measure	of	size),	as	well	as	the	side	scatter	(a	measure	of	granularity)	were	observed.	





PEV.	 Upon	 quantification,	 PEV	 were	 found	 to	 be	 significantly	 smaller	 than	 platelets,		
specifically	 >10	 times	 smaller	 based	 on	 forward	 scatter	 measurements	 (Fig.	 3.4B).	











non-arbitrary	 units.	 The	 size	 distribution	 profile	 of	 a	 representative	 PEV	 sample	was	
automatically	produced	by	the	NTA	software	version	NTA	3.0	0068	and	is	shown	in	Fig.	
3.4C.	The	diameter	of	PEV	spans	from	0-650nm.	Four	peaks	can	be	seen;	an	extremely	









stimulation	 with	 CRP-XL,	 as	 measured	 by	 nanoparticle	 tracking	 analysis.	 Data	 were	
analysed	by	t-test.	*	indicates	P<0.05,	**	indicates	P<0.01.	
The	 side	 scatter	 histogram	 (ungated)	 also	 indicated	 the	 presence	 of	 two	
populations	as	evident	by	the	presence	of	two	distinct	peaks	(Fig.	3.5A).	The	two	peaks	
corresponded	to	the	platelet	and	PEV	gate	(not	shown).	Upon	quantification,	PEV	were	
found	 to	 be	 significantly	 less	 granular	 than	 platelets	 	 (Fig.	 3.5B).	 Hence,	 PEV	 and	




(A)	 Representative	 histogram	 of	 granularity	 trace	 (side	 scatter)	 of	 PEV	 and	 platelets	





in	 experiments	with	 leukocytes.	 The	 first	molecule	 investigated	was	 GPIb,	which	 is	 a	
highly	 abundant	 adhesion	 receptor	 on	 the	 platelet	 surface.	 Washed	 platelets	 were	
stained	with	an	anti-GPIbα	antibody	coupled	to	fluorescent	tag	before	stimulation	with	
agonists	 so	 that	 both	 whole	 platelets	 and	 PEV	 get	 stained.	 Unpurified	 PEV	 were	
analysed	 by	 FACS	 upon	 platelet	 stimulation	 and	 the	 GPIbα	 expression	 trace	 for	 both	
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platelets	 and	 PEV	 was	 observed.	 Platelets/PEV	 were	 also	 stained	 with	 an	 isotype	
antibody	 as	 a	 control.	Figure	 3.6A	 shows	 overlay	 histograms	 of	 GPIbα	 expression	 of	
isotype	and	GPIbα-stained	platelets	and	PEV.	The	gate	of	positive	events	is	set	based	on	





PEV	 were	 found	 to	 express	 significantly	 less	 GPIbα	 in	 quantity	 than	 platelets.	 (Fig.	
3.6C).	
In	 order	 to	 determine	 whether	 this	 expression	 pattern	 was	 valid	 for	 other	
platelet	markers,	we	 also	 investigated	 expression	 of	 another	 highly	 abundant	 surface	




were	 also	 stained	with	 an	 isotype	 antibody	 as	 a	 control.	Figure	 3.7A	 shows	 overlay	
histograms	of	GPIIb	expression	of	isotype	and	GPIIb-stained	platelets	and	PEV.	The	gate	
of	positive	events	is	set	based	on	the	expression	profile	of	the	isotype	sample.	The	large	
shift	 to	 the	 right	 of	 GPIIb	 expression	 on	 the	 platelets	 shows	 that	 the	 whole	 platelet	
population	is	strongly	positive	for	GPIIb.	The	smaller	shift	to	the	right	on	the	GPIIb	scale	










GPIbα	 expression	 of	 platelets	 versus	 PEV,	 as	 detected	 by	 flow	 cytometry.	 Data	 are	













GPIIb	 expression	 of	 platelets	 and	 PEV,	 as	 detected	 by	 flow	 cytometry.	 Data	 are	






washed	platelets	were	stained	with	 the	 lipophilic	dye	PKH67	 that	 fluorescently	stains	
the	 cell	 membrane	 by	 incorporating	 aliphatic	 reporter	 molecules	 into	 the	 cell	
membrane	 lipid	 bilayer	 by	 selective	 partitioning.	 Platelets	 were	 stained	 before	
stimulation	with	agonists	so	that	both	whole	platelets	and	PEV	were	stained.	Unpurified	
PEV	were	analysed	by	FACS	upon	platelet	stimulation	and	the	PKH67	expression	trace	
for	 both	 platelets	 and	 PEV	 was	 observed.	 Platelets/PEV	 were	 also	 analysed	 with	
unstained	 cells	 as	 a	 control.	 Figure	 3.8A	 shows	 overlay	 histograms	 of	 PKH67	
expression	 of	 unstained	 and	 PKH67-stained	 platelets	 and	 PEV.	 The	 gate	 of	 positive	
events	is	set	based	on	the	expression	profile	of	the	unstained	sample.		
The	large	shift	to	the	right	of	PKH67	expression	of	the	whole	platelet	population	
and	 the	 whole	 PEV	 population	 shows	 that	 both	 are	 positive	 for	 PKH67.	 Upon	







(A)	Representative	 histograms	 of	 PKH67	 (membrane	marker)	 expression	 of	 platelets	
and	PEV,	as	detected	by	 flow	cytometry.	(B)	Percentage	of	platelets	and	PEV,	positive	
for	PKH67,	as	detected	by	flow	cytometry.	Data	are	represented	as	mean	+/-	SEM	of	3	
experiments.	 (C)	Median	 PKH67	 expression	 of	 platelets	 vs	 PEV,	 as	 detected	 by	 flow	
cytometry.	 Data	 are	 represented	 as	 mean	 +/-	 SEM	 of	 3	 experiments.	 All	 data	 were	
analysed	by	t-test.		**	indicates	P<0.01.	
3.4 Discussion	










et	 al.,	 1989).	 However,	 more	 recent	 observations	 found	 thrombin	 to	 be	 a	 stronger	
stimulant	than	collagen	and	CRP-XL	(Aatonen	et	al.,	2014).	
Quantification	 of	 PEV	 was	 attempted	 using	 Flow	 Cytometry	 (FC)	 and	
Nanoparticle	 Tracking	 analysis	 (NTA).	 Nanoparticle	 Tracking	 technology	 was	 able	 to	
count	>1000	times	more	PEV	than	Flow	Cytometry.	Our	data	on	PEV	quantification	by	
conventional	 flow	cytometry	agree	with	those	of	others	(Aatonen	et	al.,	2014;	van	der	
Pol	 et	 al.,	 2014).	 According	 to	 manufacturer’s	 specifications,	 an	 Accuri	 C6	 flow	
cytometer	 cannot	 detect	 particles	 smaller	 of	 500nm,	 hence	 the	 large	 discrepancy	
between	 the	 two	 instruments	 is	 logical.	 Accuri	 C6	 can	 only	 detect	 the	 larger	 PMV	 so	
caution	must	be	taken	when	interpreting	PEV	data	 from	such	flow	cytometers,	as	 it	 is	
unknown	whether	these	are	representative	of	the	whole	PEV	population.	However,	this	
method	provides	a	good	indicator	of	platelet	contamination	in	PMV-preparations.	PEV	
were	purified	using	a	 two-step	centrifugation	strategy.	This	 resulted	 from	10%	 initial	
platelet	contamination	to	<1%	platelet	contamination.	Perhaps	a	repeat	centrifugation	
step	 at	 13	 000	 x	 g	 could	 minimize	 platelet	 contamination	 more.	 More	 sensitive	
techniques	 to	 count	 PMV	 include	 nanosight	 tracking	 analysis	 (NTA),	 resistive	 pulse	
sensing	 (RPS),	 transmission	 electron	 microscopy	 (TEM),	 atomic	 force	 microscopy	
(AFM)	and	flow	cytometers	dedicated	to	detecting	submicrometer	particles	(van	der	Pol	
et	 al.,	 2014,	 Nieuwland	 et	 al.,	 2013).	 However	 these	 techniques	 (excluding	 dedicated	
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in	accordance	with	 independent	observations	made	 in	other	 labs	(Arraud	et	al.,	2014;	
Yuana	et	al.,	2010;	Gabriel	et	al.,	2010;	Aatonen	et	al.,	2014).		Independent	observations	
made	by	Brisson	and	colleagues	(2017)	suggest	that	platelet	stimulation	with	thrombin,	
TRAP	 or	 CRP-XL	 produces	 EV	 with	 similar	 size	 distribution.	 In	 our	 studies,	 the	 size	
distribution	 of	 PEV	 was	 multimodal,	 suggesting	 the	 presence	 of	 more	 than	 two	 PEV	
subpopulations	 so	PEV	may	not	be	 simply	divided	 in	exosomes	and	PMV,	but	may	be	
further	 differentiated	 in	 terms	of	 composition	 and	 the	 contents	 they	may	 carry.	With	
regards	to	protein	cargo,	the	majority	of	the	larger	PMV	were	confirmed	to	express	the	
adhesion	receptors	GPIb	and	GPIIb,	a	pattern	of	expression	also	 found	by	many	other	
labs	 (Garcia	 et	 al.,	 2005;	 Aatonen	 et	 al.,	 2014;	 Brisson	 et	 al.,	 2017).	 	 Hence	 these	
receptors	can	be	used	as	good	PMV	markers.	The	expression	level	of	GPIb	and	GPIIb	of	
PMV	 was	 significantly	 lower	 than	 the	 expression	 level	 of	 platelets,	 therefore	 we	
hypothesised	 that	 the	expression	 level	of	GPIb	or	GPIIb	can	be	perhaps	used	 in	other	
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experiments	 to	differentiate	between	platelet	or	PMV	binding,	 if	any,	 to	 the	surface	of	
monocytes	and	other	leukocytes.		
By	definition,	EV	are	membranous	vesicles,	hence	a	good	marker	for	EV	would	be	
a	 stained	 membrane.	 The	 lipophilic	 dye	 PKH67	 has	 proven	 to	 be	 very	 efficient	 in	
staining	the	PMV	membrane	as	all	detected	PMV	in	our	experiments.	In	summary,	PMV	












Increased	 levels	 of	 circulating	 PEV	 have	 been	 detected	 in	 atherosclerosis	
patients	 (Michelsen	 et	 al.,	 2009).	 In	 addition,	 elevated	 levels	 of	 monocyte-platelet	
aggregates	have	been	reported	to	circulate	in	atherosclerosis	(Shantsila	and	Lip,	2009).	
Hence,	 there	 is	 a	 possibility	 that	 PEV	 also	 form	 aggregates	 with	 monocytes	 in	
atherosclerosis	 and	 that	 the	 formation	 of	 these	 aggregates	 contributes	 to	 disease	
development.	 Since	 PEV	 possess	 various	 adhesion	 receptors	 on	 their	 surface	 such	 as	
GPIb,	GPIIb	and	P-selectin,	 there	 is	a	possibility	 that	upon	binding,	monocytes	use	the	
bound	PEV	as	a	bridge	for	recruitment	them	to	the	vessel	wall.	 In	addition,	binding	of	
PEV	 to	monocytes,	 could	 be	 followed	by	 transfer	 of	 proinflammatory	mediators	 from	
PEV,	 such	as	arachidonic	acid,	 tissue	 factor	or	 scavenger	 receptors	 such	as	CD36	 that	
could	activate	 leukocytes	and	shift	 them	towards	an	 inflammatory	phenotype.	Both	of	
these	mechanisms	could	contribute	to	progression	of	atherosclerosis.		
The	monocyte	population	 is	divided	 into	 two	main	 subsets;	 those	 that	 express	
CD16	 on	 their	 surface,	 simply	 termed	 CD16+ve	 monocytes,	 and	 those	 that	 do	 not	
express	CD16	on	their	surface,	simply	termed	CD16-ve	monocytes	and	often	delineated	
by	 CD14	 expression.	 According	 to	 proteomics	 analysis	 more	 than	 200	 proteins	 are	
differentially	 expressed	 between	 CD16+ve	 and	 CD16-ve	 monocytes,	 resulting	 in	









Platelet	 agonist	 TRAP	 (100	 μM)	was	 added	 to	 CPDA-anticoagulated	 peripheral	
blood	or	blood	was	 left	untreated	over	 the	 course	of	30	minutes	 at	37˚C	under	 shear	
stress	 induced	 by	 roller	mixer.	 Heterotypic	 aggregation	was	 detected	 by	 FACS	 (Cyan	
ADP)	 by	 the	 presence	 of	 platelet/PEV	markers	 (GPIbα	 and	 GPIIb)	 on	 the	 leukocytes.	














Representative	 flow	 cytometry	 dot-plots	 show	 acquisition	 of	 PEV-borne	GPIbα	


















4.2.	 The	 curve	 is	 shifted	 towards	 higher	 expression	 of	 GPIbα	 at	 all	 time	 points	
compared	 to	 the	 0-min	 and	 30-min	 controls,	 implying	 that	 CD16-ve	monocytes	 form	
aggregates	with	GPIbα+ve	entities.	The	expression	curve	is	almost	identical	at	all	time	
points	of	treatment,	suggesting	that	time	of	incubation	with	TRAP	does	not	have	a	major	







Figure	 4.1.	 Formation	 of	 aggregates	 between	 CD16-ve	 monocytes	 and	 platelets	
and/or	PEV	in	whole	blood	over	time	in	response	to	100μM	TRAP	
Representative	 FACS	 dotplots	 demonstrating	 percentage	 of	 GPIbα+ve	 CD16-ve	
monocytes	 over	 time	up	 to	 30	minutes	 in	 response	 to	 stimulation	with	 100μm	TRAP	
under	roller	mixing.	Gate	of	positive	events	was	set	by	isotype	sample	(not	shown).	A	0-







monocytes	 over	 time	up	 to	 30	minutes	 in	 response	 to	 stimulation	with	 100μm	TRAP	
under	 roller	 mixing.	 A	 0-min	 control	 (immediate	 fixation)	 and	 a	 30-min	 control	 (no	
TRAP,	roller	mixing)	were	 included.	The	GPIbα	expression	 trace	of	 resting	platelets	 is	
also	shown.	
The	 expression	 of	 GPIbα	 on	CD16-ve	monocytes	was	 analyzed	 graphically	 and	
statistically	 from	 a	 number	 of	 experiments.	 The	 percentage	 of	 CD16-ve	 monocytes	
expressing	GPIbα	at	30-min	with	TRAP	vs	30-min	no	TRAP	is	statistically	higher	and	the	
percentage	increases	significantly	by	increasing	incubation	time	with	TRAP	(Fig.	4.3A).	
The	 graph	 of	 median	 GPIbα	 expression	 of	 CD16-ve	 monocytes	 is	 shown	 in	
Figure	4.3D.	The	median	GPIbα	expression	of	CD16-ve	monocytes	at	30-min	incubation	
with	 TRAP	 vs	 30-min	 no	 TRAP	 is	 significantly	 higher,	 so	 TRAP	 increases	 the	median	
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GPIbα	 expression	 on	 CD16-ve	monocytes.	 The	median	 GPIbα	 expression	 on	 CD16-ve	
monocytes	increases	significantly	with	increasing	incubation	time	with	TRAP.		
The	 data	 from	 the	 overlay	 histogram	 clearly	 showed	 that	 CD16-ve	monocytes	
formed	 aggregates	 with	 PEV,	 however,	 since	 there	 was	 an	 indication	 that	 a	 small	
percentage	of	monocytes	formed	aggregates	with	platelets,	we	decided	to	also	perform	
statistical	analysis	separately	in	the	“PEV	gate”	and	“Platelet	gate”.		
The	percentage	of	CD16-ve	monocytes	binding	 to	GPIbα+ve	entities	 in	 the	PEV	
gate	(Fig.	4.3B)	increased	significantly	with	time	whereas	the	percentage	in	the	platelet	
gate	 did	 not	 change	 through	 the	 experiment	 (Fig.	 4.3C).	 The	 percentage	 of	 CD16-ve	
monocytes	 expressing	GPIbα	upon	30-minute	 incubation	with	TRAP	was	 significantly	
higher	than	the	no	TRAP	control	in	both	the	PEV	and	platelet	gate.	However,	the	GPIbα	
expression	intensity	was	not	affected	by	incubation	time	in	either	gate	(Fig.	4.3E	and	F).	









(D),	 in	 the	 PEV	 gate	 (E)	 and	 in	 the	 Platelet	 gate	 (F).	 A	 0-min	 control	 (immediate	
fixation)	 and	 a	 30-min	 control	 (no	 TRAP,	 roller	 mixing)	 are	 also	 shown.	 Data	 are	
represented	as	mean	+/-	SEM	of	3-4	experiments.	All	data	were	analysed	by	One-way	







is	 observed	 with	 the	 CD16+ve	 monocytes,	 with	 a	 higher	 number	 of	 events	 in	 the	
GPIbα+ve	gate	of	representative	flow	cytometry	dot-plots	for	the	10-,	15-,	20-,	25-	and	
30-min	 samples	 compared	 to	 the	 0-	 and	 30-min	 control	 samples	 (Fig.	 4.4).	 Hence,	
CD16+ve	 monocytes	 also	 form	 aggregates	 with	 platelets	 and/or	 PEV	 upon	 TRAP	
treatment	in	the	blood.	Again,	there	is	no	clear	trend	in	the	acquisition	rate	of	GPIbα,	so	
we	cannot	conclude	that	PEV	binding	to	CD16+ve	monocytes	is	proportional	to	time	of	






The	 GPIbα	 expression	 profile	 of	 the	 CD16+ve	 monocytes	 was	 also	 analyzed.	
Figure	4.5	displays	a	representative	histogram	for	the	CD16+ve	monocytes	with	traces	
from	each	time	point	and	controls	overlaid.	The	GPIbα	expression	trace	of	platelets	 is	





Figure	 4.4.	 Formation	 of	 aggregates	 between	 CD16+ve	monocytes	 and	 platelets	
and/or	PEV	in	whole	blood	over	time	in	response	to	100μM	TRAP	
Representative	 FACS	 dotplots	 demonstrating	 percentage	 of	 GPIbα+ve	 CD16+ve	
monocytes	 over	 time	up	 to	 30	minutes	 in	 response	 to	 stimulation	with	 100μm	TRAP	
under	roller	mixing.	Gate	of	positive	events	was	set	by	isotype	sample	(not	shown).	A	0-





GPIbα	 high	 cells	 show	 expression	 greater	 than	 platelets.	 This	 indicates	 that	 a	
percentage	 of	 this	 population	 is	 binding	whole	 platelets.	 The	 GPIbα	 “low”	 population	
shows	 staining	below	 the	 intensity	of	platelets,	 indicating	PEV	acquisition.	Hence,	 the	
GPIbα+ve	 section	 was	 separated	 into	 two	 subsections;	 a	 GPIbα+ve	 section	 of	 lower	
expression	than	the	platelet	expression	in	order	to	enable	us	to	detect	interactions	with	






monocytes	 over	 time	up	 to	 30	minutes	 in	 response	 to	 stimulation	with	 100μm	TRAP	
under	 roller	 mixing.	 A	 0-min	 control	 (immediate	 fixation)	 and	 a	 30-min	 control	 (no	




vs	 30-min	 no	 TRAP	 is	 statistically	 higher.	 The	 percentage	 of	 CD16+ve	 monocytes	
acquiring	GPIbα	increases	significantly	with	time		(Fig.	4.6A).	




Upon	 observing	 that	 CD16+ve	 monocytes	 form	 aggregates	 distinctively	 with	
platelets	and	PEV,	statistical	analysis	was	also	performed	separately	 in	the	“PEV	gate”	
and	 “Platelet	 gate”.	 Time	 of	 incubation	 does	 not	 affect	 the	 percentage	 of	 CD16+ve	
monocytes	binding	to	PEV	(Fig.	4.6B)	or	platelets	(Fig.	4.6C)	significantly,	even	though	
we	 can	 observe	 a	 decreasing	 trend	 for	 platelet	 binding	 and	 increasing	 trend	 for	 PEV	
binding.	 The	 GPIbα	 expression	 intensity	 on	 monocytes	 in	 the	 “platelet	 gate”	 is	
statistically	 the	 same	 as	 the	 GPIbα	 expression	 of	 platelets,	 suggesting	 that	 several	
platelets	bind	to	monocytes	(Fig.	 4.6F).	The	GPIbα	expression	intensity	on	monocytes	









(D),	 in	 the	 PEV	 gate	 (E)	 and	 in	 the	 Platelet	 gate	 (F).	 A	 0-min	 control	 (immediate	
fixation)	 and	 a	 30-min	 control	 (no	 TRAP,	 roller	 mixing)	 are	 also	 shown.	 Data	 are	
represented	as	mean	+/-	SEM	of	3-4	experiments.	All	data	were	analysed	by	One-way	






We	 then	 investigated	 the	 behaviour	 of	 neutrophils	 in	 order	 to	 determine	
whether	the	affinity	for	PEV	was	monocyte-specific	or	also	true	for	other	leukocytes.	We	




control	 samples,	 showing	 that	neutrophils	 also	 form	aggregates	with	platelets	 and/or	
PEV	 upon	 TRAP	 treatment	 in	 the	 blood.	 However,	 there	 is	 no	 clear	 trend	 in	 the	
acquisition	rate	of	GPIbα,	so	PEV	binding	to	neutrophils	does	not	increase	with	time.		
Analysis	 of	 the	 GPIbα	 expression	 histogram	 of	 neutrophils	 indicates	 that	 the	
main	 body	 of	 the	 curve	 shifts	 very	 little	 towards	 higher	 expression	 compared	 to	 the	
controls.	 However,	 the	 right	 tail	 extends	 towards	 noticeable	 higher	 expression	 and	
reaches	the	expression	of	platelet	(Fig.	4.8A).		
Graphical	 and	 statistical	 analysis	 is	 shown	 in	 Fig.	 4.9.	 Incubation	 with	 TRAP	
increases	 the	 percentage	 of	 GPIbα+ve	 neutrophils	 significantly	 (Fig.	 4.9A).	 The	
percentage	of	neutrophils	expressing	GPIbα	at	30-min	with	TRAP	vs	30-min	no	TRAP	is	
statistically	higher.	
The	 graph	 of	 median	 GPIbα	 expression	 of	 the	 total	 neutrophil	 population	 is	
shown	in	Figure	4.9D.	Incubation	with	TRAP	significantly	increases	the	median	GPIbα	















Representative	 FACS	 overlay	 histograms	 demonstrating	 GPIbα	 expression	 on	
neutrophils	over	 time	up	 to	30	minutes	 in	 response	 to	stimulation	with	100μm	TRAP	
under	 roller	 mixing.	 A	 0-min	 control	 (immediate	 fixation)	 and	 a	 30-min	 control	 (no	
TRAP,	roller	mixing)	were	 included.	The	GPIbα	expression	 trace	of	 resting	platelets	 is	
also	shown.	
The	 percentage	 of	 GPIbα+ve	 neutrophils	 was	 also	measured	 separately	 in	 the	
platelet	gate	and	 in	 the	PEV	gate	and	was	analyzed	statistically	over	 the	 course	of	30	
minutes.	The	percentage	of	neutrophils	binding	 to	PEV	 increases	significantly	by	 time	






Percentage	 of	 GPIbα+ve	 neutrophils	 as	 a	 whole	 (A),	 in	 the	 PEV	 gate	 (B)	 and	 in	 the	





effect	 of	 time,	 and	 where	 applicable	 data	 were	 also	 analysed	 by	 Dunnett’s	 multiple	
comparisons	test.	T-tests	were	performed	between	30-min	TRAP	vs	30-min	control	(A,	





expression	on	neutrophils	 in	 the	 “platelet	 gate”	 is	 significantly	 higher	 than	 the	GPIbα	
expression	of	platelets,	suggesting	that	neutrophils	bind	to	>1	platelets	(Fig.	4.9F).		
4.3.1.4 Formation	of	Aggregates	between	PEV	and	Lymphocytes	
We	 also	 investigated	 the	 behaviour	 of	 lymphocytes.	 The	 acquisition	 of	 PEV-
borne	 GPIbα	 by	 lymphocytes	 over	 the	 course	 of	 30	 minutes	 can	 be	 seen	 on	 the	
representative	flow	cytometry	dotplots	of	Fig.	4.10.	The	gate	for	GPIbα+ve	events	is	set	
according	to	expression	level	upon	staining	with	an	appropriate	isotype	antibody	(not	
shown).	There	 is	a	 small	percentage	of	 cells	 that	are	positive	 for	GPIbα	 in	 the	control	
samples.	 This	 increases	 to	 some	 degree	 at	 later	 time	 points,	 suggesting	 that	 some	
lymphocytes	 form	 aggregates	with	 platelets	 and/or	 PEV	upon	TRAP	 treatment	 in	 the	
blood.	However,	there	is	no	clear	trend	in	the	acquisition	rate	of	GPIbα.	




TRAP	 is	 statistically	 the	 same,	 suggesting	 that	 PEV	 do	 not	 form	 aggregates	 with	
lymphocytes.	As	a	consequence,	 time	of	 incubation	with	TRAP	does	not	have	an	effect	
on	the	percentage	of	lymphocyte-PEV	aggregates	(Fig.	4.12A).	











Gate	 of	 positive	 events	 was	 set	 by	 isotype	 sample	 (not	 shown).	 A	 0-min	 control	
(immediate	fixation)	and	a	30-min	control	(no	TRAP,	roller	mixing)	were	included.	
	
Figure	 4.11.	 	 GPIbα	 expression	 of	 lymphocytes	 over	 time	 in	 whole	 blood	 in	
response	to	whole	blood	stimulation	with	100μM	TRAP	
Representative	 FACS	 overlay	 histograms	 demonstrating	 GPIbα	 expression	 on	
lymphocytes	over	time	up	to	30	minutes	in	response	to	stimulation	with	100μm	TRAP	
under	 roller	 mixing.	 A	 0-min	 control	 (immediate	 fixation)	 and	 a	 30-min	 control	 (no	
TRAP,	roller	mixing)	were	 included.	The	GPIbα	expression	 trace	of	 resting	platelets	 is	
also	shown.	
The	 percentage	 of	 GPIbα+ve	 lymphocytes	 and	 the	 GPIbα	 expression	 intensity	
were	also	measured	separately	in	the	platelet	gate	and	in	the	PEV	gate	and	they	did	not	
change	upon	TRAP	treatment	(Fig.	4.12B,	C,	E,	F).	







Percentage	 of	 GPIbα+ve	 lymphocytes	 as	 a	whole	 (A),	 in	 the	 PEV	 gate	 (B)	 and	 in	 the	





effect	 of	 time,	 and	 where	 applicable	 data	 were	 also	 analysed	 by	 Dunnett’s	 multiple	
comparisons	test.	T-tests	were	performed	between	30-min	TRAP	vs	30-min	control	(A,	












4.13A).	 There	 is	minimal	 percentage	 of	 cells	 that	 are	 positive	 for	 GPIIb	 in	 the	 0-min	
sample.	There	 is	a	high	number	of	events	 in	the	GPIIb+ve	gate	 for	the	30-min	sample,	
suggesting	 that	 CD16-ve	monocytes	 form	 aggregates	with	 platelets	 and/or	 PEV	 upon	
TRAP	treatment	in	the	blood.		
A	 representative	 GPIIb	 expression	 histogram	 of	 the	 CD16-ve	 monocytes	 was	
analyzed	 in	 order	 to	 get	 deeper	 insights	 on	 the	 interaction	 between	 leukocytes	 and	
platelets	 and/	 or	 PEV	 (Fig.	 4.13B)	 The	 GPIIb	 expression	 trace	 of	 platelets	 is	 also	
overlaid	on	each	histogram	to	enable	us	determine	whether	leukocytes	bind	platelets	or	
PEV.	 The	 TRAP-treated	 sample	 shows	 higher	 expression	 of	 GPIIb	 compared	 to	 the	
control.	There	 is	bimodal	expression,	one	peak	of	 lower	and	one	of	higher	expression	






(A)	 Representative	 FACS	 dotplots	 demonstrating	 percentage	 of	 GPIIb+ve	 CD16-ve	
monocytes	 and	 (B)	 representative	 FACS	 overlay	 histograms	 demonstrating	 GPIIb	
expression	on	CD16-ve	monocytes	before	and	after	30	minutes	stimulation	with	100μm	







Platelet	 gate	 after	 treatment	 with	 TRAP.	 (B)	 Median	 GPIIb	 expression	 on	 CD16-ve	
monocytes	as	a	whole,	in	the	PEV	gate	and	in	the	Platelet	gate.	Data	are	represented	as	
mean	 +/-	 SEM	 of	 3	 experiments.	 All	 data	 were	 analysed	 by	 T-tests	 to	 determine	
difference	between	0-min	and	30-min	samples.	
Upon	 graphical	 analysis	 of	 a	 number	 of	 experiments,	 we	 observed	 that	 the	











in	 the	 blood	 (Fig.	 4.15A).	 The	 TRAP-treated	 sample	 also	 shows	 higher	 expression	 of	
GPIIb	compared	to	the	control.	There	is	bimodal	expression,	one	peak	of	lower	and	one	
of	 higher	 expression	 than	 the	 platelet	 expression.	 This	 result	 suggests	 that	 a	
subpopulation	 of	 CD16+ve	 monocytes	 binds	 preferentially	 to	 PEV,	 and	 another	
subpopulation	binds	to	platelets	(Fig.	4.15B).		
Upon	 graphical	 analysis	 of	 a	 number	 of	 experiments,	 we	 observed	 that	 the	
percentage	 of	 the	 whole	 CD16+ve	 monocyte	 population	 and	 the	 CD16+ve	 monocyte	
population	 in	 the	 PEV	 gate	 significantly	 increased	 upon	 treatment	 with	 TRAP	 (Fig.	







(A)	 Representative	 FACS	 dotplots	 demonstrating	 percentage	 of	 GPIIb+ve	 CD16+ve	
monocytes	 and	 (B)	 representative	 FACS	 overlay	 histograms	 demonstrating	 GPIIb	
expression	on	CD16-ve	monocytes	before	and	after	30	minutes	stimulation	with	100μm	







Platelet	 gate	 after	 treatment	 with	 TRAP.	 (B)	 Median	 GPIIb	 expression	 on	 CD16-ve	
monocytes	as	a	whole,	in	the	PEV	gate	and	in	the	Platelet	gate.	Data	are	represented	as	
mean	 +/-	 SEM	 of	 3	 experiments.	 All	 data	 were	 analysed	 by	 T-tests	 to	 determine	
difference	between	0-min	and	30-min	samples.	*	indicates	P	<	0.05.	
4.3.2.3 Formation	of	Aggregates	between	PEV	and	Neutrophils	
We	 also	 investigated	 the	 acquisition	 of	 PEV-borne	 GPIIb	 by	 the	 neutrophil	
population.	There	is	minimal	percentage	of	cells	that	are	positive	for	GPIIb	before	TRAP	
treatment	 and	 there	 is	 a	 high	 number	 of	 events	 in	 the	 GPIIb+ve	 gate	 for	 the	 30-min	




lower	 and	one	 of	 higher	 expression	 than	 the	platelet	 expression.	 This	 result	 suggests	
that	 a	 subpopulation	 of	 neutrophils	 binds	 preferentially	 to	 PEV,	 and	 another	
subpopulation	binds	to	platelets	(Fig.	4.17B).		
Upon	 graphical	 analysis	 of	 a	 number	 of	 experiments,	 we	 observed	 that	 the	







Figure	4.17.	 Formation	 of	 aggregates	 between	neutrophils	 and	platelets	 and/or	
PEV	in	whole	blood	in	response	to	treatment	with	100μM	TRAP	
(A)	 Representative	 FACS	 dotplots	 demonstrating	 percentage	 of	 GPIIb+ve	 neutrophils	
and	 (B)	 representative	 FACS	 overlay	 histograms	 demonstrating	 GPIIb	 expression	 on	

















The	 acquisition	 of	 PEV-borne	 GPIIb	 by	 the	 lymphocyte	 population	 was	 also	
investigated.	 There	 is	 minimal	 percentage	 of	 cells	 that	 are	 positive	 for	 GPIIb	 before	
TRAP	treatment	and	there	 is	a	 little	higher	number	of	events	 in	 the	GPIIb+ve	gate	 for	
the	30-min	sample,	suggesting	that	lymphocytes	form	aggregates	with	platelets	and/or	
PEV	upon	TRAP	treatment	in	the	blood	to	a	small	extent	(Fig.	4.19A).	The	TRAP-treated	
sample	 shows	 a	 little	 higher	 expression	 of	 GPIIb	 compared	 to	 the	 control.	 There	 is	
bimodal	expression,	one	peak	of	 lower	and	one	of	higher	expression	 than	 the	platelet	
expression.	 This	 result	 suggests	 that	 a	 small	 subpopulation	 of	 neutrophils	 binds	
preferentially	to	PEV,	and	another	small	subpopulation	binds	to	platelets	(Fig.	4.19B).		
Upon	 graphical	 analysis	 of	 a	 number	 of	 experiments,	 we	 observed	 that	 the	
percentage	of	the	whole	neutrophil	population	and	the	neutrophil	population	in	the	PEV	
gate	 significantly	 increased	 upon	 treatment	 with	 TRAP	 (Fig.	 4.20A).	 However,	 the	







and	 (B)	 representative	 FACS	 overlay	 histograms	 demonstrating	 GPIIb	 expression	 on	







gate	 after	 treatment	 with	 TRAP.	 (B)	 Median	 GPIIb	 expression	 on	 lymphocytes	 as	 a	
whole,	in	the	PEV	gate	and	in	the	Platelet	gate.	Data	are	represented	as	mean	+/-	SEM	of	




to	 form	aggregates	with	 leukocytes	was	 investigated.	 CPDA-anticoagulated	blood	was	
incubated	 under	 conditions	 of	 roller	 mixing	 at	 37°C	 in	 the	 presence	 of	 the	 platelet	
stimulant	TRAP	in	order	to	cause	PEV	shedding	and	to	investigate	the	binding	of	these	
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PEV,	 if	 any,	 to	 leukocytes.	 Heterotypic	 aggregation	 was	 detected	 by	 FACS,	 based	 on	
presence	of	platelet/PEV-borne	GPIb	or	GPIIb	on	the	leukocytes.	
It	has	been	shown	that	the	anticoagulant	used	critically	affects	measurement	of	





allow	 platelets	 to	 recover	 efficiently;	 hence	 platelet	 activation	 and	 associated	 PEV	
release	would	 be	 inhibited.	 Heparin	 on	 the	 other	 hand	 has	 a	 different	mechanism	 of	
action;	 it	 binds	 and	 enhances	 the	 inhibitory	 activity	 of	 plasma	 antithrombin	 against	
several	 serine	 proteases	 of	 the	 coagulation	 system	 such	 as	 thrombin	 and	 factor	 Xa.	
Heparin-anticoagulated	 blood	 was	 found	 to	 contain	 the	 highest	 level	 of	 platelet-
leukocyte	complexes	at	basal	levels	(Basavaraj	et	al.,	2012).	Hence,	CPDA	seemed	to	be	
the	best	choice.	
The	 percentage	 of	 leukocytes	 acquiring	 GPIb	 or	 GPIIb	 in	 the	 blood	 increased	
significantly	 with	 addition	 of	 TRAP.	 Based	 on	 fluorescence	 intensity	 readings,	 we	
discovered	 that	 leukocytes	 acquired	 GPIb	 /	 GPIIb	 in	 quanta	 that	 are	 significantly	
smaller	than	whole	platelets	at	resting	conditions.	This	suggested	that	leukocytes	bound	
PEV.	 This	 result	 agrees	with	 our	 data	 from	 Chapter	 3,	where	 it	was	 shown	 that	 PEV	
carry	 significantly	 lower	 GPIbα	 and	 GPIIb	 cargo	 than	 platelets.	 It	 has	 already	 been	
shown	 that	 platelet	 activation	 causes	 the	 release	 of	 GPIb+ve	PEV	 (Flaumenhaft	 et	 al.,	





these	molecules.	However	 this	 cannot	 be	 true	 as	 platelet	 activation	with	TRAP	 in	 the	
blood	 resulted	 not	 in	 a	 single	 but	 in	 two	 GPIb/GPIIb+ve	 expression	 curves	 on	 the	
leukocytes,	with	 the	higher	expression	curve	being	at	 the	 levels	of	resting	platelets	or	
even	 higher,	 and	 the	 lower	 expression	 curve	 lying	 at	 significantly	 lower	 expression	
levels	 than	 resting	 platelets.	 This	 suggested	 the	 presence	 of	 two	 distinct	 GPIb-	 or	
GPIIb+ve	populations	i.e.	platelets	and	PEV.		
Leukocyte-platelet/PEV	 aggregation	 before	 any	 treatment	 upon	 immediate	
fixation	after	venepuncture	was	minimal	 in	our	experiments.	Overall,	PEV	exhibited	a	
preferential	 affinity	 for	binding	monocytes.	 Lymphocytes	 exhibited	 the	 lowest	 affinity	
for	forming	heterotypic	aggregates	with	PEV	and	neutrophils	exhibited	an	intermediate	
affinity.	
The	 two	main	monocyte	 subsets	exhibited	similar	but	not	 identical	patterns	of	




expressed	 between	 CD16+	 and	 CD16-	 monocytes,	 resulting	 in	 functional	 differences	
between	them	(Zhao	et	al.,	2009),	hence	their	differential	interaction	with	PEV	at	times	
could	be	the	result	of	differential	expression	of	surface	receptors.	







of	 whole	 platelets	 bound	 to	 leukocytes	 (mainly	 monocytes)	 even	 without	 activation	
with	 a	 stimulant	 if	 blood	 was	 left	 under	 static	 conditions.	 However	 when	 shear	 is	
imposed	on	the	previously	static	blood,	the	platelet	unbind	from	leukocytes.	Indeed,	in	
our	 experiments	 with	 TRAP	 we	 detected	 low	 levels	 of	 whole	 platelets	 bound	 to	
leukocytes	and	the	signal	from	these	platelets	decreased	with	time	of	incubation	under	
low	shear	stress	conditions.		
In	 this	 study,	we	used	 a	 combination	 of	 CD14	 and	CD16	 expression	 as	well	 as	
forward	 scatter	 and	 side	 scatter	 characteristics	 to	 differentiate	 between	 leukocyte	
types.	 Another	 study	 used	 pan-leukocyte	 marker	 CD45	 gating	 combined	 with	 side	
scatter	 to	measure	 platelet-leukocyte	 aggregates	 by	 flow	 cytometry	 (Nagasawa	 et	 al.,	
2013).	 Both	 gating	 strategies	 appear	 to	 be	 able	 to	 differentiate	 leukocyte	 types	
adequately.	 However,	 CD45	 staining	 alone	 cannot	 differentiate	 between	 monocyte	
subsets.	
The	 number	 of	 PEV	 bound	 per	 monocyte/leukocyte	 could	 not	 be	 determined	
precisely	 in	 these	experiments	 as	we	used	a	Cyan	ADP	 to	 analyse	 leukocytes	 in	 lysed	
blood.	 A	 Cyan	 ADP	 cannot	 detect	 vesicles	 hence	 we	 could	 not	 compare	 fluorescence	
intensity	 of	 GPIb/GPIIb	 on	 a	 single	 PEV	 with	 fluorescence	 intensity	 of	 one	 of	 these	
markers	on	leukocytes	in	the	blood	to	get	an	idea	on	how	many	PEV	bound	leukocytes.	
Previous	 studies	 in	 our	 lab	 assessed	 the	 level	 of	 platelet/PEV-leukocyte	
aggregates	 in	 the	 blood	 in	 response	 to	 platelet	 activation	 using	 the	 thromboxane	
mimetic	 U46619,	 rhodocytin,	 ADP,	 CRP-XL	 and	 calf	 thymous	 histones	 (Box	 CL	 et	 al.,	
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2014).	 Rhodocytin,	 which	 is	 found	 in	 snake	 venom	 and	 activates	 platelets	 through	
binding	 the	 surface	 receptor	 CLEC-2	 (Suzuki-Inoue	 et	 al.,	 2006),	 appeared	 to	 be	 the	
most	 potent	 agonist,	 resulting	 in	 the	 highest	 number	 of	 monocyte-platelet/PEV	
aggregates.	 On	 the	 other	 hand,	 ADP,	 U46619	 and	 CRP-XL	 exhibited	 a	 much	 lower	
maximum	response.	A	lower	level	of	heterotypic	aggregates	was	expected	with	ADP	and	
the	 thromboxane	 mimetic	 as	 these	 are	 known	 to	 be	 weak	 activators	 (secondary,	
released	from	the	platelets).	
In	 this	 study	we	assumed	 that	 the	presence	of	 the	platelet	 receptors	GPIb	 and	
GPIIb	on	leukocytes	is	evidence	of	PEV	binding.	However	there	is	a	possibility	that	these	
















TRAP	results	 in	 the	 release	of	PEV	 from	platelets	 that	preferentially	 form	heterotypic	
aggregates	with	monocytes.	 Preferential	 affinity	 for	monocytes	 by	 PEV	 has	 been	 also	
recently	 observed	 in	 anti-coagulated	 whole	 blood	 that	 was	 stored	 for	 3	 hours	 upon	
collection	 (Weiss	 et	 al.,	 2018).	However,	 formation	of	PEV-leukocyte	 aggregates	upon	
exogenous	PEV	administration	has	not	been	exclusively	investigated	to	date.	
Eitan	 et	 al.,	 2017	 showed	 that	 incubation	 of	 plasma-derived	 EV	 with	 washed	
PBMCs	resulted	in	the	formation	of	aggregates	between	EV	and	monocytes	and	between	
EV	 and	 B	 cells.	 T	 cells	 did	 not	 form	 aggregates	 with	 the	 EV.	 A	 higher	 percentage	 of	
monocytes	aggregated	with	 the	plasma	EV	 than	B	 cells.	The	percentage	of	monocytes	
and	 B	 cells	 that	 aggregated	 with	 the	 plasma	 EV	 was	 dose-dependent	 and	 time-
responsive	 in	 the	assay.	 In	 these	experiments,	plasma	EVs	activated	monocytes	and	B	
cells.	Other	studies	have	found	that	EV	from	RBC	units	bound	to	purified	monocytes	but	
not	T-cells	when	incubated	together	in	culture	and	induced	pro-inflammatory	cytokine	
secretion	 (Danesh	 et	 al.,	 2013).	 In	 addition,	 EV	 from	 the	 blood	 of	 diabetes	 patients	
formed	preferential	aggregates	with	monocytes	than	with	the	rest	blood	cells	and	also	





whole	 platelets.	 However	 there	 is	 a	 possibility	 that	 these	 receptors	 were	 shed	 from	
platelets	independently	of	vesicles.	One	way	to	answer	this	question	would	be	to	label	a	
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interact	 with	 leukocytes,	 which	 are	 all	 available	 upon	 addition.	 When	 inducing	 PEV	
release	 in	 the	 blood	 with	 agonists	 or	 during	 prolonged	 storage,	 there	 is	 continuous	
shedding	 of	 PEV	 in	 the	 blood	 hence	 the	 number	 of	 PEV	 available	 to	 interact	 with	
leukocytes	 increases	 with	 time.	 In	 addition,	 incubation	 of	 exogenous	 PEV	 with	
leukocytes	allows	investigation	of	PEV	binding	independently	of	platelets.	Only	PEV	are	
labeled	in	theory	(given	that	purification	of	PEV	from	whole	platelets	is	efficient),	hence	














Purified	 PEV	 (produced	 from	 platelet	 stimulation	 with	 CRP-XL),	 stained	 with	
anti-GPIbα	antibody	or	PKH67	dye	were	incubated	with	CPDA-anticoagulated	blood	at	
37˚C	 on	 a	 roller	 mixer,	 either	 over	 the	 course	 of	 20	 minutes	 or	 for	 10	 minutes	 at	
different	concentrations	of	PEV	(from	2	x	107	PEV	to	2	x	1010	PEV	incubated	with	200μl	
of	blood)	in	order	to	generate	PEV-leukocyte	aggregates	and	investigate	the	dynamics	of	
the	 interaction.	Heterotypic	aggregation	was	detected	by	FACS	 (Cyan	ADP).	 Statistical	




Purified	 PEV	 were	 incubated	 with	 washed	 monocytes	 in	 phosphate	 buffered	
saline	with	Ca2+/Mg2+	(0.2μm	pore-filtered)	over	the	course	of	65	minutes	at	37˚C	on	a	
roller	 mixer	 in	 order	 to	 investigate	 the	 dynamics	 of	 heterotypic	 aggregation.	





Upon	 observing	 that	 platelet	 activation	 in	 the	 blood	 resulted	 in	 the	 release	 of	
PEV	 that	 form	 aggregates	 with	 leukocytes,	 preferentially	 monocytes,	 we	 wanted	 to	
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investigate	 this	 interaction	 in	 more	 detail.	 In	 this	 case,	 we	 generated	 purified	 PEV,	
stained	for	GPIbα,	and	incubated	them	with	blood,	under	shear	over	a	20-minute	time-




Representative	 flow	 cytometry	 dot-plots	 show	 acquisition	 of	 PEV	 by	 CD16-ve	
monocytes	 over	 the	 course	 of	 20	 minutes	 (Fig.	 5.1).	 There	 is	 negligible	 background	
signal	for	GPIbα	expression	before	PEV	addition	to	the	blood	(0-min	sample).	There	is	
clearly	a	higher	percentage	of	cells	positive		for	GPIbα	at	all	time	points	compared	to	the	
0-min	 control,	 hence	 exogenously-provided	 PEV	 are	 forming	 heterotypic	 aggregates	
with	the	CD16-ve	monocytes.	The	percentage	of	GPIbα-ve	CD16-ve	monocytes	increases	
with	time.	
We	 also	 analysed	 the	GPIbα	histograms	 of	 the	 CD16-ve	monocytes.	 The	 traces	
from	 each	 time	 point	 and	 controls	 were	 overlaid.	 The	 GPIbα	 expression	 trace	 of	
platelets	 was	 also	 overlaid	 on	 each	 histogram.	 The	 distribution	 curve	 is	 at	 all	 time	
points	 greatly	 shifted	 towards	 higher	 expression	 compared	 to	 the	 0-min	 control.	 The	
shift	becomes	 larger	with	 time	 (Fig.	 5.2A).	The	expression	at	all	 times	 is	 significantly	
lower	than	the	platelet	expression	indicating	that	CD16-ve	monocytes	are	only	binding	
PEV.	
The	 percentage	 of	 CD16-ve	 monocytes	 expressing	 GPIbα	 was	 analysed	
statistically.	 The	 percentage	 expressing	 GPIbα	 increases	 significantly	 by	 time	 of	
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incubation	 with	 PEV,	 hence	 formation	 of	 CD16-ve	monocyte-PEV	 aggregates	 is	 time-
dependent	(one-way	anova)	(Fig.	5.2B).		
	
Figure	 5.1.	 Formation	 of	 aggregates	 between	 CD16-ve	 Monocytes	 in	 blood	 and	
added	PEV	over	time		
Representative	 FACS	 dotplots	 demonstrating	 percentage	 of	 CD16-ve	 monocytes	
positive	 for	 GPIbα	 over	 time.	 Gate	 of	 positive	 events	was	 set	 by	 isotype	 sample	 (not	
shown).		
The	median	 fluorescence	 intensity	of	GPIbα	expression	on	CD16-ve	monocytes	
was	 also	 analysed	 statistically	 and	 found	 to	 increase	 significantly	 with	 time	 of	








CD16-ve	monocytes	 over	 time.	 (C)	 Median	 GPIbα	 expression	 on	 CD16-ve	monocytes	
and.	Data	are	represented	as	mean	+/-	SEM	of	3-4	experiments.	Data	were	analysed	by	
One-way	ANOVA	to	determine	effect	of	time.	All	data	were	analysed	by	One-way	ANOVA	
to	determine	 effect	 of	 time,	 and	by	Dunnett’s	multiple	 comparisons	 test.	 	 **	 indicates	
P<0.01.	
5.3.1.2 Formation	of	Aggregates	between	PEV	and	CD16+ve	Monocytes	









Figure	 5.3.	 Formation	 of	 aggregates	 between	 CD16+ve	monocytes	 in	 blood	 and	
added	PEV	over	time	
Representative	 FACS	 dotplots	 demonstrating	 percentage	 of	 GPIbα+ve	 CD16+ve	
monocytes	over	time.	Gate	of	positive	events	was	set	by	isotype	sample	(not	shown).		
The	 histogram	 of	 GPIbα	 expression	 is	 different	 for	 the	 CD16+ve	 monocytes	
compared	 to	CD16-ve	 (Fig.	 5.4A).	 	This	distribution	seems	 to	be	bimodal,	having	 two	
peaks,	even	though	the	peak	of	higher	expression	is	relatively	small.	This	peak	falls	at	











(A)	 Representative	 FACS	 overlay	 histograms	 demonstrating	 GPIbα	 expression	 on	
CD16+ve	 monocytes	 over	 time.	 The	 trace	 of	 platelets	 is	 overlaid.	 (B)	 Percentage	 of	
GPIIb+ve	 CD16+ve	 monocytes	 over	 time.	 (C)	 Median	 GPIbα	 expression	 on	 CD16+ve	
monocytes	and.	Data	are	represented	as	mean	+/-	SEM	of	3-4	experiments.	Data	were	




Interestingly,	 in	 this	 format	 of	 the	 PEV	 binding	 assay,	 we	 could	 not	 observe	
significant	 acquisition	 of	 GPIb	 on	 neutrophils	 (Fig.	 5.5	 and	 5.6).	 Although	 a	 small	
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population	 (<5%	 showed	 some	 positive	 staining,	 this	 was	 extremely	 low	 fluorescent	
intensity	and	was	not	significantly	different	from	untreated	control	samples).	
Lymphocytes	 showed	 a	 similar	 response,	 with	 a	 small	 population	 (1-2%)	











(A)	 Representative	 FACS	 overlay	 histograms	 demonstrating	 GPIbα	 expression	 on	
neutrophils	 over	 time.	 The	 trace	 of	 platelets	 is	 overlaid.	 (B)	 Percentage	 of	 GPIIb+ve	
neutrophils	 over	 time.	 (C)	 Median	 GPIbα	 expression	 on	 neutrophils.	 Data	 are	












Figure	 5.8.	 Formation	 of	 aggregates	 between	 Lymphocytes	 in	 blood	 and	
exogenously	provided	PEV	over	time		
(A)	 Representative	 FACS	 overlay	 histograms	 demonstrating	 GPIbα	 expression	 on	
lymphocytes	 over	 time.	 The	 trace	 of	 platelets	 is	 overlaid.	 (B)	 Percentage	 of	 GPIIb+ve	
lymphocytes	 over	 time.	 (C)	 Median	 GPIbα	 expression	 on	 lymphocytes.	 Data	 are	





monocytes	 in	a	 time-dependent	manner,	we	hypothesized	 that	 the	 formation	of	 these	
heterotypic	aggregates	depends	on	 the	number	of	PEV	 incubated	with	blood	and	 that	
there	is	a	threshold	beyond	which,	monocytes	can	no	longer	aggregate	with	any	more	
PEV.	 Hence,	 we	 added	 GPIbα-stained	 purified	 PEV	 into	 blood	 over	 a	 concentration	
gradient;	from	subphysiological	numbers	(2	x	108),	to	physiological	numbers	(2	x	1010)	




Representative	 flow	 cytometry	 dot-plots	 and	 histograms	 can	 be	 found	 in	
Supplementary	Material	 (Fig.	 12.1	 –	 12.5).	 The	 percentage	 of	 leukocytes	 expressing	
GPIbα	and	the	median	fluorescence	intensity	of	GPIbα	from	a	number	of	experiments	on	
the	different	 leukocyte	populations	 is	 shown	 in	Fig.	 5.10.	 The	percentage	of	CD16-ve	
and	 CD16+ve	 monocytes	 and	 that	 of	 neutrophils	 expressing	 GPIbα	 increases	











different	 leukocyte	 populations.	 Data	 are	 represented	 as	 mean	 +/-	 SEM	 of	 3-4	
experiments.	 Data	 were	 analysed	 by	 One-way	 ANOVA	 to	 determine	 effect	 of	 PEV	








the	 formation	of	 aggregates	with	 leukocytes	due	 to	 the	 comparable	 size	of	 antibodies	
with	the	smallest	of	exosomes.	In	addition,	PEV	were	about	75%	positive	for	GPIbα	as	
judged	by	 FACS,	whereas	PKH67	 lipophilic	 dye	was	 found	 to	 label	 100%	of	 PEV	 (see	
section	3.3.1).	Hence,	we	decided	to	repeat	 incubation	of	blood	with	washed	PEV,	 this	
time	 by	 staining	 with	 PKH67	 that	 marks	 the	 PEV	membrane,	 over	 the	 same	 20-min	
time-course.	 The	 PKH67	 dye	 was	 used	 because	 it	 does	 not	 leak	 and	 it	 does	 not	 get	
transferred	from	cell	to	cell.	
Representative	 flow	 cytometry	 dot-plots	 and	 histograms	 can	 be	 found	 in	 the	
Supplementary	Material	(Fig.	12.6	–	12.10).	The	percentage	of	the	different	leukocytes	
expressing	PKH67	and	their	respective	fluorescence	intensity	is	shown	in	Figure	5.10.	
The	 percentage	 of	 CD16-ve	 and	 CD16+ve	 monocytes	 expressing	 PKH67	 increases	





Figure	 5.10.	 Formation	 of	 aggregates	 between	 leukocytes	 in	 blood	 and	
exogenously	provided	PEV	over	time		
(A)	Percentage	of	PKH67+ve	leukocytes	over	time.	(C)	Median	PKH67	expression	on	the	









Upon	observation	 that	PEV	 show	a	preferential	 affinity	 for	binding	monocytes,	




Representative	 flow	 cytometry	 dot-plots	 can	 be	 found	 in	 the	 Supplementary	
Material	(Fig.	12.11).	The	GPIbα	expression	histograms	for	CD16-ve	at	all	time	points	
are	shown	in	Figure	5.11A.	The	expression	profile	for	platelets	is	also	overlaid.	CD16-
ve	 monocytes	 exhibit	 one	 peaks	 of	 positive	 GPIbα	 expression;	 Lower	 than	 that	 of	
platelets.	 Hence,	 CD16-ve	monocytes	 aggregated	 with	 PEV.	 The	 expression	 profile	 of	
monocytes	 from	10	minutes	of	 incubation	onwards	 is	about	 the	same.	The	expression	
profile	of	monocytes	at	5	minutes	of	incubation	is	lower.	Hence,	heterotypic	aggregation	
is	 time-dependent,	 but	 after10	 minutes	 of	 incubation,	 monocytes	 reach	 a	 point	 of	
saturation.	
Upon	 statistical	 analysis,	 the	 percentage	 of	 CD16-ve	 monocytes	 was	 found	 to	
increase	 significantly	with	 time	 (Fig.	 5.11B).	 However,	 the	median	 GPIbα	 expression	
does	not	change	significantly	with	time	(Fig.	5.11C).	However,	there	seems	to	be	a	clear	
trend	with	CD16-ve	monocytes	acquiring	GPIbα	at	an	increasing	trend	up	to	20	minutes	













Representative	 flow	 cytometry	 dot-plots	 can	 be	 found	 in	 the	 Supplementary	
Material	(Fig.	12.12).	The	GPIbα	expression	histograms	for	CD16+ve	at	all	time	points	
are	shown	in	Figure	5.12A.	The	expression	profile	for	platelets	is	also	overlaid.	CD16-
ve	 monocytes	 exhibit	 one	 peak	 of	 positive	 GPIbα	 expression;	 Lower	 than	 that	 of	
platelets.	 Hence,	 CD16+ve	monocytes	 aggregated	with	 PEV.	 The	 expression	 profile	 of	
monocytes	 from	10	minutes	of	 incubation	onwards	 is	about	 the	same.	The	expression	
profile	of	monocytes	at	5	minutes	of	incubation	is	lower.	Hence,	heterotypic	aggregation	
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is	 time-dependent,	 but	 after10	 minutes	 of	 incubation,	 monocytes	 reach	 a	 point	 of	
saturation.	
Upon	 statistical	 analysis,	 the	 percentage	 of	 CD16-ve	 monocytes	 was	 found	 to	
increase	 significantly	with	 time	 (Fig.	 5.12B).	 However,	 the	median	 GPIbα	 expression	
does	not	change	significantly	by	time	(Fig.	5.12C).	However,	there	seems	to	be	a	clear	
trend	with	CD16-ve	monocytes	acquiring	GPIbα	at	an	increasing	trend	up	to	20	minutes	
of	 incubation,	 reaching	 a	maximum,	 and	 subsequently	 start	decreasing	 the	 amount	of	
GPIbα	on	them.	
	
Figure	 5.12.	 Formation	 of	 aggregates	 between	washed	 CD16+ve	monocytes	 and	
washed	PEV	over	time	
(A)	 Representative	 FACS	 overlay	 histograms	 demonstrating	 GPIbα	 expression	 on	
CD16+ve	 monocytes	 over	 time.	 The	 trace	 of	 platelets	 is	 overlaid.	 (B)	 Percentage	 of	
GPIbα+ve	 CD16+ve	monocytes	 over	 time.	 (C)	 Median	 GPIbα	 expression	 on	 CD16+ve	
monocytes.	 Data	 are	 represented	 as	 mean	 +/-	 SEM	 of	 3-4	 experiments.	 Data	 were	




The	potential	of	PEV	released	 from	activated	platelets	 to	 form	aggregates	with	
leukocytes	 was	 investigated.	 To	 our	 knowledge	 this	 was	 the	 first	 study	 to	 assess	
formation	 of	 aggregates	 between	 leukocytes	 and	 exogenously	 added	 PEV.	 PEV	 were	
produced	 from	 stimulation	 of	 washed	 platelets	 with	 CRP-XL	 and	 they	 were	
subsequently	 incubated	with	whole	 blood	 or	 washed	monocytes	 under	 conditions	 of	
roller	 mixing.	 Heterotypic	 aggregation	 was	 detected	 by	 FACS,	 based	 on	 presence	 of	
platelet/PEV	markers	on	the	leukocytes.	The	dynamics	of	this	experiment	are	different	
from	 the	 previous	 experiment	 in	 Chapter	 4	 where	 platelets	 were	 being	 stimulated	
continuously	in	the	blood,	and	blood	was	stained	for	platelet/PEV	markers	at	the	end	of	
incubation.	In	this	case,	PEV	were	exogenously	provided	so	that	a	stable	number	of	PEV	
to	 leukocytes.	 In	 addition,	 these	 PEV	 are	 purified	 and	 stained	 before	 incubation	with	
blood	so	that	platelet	contamination	is	limited	and	so	we	can	observe	only	stained	PEV-
leukocyte	interactions	without	platelet	interference.		
Overall,	 PEV	 exhibited	 a	 preferential	 affinity	 for	 binding	 monocytes.	 The	
neutrophils	 and	 the	 lymphocytes	 exhibited	 some	 indications	 of	 binding	 with	 PEV,	
however	this	behaviour	was	significantly	 lower	than	the	behaviour	of	monocytes.	The	
two	monocyte	subsets	exhibited	similar	mode	of	PEV	acquisition.	The	binding	of	PEV	to	
both	monocyte	 subsets	 is	 time-dependent	and	proportional	 to	 the	PEV	concentration.	
These	results	agree	with	our	results	in	Chapter	4.	
Presence	 of	 PEV	 on	 the	monocytes	was	 confirmed	 by	 antigen	 expression	GPIb	












them	 but	we	 do	 not	 know	 if	 this	 is	 also	 true	 for	 the	 smaller	 PMV	 that	 could	 not	 get	
detected	 by	 flow	 cytometry	 and	 the	 exosomes.	 A	 higher	 percentage	 of	 aggregates	
between	monocytes	 and	PEV	was	 also	 noted	when	PEV	were	 incubated	with	washed	














Presence	 of	 PEV-borne	GPIbα	 in	monocytes	 raised	 the	 critical	 prospect	 of	 this	
adopted	GPIbα	being	functional.	GPIbα	is	part	of	the	GPIb-IX	complex	receptor	for	von	
Willebrand	 factor	 (VWF)	 that	mediates	 initial	 platelet	 binding	 to	 the	 subendothelium	
(Savage	et	al.;	1996;	Savage	et	al.,	1998;	Morrison	et	al.,	2014).	Indeed,	further	studies	
from	 our	 group	 revealed	 that	 perfusion	 of	 monocytes	 ‘decorated’	 with	 PEV	 across	
immobilised	 human	 VWF	 resulted	 in	 significantly	 higher	 monocyte	 recruitment	
compared	 to	 monocytes	 perfused	 alone.	 This	 behaviour	 was	 GPIbα-dependent	 as	
monocyte	 recruitment	 was	 inhibited	 by	 the	 use	 of	 a	 function-neutralizing	 antibody	
















In	 chapters	 4	 and	 5,	 it	 was	 found	 that	 PEV	 are	 able	 to	 form	 aggregates	 with	
leukocytes,	 preferentially	 monocytes.	 Experiments	 using	 acid	 (Feng	 et	 al.,	 2010)	 or	
trypsin	 (Franzen	 et	 al.,	 2014)	 that	 strip	 surface-bound	 EV	 off	 and	 staining	 EV	 with	
fluorescent	lipid	membrane	dyes	such	as	PKH67	(Na	̈slund	et	al.,	2014;	Christianson	et	
al.,	 2013)	 have	 proven	 microscopically	 that	 EV	 in	 general	 are	 largely	 endocytosed.	
Hence,	we	speculated	that	PEV	could	also	get	endocytosed	in	monocytes. 
Endocytosis	 is	 the	 internalisation	 of	 extracellular	 material	 without	 passing	




plasma	 membrane-derived	 vacuoles	 called	 phagosomes.	 Upon	 detachment	 from	 the	
plasma	 membrane,	 the	 phagosomes	 fuse	 with	 endosomes	 and	 lysosomes,	 forming	
phagolysosomes,	 which	 degrade	 the	 internalized	 particles	 (Botelho	 and	 Grinstein,	
2011).	 This	 process	 is	 largely	 and	 efficiently	 used	 by	 monocytes,	 macrophages	 and	




Macropinocytosis	 is	 a	 non-selective	 mechanism	 of	 extracellular	 fluid	
internalisation	 associated	 with	 cell	 surface	 ruffling.	 	 It	 is	 actin-driven,	 induced	 by	
activation	of	growth	factor	signalling	pathways	and	requires	Na+/H+	exchanger	activity		
(Kerr	 and	 Teasdale,	 2009).	 Extracellular	 material	 is	 endocytosed	 as	 part	 of	 the	
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Caveolin-dependent	 endocytosis	 involves	 caveolae,	 which	 are	 small	 cave-like	
invaginations	of	the	plasma	membrane,	which,	like	clathrin-coated	pits,	get	internalised	
in	 the	 cytoplasm.	 Caveolae	 are	 mainly	 composed	 of	 cholesterol,	 sphingolipids	 and	
proteins	 of	 the	 caveolin	 gene	 family	 (caveolin-1.	 -2,	 -3)	 (Kiss	 and	 Botos,	 2009).	 This	
route	has	been	shown	to	facilitate	the	entry	of	nanoparticles	up	to	100	nm	in	diameter	
(Wang	 et	 al.,	 2009).	 Clathrin-	 and	 caveolin-dependent	 endocytosis	 both	 require	
dynamin2	 for	 the	 formation	and	expansion	of	 the	endocytic	vesicles	and	 its	 inhibition	
ablates	endocytosis	(Barre’s	et	al.,	2010).	
EV	have	also	been	shown	to	gain	entry	for	their	cargo	in	recipient	cells	by	non-
endocytic	 pathways	 i.e.	 by	 EV	 membrane	 fusion	 with	 the	 plasma	 membrane	 of	 the	
recipient	 cells,	 followed	 by	 EV	 cytosol	 merging	 with	 the	 recipient	 cell	 cytoplasm	
(Montecalvo	et	al.,	2012).	
	 139	
It	 is	 important	 to	 discover	 the	 internalisation	mechanism	 as	 it	 determines	 the	
trafficking	 and	 intracellular	 fate	 of	 particles.	 EV	 uptake	 is	 affected	 by	 EV	 size,	 shape,	
material	 and	 surface	 coating	 and	 acceptor	 cell	 type,	 age	 and	 cellular	 environment	




Extracellular	 matter	 is	 mainly	 internalised	 by	 phagocytosis	 or	 macropinocytosis	 that	
depend	largely	on	the	actin-mediated	remodelling	of	the	cell	membrane,	or	by		clathrin-
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mediated	 endocytosis	 and	 caveolin-mediated	 endocytosis	 that	 depend	 on	 dynamin-
mediated	formation	of	endocytic	vesicles.	
PEV	internalisation	investigation	by	monocytes	could	provide	us	with	insights	on	
atherosclerosis	pathology	as	 it	could	be	 linked	to	the	dysregulation	of	 the	LDL	uptake	
cycle.	In	normal	cells,	the	low-density	lipoprotein	receptor	mediates	the	endocytosis	of	
LDL,	which	 provides	 the	 cells	with	 the	 essential	 lipids	 to	 be	 used	 for	 growth	 of	 their	
membranes	 and	 as	 an	 energy	 source.	 The	 LDL	 is	 transferred	 to	 late	 endosomes	 and	
lysosomes,	where	lysosomal	enzymes	digest	the	cholesteryl	esters	of	the	LDL,	releasing	
cholesterol	and	fatty	acids	(Goldstein	and	Brown,	2009).	The	cholesterol	is	either	stored	
in	 the	macrophages	as	cholesteryl	esters	 in	 lipid	droplets	or	effluxed	to	HDL	particles	
that	transfer	it	to	the	liver	(Maxfield	and	Tabas,	2005).	
In	 atherosclerosis,	 this	 process	 is	 dysregulated.	 Macrophages	 internalise	
excessive	 amounts	 of	 LDL,	 their	 cytoplasm	becomes	 filled	with	 cholesteryl	 ester	 lipid	
droplets	and	 they	enlarge	and	eventually	 the	cells	die	of	 intracellular	stress	 (Maxfield	
and	Tabas,	2005;	Moore	and	Tabas,	2011).		
Platelets	 contain	 lysosomes	 that	 digest	 phagocytic	 and	 cytosolic	 components,	
similarly	 to	 nucleated	 cells.	 The	 function	 of	 platelet	 lysosomes	 has	 not	 been	 studied	
well,	 but	 platelet	 lysosomal	 glycohydrolases	 were	 found	 to	 be	 released	 “in	 vivo”	 in	
humans	 upon	 platelet	 activation	 (Ciferri	 et	 al.,	 2000).	 In	 addition,	 platelet-specific	
ablation	of	PIKfyve	kinase,	whose	activity	 is	essential	 for	vesicle	 trafficking	and	cargo	
transport	along	the	endosomal-lysosomal	pathway	(McCartney	et	al.,	2014),	resulted	in	
impaired	 lysosomal	 secretion	 associated	 with	 accelerated	 arterial	 thrombosis	 and	
macrophage	accumulation	(Sang	et	al.,	2014).	Hence,	there	seems	to	be	a	link	between	
platelet	lysosomes	and	macrophage	action	in	atherosclerosis	and	we	further	speculate	













a)	 first	 stained	 with	 anti-GPIbα	 antibody	 for	 30	 minutes	 before	 fixation	 and	
permeabilisation	 (this	 procedure	 lasted	 30	 minutes),	 or	 b)	 were	 first	 fixed	 and	
permeabilised	 and	 secondly	 stained	 with	 anti-GPIbα	 antibody.	 All	 monocytes	 were	
analysed	 by	 FACS	 (Cyan	 ADP)	 to	 measure	 surface	 PEV	 signal	 and	 total	 PEV	 signal	
(surface	 +	 intracellular).	 Statistical	 analysis	was	 performed	using	Graph	Pad	Prism	6.	
(For	further	detail	see	methods	chapter	3).	
6.2.2 Imaging	of	internalised	PEV	
Purified	 PEV	 (unstained	 or	 stained	 with	 the	 lipophilic	 PKH67	 dye)	 were	
incubated	with	washed	monocytes	for	30	minutes	at	37˚C	on	a	roller	mixer.	Monocytes	
were	then	centrifuged	to	remove	unbound	PEV	and	were	cultured	in	plates	at	37°C	for	
30	minutes	 or	 as	 indicated.	 The	 cells	were	 then	 fixed	 and	 stained	with	 anti-GPIbα	or	
isotype	control,	 anti-CD14	antibody,	anti-LAMP1	(lysosomal	marker),	 and	DAPI	 in	 the	
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presence	of	FcR	blocking	reagent.	Monocytes	were	 imaged	using	confocal	microscopy.	
Images	 were	 analysed	 using	 FIJI	 software.	 Statistical	 analysis	 was	 performed	 using	
Graph	Pad	Prism	6.	(For	further	detail	see	methods	chapter	2).	
6.2.3 Inhibition	of	Endocytosis	




either	 a)	 first	 stained	 with	 anti-GPIbα	 antibody	 for	 30	 minutes	 before	 fixation	 and	
permeabilisation	(this	procedure	lasted	30	minutes)	in	the	presence	of	the	inhibitors,	or	
b)	 were	 first	 fixed	 and	 permeabilised	 in	 the	 presence	 of	 the	 inhibitors	 and	 secondly	
stained	with	anti-GPIbα	antibody.	All	monocytes	were	analysed	by	FACS	(Cyan	ADP)	to	
measure	 surface	 PEV	 signal	 and	 total	 PEV	 signal	 (surface	 +	 intracellular).	 Statistical	




In	 order	 to	 determine	 whether	 PEV	 get	 internalized	 into	 monocytes	 the	 PEV	








The	 GPIbα	 histograms	were	 also	 analyzed.	 The	 traces	 of	 the	 surface	 and	 total	
expression	were	overlaid.	The	distribution	curve	 is	shifted	 towards	higher	expression	
for	the	total	expression	sample	compared	to	the	surface	expression	(Fig.	6.2B).	
The	 percentage	 of	 GPIbα+ve	 events	 and	 the	 median	 GPIbα	 expression	 were	





















(A)	 Representative	 FACS	 dotplots	 indicating	 percentage	 of	 cells	 expressing	 GPIbα	 on	
their	 surface	 and	 total	 (surface	 and	 intracellular)	 GPIbα	 expression	 upon	 30	minutes	
incubation	with	 PEV.	 (B)	 Representative	 FACS	 overlay	 histograms	 demonstrating	 the	
surface	 and	 the	 total	 GPIbα	 expression.	 (C)	 Percentage	 of	 cells	 expressing	 GPIbα	 on	
their	 surface	 and	 total	 GPIbα	 expression	 and	 (D)	median	GPIbα	 expression.	Data	 are	





(A)	 Representative	 FACS	 dotplots	 indicating	 percentage	 of	 cells	 expressing	 GPIbα	 on	
their	 surface	 and	 total	 (surface	 and	 intracellular)	 GPIbα	 expression	 upon	 30	minutes	
incubation	with	 PEV.	 (B)	 Representative	 FACS	 overlay	 histograms	 demonstrating	 the	
surface	 and	 the	 total	 GPIbα	 expression.	 (C)	 Percentage	 of	 cells	 expressing	 GPIbα	 on	
their	 surface	 and	 total	 GPIbα	 expression	 and	 (D)	median	GPIbα	 expression.	Data	 are	











aggregated	 with	 PEV.	 Aggregated	 monocytes	 were	 stained	 for	 GPIbα	 (Fig.	 6.4A)	 to	
visualise	PEV	or	with	an	isotype	control	(Fig.	6.4B)	to	check	for	any	non-specific	signal	
in	 the	 green	 channel.	 Each	 successive	 frame	 shows	 signal	 0.6μm	deeper	 into	 the	 cell.	
Individual	 cells	 were	 identified	 by	 a	 DAPI-stained	 nucleus	 and	 CD14-stained	 surface	
(not	 shown	 on	 the	 z-stack	 frames).	 Clearly,	 numerous,	 distinct,	 green	 dots	 appear	 at	
different	frames	of	the	z-stack,	away	from	the	top	(frame	1)	and	bottom	(frame	10)	cell	








The	 signal	 intensity	 in	 the	 green	 channel	 per	 cell	 and	 the	 individual	 particles	
were	analyzed	using	the	FIJI	software	and	are	shown	graphically	in	Fig.	6.6.	The	signal	
intensity	 in	 the	 green	 channel	 is	 significantly	 higher	 in	 the	 GPIbα-stained	 aggregates	
compared	 to	 the	 isotype	 control	 (Fig.	 6.6A).	 The	 number	 of	 particles	 per	 cell	 is	 not	
higher	 in	 the	 GPIbα-stained	 sample	 compared	 to	 the	 isotype	 control	 (Fig.	 6.6B),	




Figure	 6.4.	 GPIbα	 distribution	 in	 monocytes	 after	 1	 hour	 of	 initial	 PEV	
introduction	






Figure	 6.5.	 GPIbα	 distribution	 in	 monocytes	 after	 1	 hour	 of	 initial	 PEV	
introduction	
Representative	composite	images	from	z-stacks	of	monocyte-PEV	aggregates.	PEV	were	







Mean	 expression	 of	 GPIbα	 or	 isotype	 control	 per	 monocyte	 (A),	 number	 (B)	 and	
average	 particle	 size	 (C)	 upon	 staining	with	 GPIbα	 or	 isotype	 control	 as	 determined	





aggregated	 with	 PEV.	 PEV	 were	 stained	 with	 the	 PKH67	 dye	 before	 incubation	 with	











DAPI-stained	 nucleus	 (Fig.	 6.8B).	 An	 unstained	 sample	 was	 considered	 to	 be	 an	
adequate	 control	 because	 the	 PKH67	 dye	 showed	 no	 signs	 of	 “leaking”	 out	 of	 the	
vesicles	 in	 Chapter	 5,	 as	 judged	 from	 the	 fact	 that	 lymphocytes	 for	 example	 did	 not	
acquire	significant	PKH67	signal	upon	incubation	with	exogenous	PKH67-stained	PEV.	
The	 signal	 intensity	 in	 the	 green	 channel	 per	 cell	 and	 the	 individual	 particles	
were	analyzed	using	the	FIJI	software	and	are	shown	graphically	in	Fig.	6.9.	The	signal	
intensity	 in	 the	 green	 channel	 is	 significantly	 higher	 in	 the	 PKH67-stained	 sample	
compared	 to	 the	unstained	 control	 (Fig.	 6.9A).	The	number	of	particles	per	 cell	 (Fig.	





























After	observing	 that	PEV	get	 internalized	 into	monocytes,	we	wondered	where	
they	 end	 up	 inside	 the	 monocytes;	 whether	 they	 get	 transferred	 into	 lysosomes	 for	
degradation	or	whether	they	get	recycled	and	used	somewhere	by	monocytes?	In	order	














Representative	 composite	 images	 from	 z-stacks	 of	 monocyte-PEV	 aggregates.	






however	 even	 after	 20	 hours,	 the	 colocalization	 value	 is	 low	 meaning	 that	 a	 small	
number	of	PEV	 (≈25%)	 colocalize	with	 lysosomes;	most	of	 them	do	not	 (Fig.	 6.11A).	
The	number	of	individual	GPIbα+ve	particles	was	also	counted	at	each	time	point	using	
FIJI	 software	 and	 was	 found	 not	 to	 change	 significantly	 with	 time.	 In	 addition,	 the	




(A)	 Pearson’s	 colocalization	 coefficient	 of	 GPIbα	 and	 LAMP1	 as	 calculated	 using	 FIJI	
software	 in	 monocytes	 over	 time.	 (B)	 Number	 of	 GPIbα+ve	 particles.	 Data	 are	




















Representative	 FACS	dotplots	 indicating	 percentage	 of	monocytes	 that	 express	GPIbα	












expression	 on	 monocytes	 upon	 30	 minutes	 incubation	 with	 PEV	 in	 the	 presence	 of	
Cytochalasin	D	(C.D)	or	DMSO	control	which	blocks	actin	polymerization.	
The	 percentage	 of	 GPIbα+ve	 events	 and	 the	 median	 GPIbα	 expression	 were	
analyzed	 graphically	 and	 statistically	 (Fig.	 6.14).	 The	 percentage	 of	 surface	 and	 total	
expression	of	Cytochalasin	D	is	not	significantly	lower	than	the	percentage	of	the	DMSO	
expression	 (Fig.	 6.14A).	 	 The	 median	 total	 GPIbα	 expression	 in	 the	 presence	 of	

































The	 percentage	 of	 GPIbα+ve	 events	 and	 the	 median	 GPIbα	 expression	 were	












Representative	 FACS	dotplots	 indicating	 percentage	 of	monocytes	 that	 express	GPIbα	


























The	role	of	sodium/proton	exchanger,	which	 is	 important	 in	macropinocytosis,	










The	 percentage	 of	 GPIbα+ve	 events	 and	 the	 median	 GPIbα	 expression	 were	
analyzed	 graphically	 and	 statistically	 (Fig.	 6.20).	 The	 percentage	 of	 surface	 and	 total	











Figure	 6.18.	 Role	 of	 the	 sodium/proton	 exchanger	 on	 the	 uptake	 of	 PEV	 by	
Monocytes	
Representative	 FACS	dotplots	 indicating	 percentage	 of	monocytes	 that	 express	GPIbα	
on	 their	 surface	 and	 total	 (surface	 and	 intracellular)	 GPIbα	 expressionn	 upon	 30	












Figure	 6.20.	 Role	 of	 the	 sodium/proton	 exchanger	 on	 the	 uptake	 of	 PEV	 by	
Monocytes	
Percentage	 of	 monocytes	 that	 express	 GPIbα	 on	 their	 surface	 and	 total	 GPIbα	
expression	(A)	and	median	GPIbα	expression	(B)	upon	30	minutes	incubation	with	PEV	
in	 the	presence	of	EIPA,	which	 inhibits	 the	action	of	 the	sodium/proton	exchanger	or	
DMSO	control.	Data	 are	 represented	as	mean	+/-	 SEM	of	3	 experiments.	T-tests	were	
performed	between	surface	and	total	expression	with	EIPA,	between	surface	expression	
of	DMSO	vehicle	and	surface	expression	of	EIPA	and	between	total	expression	of	DMSO	













observe	 that	 the	 percentage	 of	 GPIbα+ve	 events	 decreases	 in	 the	 Dynasore-treated	
samples.	
The	 GPIbα	 histograms	were	 also	 analyzed.	 The	 traces	 of	 the	 surface	 and	 total	
expression	 of	 DMSO	 and	 Dynasore	 were	 overlaid.	 The	 distribution	 curve	 is	 shifted	
towards	lower	total	expression	for	the	Dynasore-treated	sample	compared	to	the	DMSO	
control	(Fig.	6.22).	The	surface	curve	is	the	same	for	both	samples.	
The	 percentage	 of	 GPIbα+ve	 events	 and	 the	 median	 GPIbα	 expression	 were	
analyzed	 graphically	 and	 statistically	 (Fig.	 6.23).	 The	 percentage	 of	 surface	 and	 total	




surface	GPIbα	 expression	 of	 the	 control,	 however	 it	 does	 not	 reach	 significance.	 	 The	
median	 total	GPIbα	expression	 in	 the	presence	of	Dynasore	 is	not	 significantly	higher	






Representative	 FACS	dotplots	 indicating	 percentage	 of	monocytes	 that	 express	GPIbα	
on	 their	 surface	 and	 total	 (surface	 and	 intracellular)	 GPIbα	 expressionn	 upon	 30	


















expression	 with	 Dynasore,	 between	 surface	 expression	 of	 DMSO	 vehicle	 and	 surface	






and	 total	 GPIbα	 signal	 revealed	 that	 the	 majority	 of	 GPIbα	 molecules	 were	 located	
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intracellularly.	 This	 observation	 was	 not	 surprising	 as	 EV	 in	 general	 are	 largely	
endocytosed	 by	 various	 cells	 (Feng	 et	 al.,	 2010;	 Franzen	 et	 al.,	 2014;	Na	̈slund	 et	 al.,	
2014;	Christianson	et	al.,	2013).		
The	 two	 main	 monocyte	 subsets;	 CD16-ve	 and	 CD16+ve,	 exhibited	 the	 same	
capacity	 to	 internalise	PEV.	This	 is	 in	contrast	 to	 the	 literature	where	one	subset	(not	
always	the	same	one)	is	shown	to	be	more	phagocytic	than	the	other	(Mosig	et	al.,	2008;	
Mukherjee	 et	 al.,	 2015;	 Boyette	 et	 al.,	 2017).	 However,	 this	 observation	 led	 us	 to	
speculate	that	PEV	get	internalized	in	a	non-phagocytotic	mechanism.		
In	 order	 to	 shed	 some	 light	 on	 the	 post-internalisation	 fate	 of	 PEV,	 PEV	were	
imaged.	 Confocal	 imaging	 of	 monocyte-PEV	 aggregates	 revealed	 the	 presence	 of	
numerous	 GPIbα+ve	 particles	 in	 the	 microvesicle	 size	 range	 (100-200nm	 diameter),	
scattered	throughout	the	cells.	Labeling	PEV	with	the	lipophilic	dye	PKH67	resulted	in	




GPIbα	 antibody,	 associate	 with	 proteins.	 Different	 EV	 molecules	 might	 separate	 and	
have	different	post-internalization	fate	inside	the	monocytes.	A	study	deduced	that	EV	
proteins	 start	 separating	 from	 the	 EV	membrane	within	 3	 hours	 of	 endocytosis.	 The	
separation	occurred	possibly	by	fusion	of	EV	to	endosome	or	acidified	environment	in	










There	 is	 concern	 that	 the	 presence	 of	 fluorescent	 molecules	 in	 membrane-
binding	 dyes	 or	 the	 presence	 of	 antibodies	 might	 affect	 the	 behavior	 of	 EV.	 The	
fluorescent	molecules	from	the	lipophilic	dyes	might	 in	theory	leach	from	EV	onto	the	
recipient	 cell’s	 plasma	 membrane.	 A	 significant	 improvement	 to	 our	 experiment	 in	




presence	 of	 various	 endocytosis	 inhibitors.	 The	 chemical	 compound	 Cytochalasin	 D	
which	 depolymerizes	 F-actin	 and	 inhibits	 most	 endocytic	 pathways	 (phagocytosis,	
macropinocytosis	 and	 clathrin-dependent	 endocytosis)	 decreased	 significantly	
internalization	of	PEV	by	monocytes,	however	 the	chemical	compound	Ly294002	that	
inhibits	phagocytosis	only,	by	blocking	 the	action	of	PI3Ks,	did	not	have	any	effect	on	
the	 uptake	 of	 PEV	 by	 monocytes.	 Hence,	 it	 is	 most	 likely	 that	 PEV	 do	 not	 get	
endocytosed	by	phagocytosis	and	that	the	inhibitory	effect	observed	with	Cytochalasin	
D	is	attributed	to	macropinocytosis	or/and	clathrin-dependent	endocytosis.		
Contribution	of	macropinocytosis	was	 further	 confirmed	by	 the	use	of	 another	
chemical	 macropinocytosis	 inhibitor,	 EIPA,	 that	 acts	 by	 blocking	 the	 sodium/proton	
exchanger,	which	also	(partly)	inhibited	internalization	of	GPIbα.	Nonetheless,	EIPA	did	
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not	block	 internalization	of	PEV	 completely,	 suggesting	 that	PEV	get	 internalized	 into	
monocytes	via	non-macropinocytotic	mechanisms	as	well.	This	observation	agrees	with	
literature	where	EV	are	usually	taken	up	by	cells	via	more	than	one	mechanism	(Barre`s	
et	 al.,	 2010;	 Feng	 et	 al.,	 2010;	Morelli	 et	 al.,	 2004;	Tian	 et	 al.,	 2010;	Escrevente	 et	 al.,	
2011;	Hao	et	al.,	2007).	
Since	macropinocytosis	 blocking	 did	 not	 block	 PEV	 internalization	 completely,	




should	 include	 tracking	 of	 PEV	 into	 monocytes	 in	 real	 time,	 along	 with	 staining	 of	




transferred	 to	 the	 lysosomes	 for	 degradation.	 The	 distribution	 of	 GPIbα	 inside	 the	
monocytes	 (numerous	particles	 scattered	 throughout	 inside	of	 cells)	and	 the	 fact	 that	
PEV	were	 found	 to	be	 internalized	 into	monocytes	via	 endocytosis	 (macropinocytosis	
and	clathrin/caveolin-mediated	endocytosis)	led	us	to	speculate	that	PEV	might	end	up	
in	monocyte	lysosomes.	Such	an	observation	would	strengthen	our	hypothesis	that	PEV	
might	 contribute	 to	 the	 lysosomal	 dysfunction	 that	 might	 cause	 atherosclerosis.	
However,	 after	 1,	 3	 or	 20	 hours	 of	 initial	 introduction,	 GPIbα+ve	 molecules	 did	 not	
localize	 inside	 lysosomes.	There	seems	 to	be	a	variation	 in	 the	 time	 it	 takes	 for	EV	 to	
reach	 lysosomes.	EV	have	been	 shown	 to	 localize	 into	 lysosomes	2	hours	upon	 initial	
	 174	
introduction	 (Fitzner	 et	 al.,	 2011).	 However,	 another	 study	 found	 colocalized	 EV	
membrane	proteins	with	 lysosomes	12	hours	upon	 initial	EV	 introduction	(Tian	et	al.,	
2010)	and	another	study	 found	high	colocalization	(50-60%)	of	EV	with	 lysosomes	 in	
fibroblasts	after	48	hours	upon	addition	of	EV	(Heusermann	et	al.,	2016).	 	Hence	 it	 is	
possible	 that	 the	 time	 points	 in	 our	 experiment	were	 not	 appropriate.	 However,	 this	
might	be	 a	 true	 result.	The	GPIbα	protein	might	be	 recycled	by	monocytes.	 Indeed,	 it	
was	 found	 in	 our	 lab	 that	 monocytes	 pre-incubated	 with	 PEV	 bound	 to	 human	
immobilized	vWF	or	stimulated	cultured	endothelial	cells	in	flow	in	a	GPIbα-dependent	
way	(Chimen	et	al.,	unpublished).		
Uptake	 of	 EV	 by	 cells	 is	 usually	 mediated	 by	 protein-protein	 interactions.	
Platelets	 and	 monocytes	 contain	 various	 tetraspanins,	 integrins,	 immunoglobulins,	




Monocytes	 internalize	 PEV	 by	 macropinocytosis	 and	 clathrin/caveolin-
dependent	 endocytosis.	 Both	 CD16-ve	 and	 CD16+ve	 exhibit	 the	 same	 efficiency	 in	
internalizing	 PEV.	 The	 majority	 of	 PEV-derived	 GPIbα	 does	 not	 end	 up	 in	 monocyte	
lysosomes	upon	endocytosis.	Further	experimentation	and	 live	 tracking	 is	required	 to	









We	 have	 shown	 by	 FACS	 and	 confocal	 microscopy	 in	 Chapter	 6	 that	 PEV	 are	
internalized	 by	 monocytes.	 This	 raises	 the	 interesting	 prospect	 of	 transfer	 of	 PEV	
components	 that	 can	 affect	 monocyte	 behavior	 in	 atherosclerosis.	 An	 interesting	
observation	made	 by	 Boudreau	 et	 al.	 (2014)	 is	 the	 presence	 of	mitochondria	 in	 PEV.	
Upon	 internalization	 by	 neutrophils	 and	 subsequent	 hydrolysis	 of	 the	 PEV-derived	
mitochondrial	 membrane	 by	 the	 bactericidal	 phospholipase	 A2	 (PLA2	 IIA),	 different	
inflammatory	 stimuli	 were	 produced;	 in	 particular	 lysophospholipid,	 fatty	 acids	 and	
mtDNA.	These	mediators	activated	neutrophils	 in	vivo	 (Boudreau	et	al.,	2014)	and	are	
known	 to	 activate	 leukocytes	 and	 promote	 the	 progression	 of	 atherosclerosis.	Hence,	
we	hypothesized	that	PEV	can	transfer	platelet	mitochondria	to	monocytes	and	confer	
monocyte	mitochondrial	dysfunction,	associated	with	atherosclerosis.	
Mitochondria	 can	 regulate	 cell	 death,	 inflammation,	 ROS	 generation	 and	
metabolism.	Hence,	mitochondrial	 DNA	 (mtDNA)	 damage	 that	 leads	 to	mitochondrial	
dysfunction	 can	 directly	 promote	 atherosclerosis	 (Yu	 and	 Bennet,	 2014).	 ROS	 are	
responsible	for	oxidation	of	the	lipids	that	accumulate	at	sites	of	endothelial	damage	in	
atherosclerosis	and	are	mainly	generated	as	a	byproduct	of	mitochondrial	 respiration	




DNA	 and	 is	 located	 close	 to	 the	 site	 of	 ROS	 production,	 conditions	 that	 render	 it	
susceptible	 to	 damage.	 Damaged	 mtDNA	 was	 discovered	 in	 blood	 cells	 and	 in	
atherosclerotic	 plaques	 in	 patients	 with	 coronary	 artery	 disease	 and	 was	 associated	
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with	 high-risk	 plaques	 in	 humans,	 implying	 that	 it	 has	 a	 role	 in	 atherosclerosis	
progression	independently	of	ROS	(Botto	et	al.,	2005;	Corral-Debrinski	et	al.,	1992;	Yu	
et	al.,	2013).	 	Monocytes	exhibited	 increased	apoptosis	and	a	proinflammatory	status.	




of	 bases	 along	 its	 5’	 ->	 3’	 direction).	 These	 can	 act	 as	 DAMPs	 (damage-associated	
molecular	 patterns)	 and	 activate	 TLR9	 (Toll-like	 receptor	 9)	 (Zhang	 et	 al.,	 2010).	
Activated	 TLR9	 increases	 nuclear	 factor	 kappa	 B	 (NFκB)	 signaling	 that	 results	 in	
proinflammatory	cytokine	expression	(Oka	et	al.,	2012).	Mitochondrial	dysfunction	can	
promote	 inflammation	 also	 through	 activation	 of	 the	 NRLP3	 inflammasome	 through	
ROS,	 mtDNA	 release,	 cardiolipin	 release	 and	 by	 altering	 NAD/NADH	 ratios	 (Yu	 and	
Bennet,	2014).	
Mitochondrial	dysfunction	promotes	cell	apoptosis.	Apoptotic	signals	in	the	cells	




Mitochondria	 also	 affect	 metabolism.	 They	 do	 so	 by	 generating	 ATP	 using	
compounds	from	the	Krebs	cycle,	which	are	obtained	from	lipids,	sugars	and	proteins.	
Dysfunctional	 mitochondria	 that	 result	 in	 insufficient	 levels	 of	 ATP,	 lead	 to	 the	





Mitochondrial	 dysfunction	 can	 directly	 promote	 atherosclerosis.	 Dysfunctional	
mitochondria	produce	reactive	oxygen	species	(ROS),	release	cardiolipin	and	damaged	
mitochondrial	DNA	(mtDNA)	that	can	activate	the	NLRP3	inflammasome.	They	can	also	
release	 cytochrome	 C	 upon	 sensing	 apoptotic	 signals	 that	 further	 promotes	 cellular	




fission	 (division)	 forming	mitochondrial	networks.	 Integrity	of	 these	networks	 is	vital	
for	cell	survival	and	health.	Hence,	we	speculate	that	 internalized	PEV	into	monocytes	
transfer	mitochondria,	which	can	get	integrated	in	the	existing	mitochondrial	networks.	










Resting	 platelets	 were	 stained	 with	 MitoTracker	 dyes	 (Green/	 Deep	 Red)	 at	
different	concentrations	and	with	PKH67	dye	where	necessary	and	washed	extensively.	
Stained	 platelets	 were	 stimulated	 using	 CRP-XL/	 thrombin	 to	 shed	 PEV-containing	














by	 by	 FACS	 (Cyan	 ADP)	 and	 confocal	 microscopy.	 Images	 were	 analysed	 using	 FIJI	





enclosed	 in	vesicular	membranes	or	are	 “naked”	mitochondria,	platelets	were	 stained	
with	 the	 mitochondrial	 dye	 MitoTracker	 Deep	 Red	 and/or	 with	 the	 membrane	 dye	
PKH67	before	 stimulation	and	 subsequent	 shedding	of	PEV.	The	 level	of	 staining	was	
assessed	 by	 FACS.	 Fig.	 7.2	 shows	 representative	 histograms	 of	 MitoTracker	 Deep	
Red/PKH67	expression	by	PEV.	When	PEV	were	only	stained	with	MitoTracker,	>90%	
of	PEV	appeared	positive,	indicating	that	many	of	the	PEV	detectable	by	FACS	contained	
high	presence	of	mitochondria	 (Fig.	 7.2A,	 left	 histogram).	However,	when	PEV	were	
also	 stained	 with	 PKH67	 in	 order	 to	 see	 what	 percentage	 of	 the	 mitochondria	 were	
membrane-enclosed	 or	 not,	 the	 level	 of	 MitoTracker	 staining	 decreased	 by	
approximately	 one	 third	 (Fig.	 7.2A,	 right	 histogram).	 All	 MitoTracker+ve	 particles	
were	also	positive	for	PKH67,	indicating	that	mitochondria	were	always	shed	within	an	
envelopeof	platelet	membrane	(Fig.	7.2B,	left	histogram).	When	PEV	were	stained	only	
with	 PKH67	 dye,	 almost	 100%	 of	 them	 were	 found	 positive	 (Fig.	 7.2B,	 right	
histogram).	
The	percentage	of	MitoTracker+ve/PKH67+ve	events	was	 analysed	graphically	
and	 statistically	 from	 a	 number	 of	 experiments	 (Fig.	 7.3).	 The	 percentage	 of	
MitoTracker+ve	 vesicles	 decreases	 significantly	 when	 PEV	 were	 also	 stained	 with	
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Before	 introduction	 of	 PEV	 mitochondria	 to	 monocytes,	 we	 wanted	 to	 first	
observe	and	characterize	the	behaviour	of	endogenous	mitochondria	 in	monocytes,	as	
well	as	optimise	imaging	conditions.	Live	mitochondria	were	stained	with	MitoTracker	
Deep	 Red	 and	 imaged	 in	 real	 time	 by	 STORM	 (Stochastic	 Optical	 Reconstruction	
Microscopy).	 Figure	 7.4	 shows	 representative	 images	 of	 mitochondria	 in	 two	 live	




using	 the	Trackmate	plugin	on	FIJI	 software	 and	 is	 shown	 in	different	 colours	 in	Fig.	
7.5.	 Individual	 mitochondria	 were	 constantly	 moving,	 fusing	 with	 each	 other	 and	















Since	 PEV	 were	 found	 to	 carry	 mitochondria	 and	 since	 PEV	 were	 found	 in	
Chapter	 6	 to	 be	 internalized	 by	 monocytes,	 we	 hypothesized	 that	 PEV-borne	
mitochondria	can	also	gain	entry	into	monocytes.	In	order	to	investigate	this	possibility,	
induced-PEV	 were	 stained	 with	 MitoTracker	 dyes	 and	 incubated	 with	 washed	
monocytes	 over	 a	 50-minute	 time-course.	 As	 a	 control,	 the	 filtrate	 (filtration	 through	
0.25um	pores)	from	the	PEV	suspension	was	also	incubated	with	washed	monocytes.	
7.3.3.1 Investigation	by	FACS	
Acquisition	 of	 PEV-derived	 mitochondria	 by	 monocytes	 is	 shown	 in	 flow	
cytometry	dotplots	in	Figure	7.6.	PEV	were	stained	with	MitoTracker	Green.	Almost	all	
monocytes	become	positive	 for	MitoTracker	Green	upon	 incubation	with	PEV	or	with	
the	 filtrate	 at	 all	 time	 points.	 Monocytes	 seem	 to	 acquire	 MitoTracker	 Green	 with	
increased	intensity	by	time.	
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The	 histograms	 of	 MitoTracker	 Green	 expression	 by	 monocytes	 were	 also	
analysed.	 They	 show	 clearly	 that	 most	 monocytes	 become	 positive	 for	 MitoTracker	
Green	upon	 incubation	with	both	PEV	or	 the	 filtrate	 from	PEV	at	 all	 time	points.	The	
fluorescence	 intensity	 however	 increases	 with	 time	 with	 both	 PEV	 and	 filtrate.	 The	
signal	starts	to	saturate	between	30-50	minutes	(Fig.	7.7).		
The	 percentage	 of	 MitoTracker	 Green+ve	 monocytes	 and	 the	 median	
fluorescence	intensity	of	monocytes	were	plotted	graphically	and	analysed	statistically	
(Fig.	 7.8).	Most	monocytes	 become	positive	with	MitoTracker	Green	when	 incubated	
with	PEV	suspension	or	the	filtrate	from	PEV	from	as	early	as	5	minutes	of	incubation	
(Fig.	 7.8A).	 The	 fluorescence	 intensity	 increases	 significantly	 with	 time	 up	 to	 50	

















Monocytes	 exposed	 to	 PEV	 or	 a	 filtered	 supernatant	 from	 PEV	 suspensions	 were	




Incubation	 of	 monocytes	 with	 the	 filtrate	 of	 PEV	 (control	 sample)	 resulted	 in	
detectable	signal	on	the	monocytes	 that	significantly	 increased	by	time.	However,	 this	
signal	 was	 significantly	 lower	 than	 the	 signal	 with	 the	 PEV.	 We	 wanted	 to	 image	




Representative	 images	 are	 shown	 in	Fig.	 7.9.	 The	 positive	 control	 (monocytes	
stained	 with	 MitoTracker	 Green)	 shows	 clearly	 defined	 dots	 of	 high	 fluorescent	
intensity.	 The	 unstained	 monocyte	 that	 was	 incubated	 with	 PEV	 stained	 with	
MitoTracker	 shows	 less-defined	 dots	 that	 are	 of	 lower	 fluorescent	 intensity.	 The	




Monocytes	were	 either	 stained	with	MitoTracker	 Green	 or	were	 incubated	with	 PEV	
stained	with	MitoTracker	Green	or	with	the	filtrate	from	stained	PEV.	Scale	bar	is	10um.		
	
The	 fluorescence	 intensity	 from	 a	 number	 of	 cells	 was	 quantified	 using	 FIJI	






Monocytes	were	 either	 stained	with	MitoTracker	 Green	 or	were	 incubated	with	 PEV	





Upon	 observing	 that	 incubation	 of	 monocytes	 with	 the	 filtrate	 from	 PEV	
suspension	 results	 in	 significant	 mitochondrial	 signal	 expressed	 by	 monocytes,	 we	








colour	 images,	 a	 low	 level	 of	 red	 fluorescence	 is	 revealed.	 The	 platelet	 in	 the	 blue	
dashed	 circle	 clearly	 contains	 both	 red	 and	 green	mitochondria	 aligned	 next	 to	 each	





of	 green,	 yellow	 and	 orange.	 	 This	 shows	 that	 monocyte	 mitochondria	 acquired	
MitoTracker	Deep	Red	dye.	Hence,	there	is	a	large	level	of	dye	leakage.	
Colocalization	 analysis	 using	 FIJI	 software	 revealed	 two	 different	 correlations	
between	the	green	and	red	fluorescence	intensities	(dashed	blue	and	green	lines).	The	
overall	 correlation	 coefficient	 was	 0.82,	 which	 is	 indicative	 of	 high	 correlation	 (Fig.	
7.11B).	The	existence	of	two	correlations	reveals	the	presence	of	two	separate	entities.	
The	blue-lined	correlation	represents	mitochondria	originally	stained	with	MitoTracker	
Green	 and	 later	 stained	 with	 MitoTracker	 Deep	 Red	 (these	 show	 higher	 green	
fluorescence	 and	 lower	 red	 fluorescence)	 and	 the	 green-lined	 correlation	 represents	





Monocytes	 stained	 with	 MitoTracker	 Green	 were	 incubated	 with	 resting	 platelets	
stained	 with	 MitoTracker	 Deep	 Red	 and	 imaged	 live	 by	 confocal	 microscopy.	 (A)	






of	 MitoTracker	 Deep	 Red	 expression	 on	 the	 monocytes	 was	 assessed	 by	 FACS.	 A	
representative	 overlay	 histogram	 indicates	 that	 all	 monocytes	 become	 positive	 for	
MitoTracker	 Deep	 Red	 upon	 incubation	with	 any	 suspension	 or	 solution.	 The	 lowest	
fluorescence	 is	 acquired	 with	 the	 platelet	 filtrate,	 followed	 by	 PEV	 filtrate,	 PEV	 and	
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platelets	 in	 ascending	 order	 of	 fluorescence.	 Incubation	 with	 the	 filtrates	 resulted	 in	
lower	fluorescence	than	that	expressed	by	platelets,	whereas	incubation	with	platelets	









The	 percentage	 and	 fluorescence	 intensity	 were	 assessed	 graphically	 and	
statistically	 from	 a	 number	 of	 experiments.	 All	 monocytes	 became	 positive	 for	
MitoTracker	 Deep	 Red	 upon	 incubation	 with	 platelets/PEV/filtrates.	 However	 the	
fluorescence	 acquired	 by	 monocytes	 varies	 in	 each	 case.	 Incubation	 with	 the	 filtrate	
from	platelets	 results	 in	very	 low	MitoTracker	expression	by	monocytes;	 significantly	
lower	 than	 the	 expression	 when	 incubated	 with	 platelets.	 This	 means	 that	 the	 high	
expression	encountered	when	 incubated	with	platelets	 is	not	 the	 result	of	 inadequate	
	 194	
washing	of	 the	platelets	 that	 results	 in	high	 levels	of	 free	dye	outside	of	 the	cells	and	







intensity	 of	 platelets	 is	 also	 shown	 as	 a	 reference.	 Data	 are	 represented	 as	mean	 +/-	




directly	promote	atherosclerosis.	A	 recent	publication	 showed	 that	activated	platelets	
can	 release	 free	 mitochondria	 and	 mitochondria	 enclosed	 in	 extracellular	 vesicles	
(Boudreau	et	al.,	2014).		Hence,	since	PEV	can	get	internalized	into	monocytes	(Chapter	
6),	 we	 hypothesized	 that	 PEV	 can	 also	 transfer	 mitochondria	 or	 mitochondrial	




We	 attempted	 to	 replicate	 this	 result	 in	 our	 experiments.	 Platelets	 were	 co-
stained	 with	 the	 MitoTracker	 Deep	 Red	 dye	 that	 marks	 mitochondria	 and	 with	 the	
PKH67	 dye	 that	 marks	 cell	 membrane.	 >90%	 of	 PEV	 were	 found	 positive	 for	
mitochondria.	 However,	 all	mitochondria	 detected	were	membrane-enclosed.	 No	 free	
mitochondria	 were	 detected.	 This	 contradicts	 the	 observations	 of	 Boudreau	 and	
colleagues	 (2014).	 This	 outcome	 could	be	due	 to	 size	detection	 limitation	of	 the	 flow	
cytometer	(Accuri	C6	has	a	0.5	μm	cut-off).	Boudreau	et	al.	used	a	high	sensitivity	flow	
cytometry	configuration	that	according	to	them	allowed	detection	of	particles	from	100	
nm	 in	 size	 to	be	detected	simultaneously.	Further	 investigation	with	a	more	sensitive	
flow	 cytometer	 is	 hence	 required	 in	 order	 to	 say	 with	 confidence	 whether	 naked	
mitochondria	exist	in	our	preparations	or	not.	
Live	 imaging	 of	monocyte	mitochondria	 revealed	 that	monocyte	mitochondria	
are	highly	motile	and	that	they	constantly	move	in	a	relatively	organized	way	forming	
mitochondrial	networks.	Due	to	the	high	and	fast	motility	of	monocyte	mitochondria	it	
is	 difficult	 to	 image	 them	 live	 if	 two-coloured	 laser	 is	 required,	 i.e.	 when	 PEV	
mitochondria	are	also	stained	with	a	different	colour	MitoTracker.	
The	MitoTracker	dyes	 contain	 a	mildly	 thiol-reactive	 chloromethyl	moiety	 that	
passively	diffuse	across	the	plasma	membrane	and	stain	active	mitochondria.	They	have	
been	 used	 extensively	 in	 the	 literature	 (Bosnjak	 et	 al.,	 2012;	 Arnaudeau	 et	 al.,	 2002;	
Jambrina	et	al.,	2003;	Hobbs	et	al.,	2001).	However,	 in	our	studies	 these	proved	 to	be	
unsuitable	as	incubation	of	monocytes	with	the	filtrate	from	PEV	suspension	resulted	in	
mitochondrial	 signal	 to	 monocytes.	 In	 addition,	 monocyte	 incubation	 with	 resting	




mitochondria	 (observation	 in	 our	 lab,	 not	 shown	 here),	 it	 is	 unlikely	 that	 this	 result	
represents	true	mitochondria	transfer.	It	seems	to	be	the	result	of	dye	transfer.		





in	 minimal	 monocyte	 MitoTracker	 signal;	 hence	 not	 much	 free	 dye	 is	 present	
extracellularly,	but	when	the	filtrate	from	PEV	is	incubated	with	monocytes,	this	results	
in	 higher	 signal	 on	 the	 monocytes.	 We	 cannot	 exclude	 the	 possibility	 of	 inadequate	
filtration.	 A	 syringe	 system	was	 used	 to	 push	 PEV	 through	 a	 250nm	 pore	 filter.	 The	
resulting	 filtrate	 that	 in	 theory	 contains	 vesicles	 smaller	 than	 250nm,	 could	 not	 be	
assessed	 by	 FACS	 in	 order	 to	 check	 whether	 it	 contained	 mitochondria,	 as	 our	 flow	
cytometer	has	a	500nm	cut-off.	Hence,	the	high	signal	with	the	PEV	filtrate	could	be	the	
result	 of	 insufficient	 exclusion	 of	 mitochondria.	 However,	 there	 is	 another	 possible	
explanation	for	the	presence	of	MitoTracker	dye	in	the	PEV	filtrate.	When	the	platelets	
are	 activated	 to	 shed	 PEV,	 mitochondria	 tend	 to	 depolarize,	 which	 could	 result	 in	
uncoupling	of	 the	dye	 that	 later	diffuses	 through	 the	monocyte	membrane	 and	 stains	
monocyte	mitochondria.	Our	results	are	in	accordance	with	studies	from	Cselenyak	and	





an	 antibody	 that	 binds	 PEV,	 i.e.	 anti-GPIb	 as	 in	 Chapter	 6.	 In	 this	 case,	mitochondria	
inside	 monocytes	 that	 also	 express	 GPIb	 would	 be	 identified	 as	 PEV-derived.	 In	 this	
experiment	MitoTracker	dye	needs	to	be	added	first	when	PEV	are	active	(i.e.	alive,	at	
the	 platelet	 stage	 before	 stimulation	 to	 shed	 the	 PEV),	 whereas	 anti-GPIb	 antibody	
needs	to	be	added	second,	after	PEV	are	incubated	with	monocytes,	because	we	found	
that	 antibody	 presentation	 on	 PEV	 inhibits	 PEV	 aggregation	 with	 monocytes	 (not	
shown).	However,	when	 this	was	 attempted	we	 could	 not	 detect	 any	 signal	 for	 GPIb.	
According	to	Thermo	Fisher	Scientific	the	chloromethyl	group	of	the	MitoTracker	dyes	
may	covalently	bind	 to	proteins	 in	 the	 cell	 so	 it	 is	possible	 to	 interfere	with	antibody	
binding.	
The	 use	 of	 the	 MitoTracker	 dyes	 has	 another	 weakness	 in	 our	 experimental	






PEV	 without	 presence	 of	 mitochondria.	 (Staining	 of	 PEV	 with	 MitoTrackers	 was	








the	use	 of	 fluorescent	 proteins	 such	 as	GFP	 could	be	 employed.	Transgenic	mice	 that	




Another	 approach	 involves	 the	 use	 of	 mitochondrial	 antibodies.	 However,	 the	
use	of	a	mitochondrial	antibody	pre-requires	that	the	cells/vesicles	are	permeabilized.	
Mitochondria	 cannot	 be	 stained	 with	 an	 antibody	 while	 in	 the	 platelet,	 because	
permeabilised	 platelets	 cannot	 be	 stimulated	 to	 shed	 PEV.	 Hence,	 PEV	 mitochondria	
have	 to	be	stained	after	 incubation	with	monocytes	and	subsequent	permeabilization.	
However,	 this	 would	 stain	 also	 monocyte	 mitochondria.	 This	 problem	 could	 be	
overcome	 if	 we	 take	 an	 inter-species	 approach.	 For	 example,	 human	 PEV	 could	 be	




The	majority	 of	 PMV	 contain	 a	 mitochondrion.	 No	 further	 conclusions	 can	 be	
made	 with	 certainty	 as	 to	 whether	 PEV	 transfer	 their	 mitochondria	 into	 monocytes.	












Any	 damage	 to	 the	 vascular	 endothelium	 that	 exposes	 the	 subendothelial	
extracellular	matrix	(ECM)	triggers	platelet	recruitment	at	 the	 injured	site.	Circulating	
platelets	 initially	 decelerate	 over	 the	 compromised	 site	 due	 to	 transient	 interactions	
with	the	extracellular	matrix.	These	initial	interactions	trigger	platelet	activation,	which	




stress,	 platelets	 bind	 directly	 to	 exposed	 collagen,	 fibronectin	 and	 laminin.	 However	




al.,	1986),	a	 subunit	of	GPIb-IX-V.	This	binding	has	a	 fast	dissociation	rate;	hence	 it	 is	
incapable	 of	 mediating	 stable	 adhesion.	 However,	 this	 interaction	 keeps	 platelets	 in	
close	proximity	with	the	vessel	surface,	with	rolling	along	the	VWF	in	the	direction	of	
blood	 flow.	 The	 resulting	 deceleration	 or	 “rolling”	 enables	 another	 platelet	 receptor,	
called	 glycoprotein-VI	 (GPVI),	 to	 interact	with	 exposed	 collagen.	GP	VI	 binds	 collagen	
with	low	affinity;	therefore	it	is	incapable	of	mediating	stable	adhesion	either.	However,	
it	 induces	 intracellular	 signaling	 that	 activates	 platelets	 and	 transforms	 platelet	
integrins	to	a	high-affinity	state.	Platelet	activation,	results	in	the	activation	of	integrin	




endothelium	 can	 be	 exploited	 by	 monocytes	 in	 inflammation.	 In	 a	 model	 of	 allergic	
inflammation	circulating	platelets	were	 found	to	 form	aggregates	with	 leukocytes	and	
to	be	essential	for	their	recruitment	(Pitchford	et	al.,	2003).	In	addition,	our	group	has	
shown	in	the	past	that	in	cocultures	of	ECs	and	secretory	SMCs	(the	phenotype	seen	in	
atherosclerotic	 vessel	 wall),	 a	matrix	 of	 vWF	 is	 presented	 to	 flowing	 blood,	 allowing	
platelets	 to	 attach	 to	 the	 endothelium	 (Tull	 et	 al.,	 2006).	 These	 adhered	platelets	 can	
serve	 as	 adhesive	 bridges	 between	 flowing	 monocytes	 in	 blood	 and	 the	 EC	 surface	
(Kuckleburg	et	al.,	2011).	
However,	 not	much	 research	 has	 gone	 into	 PEV	 or	 PEV-mediated	 recruitment.	
Studies	 by	 Merten	 and	 colleagues	 (1999)	 showed	 that	 infusion	 of	 PEV	 into	 the	
abdominal	 aorta	 of	 rabbits	 after	 induction	 of	 endothelial	 injury	 resulted	 in	 increased	
recruitment	 at	 the	 iliac	 artery.	 In	 addition,	 recent	 in	 vitro	 studies	 from	 our	 group	
revealed	 that	 perfusion	 of	monocytes	 that	 are	 “decorated”	with	 PEV	 on	 their	 surface	
over	 immobilized	 vWF	 or	 TGFβ-stimulated	 endothelial	 cells	 up-regulates	 monocyte	
adhesion	(Chimen	et	al.;	under	review).	Our	group	also	replicated	this	result	 in	vivo	 in	
the	microcirculation	of	 a	mouse	model	 of	 induced	 inflammation	(Chimen	et	 al.;	 under	


















from	 10	 weeks	 of	 age)	 were	 injected	 with	 Cell-Tracker	 Orange-stained	 monocytes	
(derived	 from	human	blood)	 alone	 or	monocytes	 aggregated	with	 PEV	 (derived	 from	
murine	platelets)	 in	 the	 circulation	 through	 the	 left	 common	carotid	artery	 through	a	
cannula.		
Interaction	 of	 injected	 cells	 with	 the	 vessel	 wall	 was	 monitored	 in	 vivo	 by	
fluorescent	 video-microscopy	 in	 the	 right	 common	 carotid	 artery	 at	 the	 athero-prone	
“fork”	site.	The	number,	velocity	and	duration	of	adhesion	interactions	were	manually	









monocytes	 from	 the	 mouse	 circulation	 was	 very	 low	 so	 we	 decided	 to	 try	 an	 inter-
species	 approach	 i.e.	 to	 perfuse	 heterotypic	 aggregates	 of	 human	 monocytes	 with	
murine	PEV	into	the	mouse	circulation	and	check	whether	these	would	get	recruited	to	
the	 endothelium.	Before	 infusing	 these	 aggregates,	we	 checked	by	 FACS	whether	 this	
inter-species	heterotypic	aggregation	could	take	place.	
Figure	 8.1.	 shows	 the	 expression	 of	 mouse	 GPIbα	 on	 human	 monocytes	 that	
were	 incubated	 with	 mouse	 PEV,	 as	 opposed	 to	 the	 expression	 of	 mouse	 GPIbα	 on	
human	 monocytes	 before	 the	 introduction	 of	 the	 PEV.	 	 It	 is	 clear	 that	 almost	 all	










stained)	 in	 the	ApoE	 KO	mouse	 circulation,	 a	 number	 of	 stable	 and	unstable	 (rolling)	
interactions	 were	 noted	 at	 the	 fork	 site	 of	 the	 right	 common	 carotid	 artery.	 A	
representative	monocyte	 exhibiting	 both	 types	 of	 adhesive	 behavior	 is	 shown	 in	Fig.	
8.2.		
The	 stable	 and	 rolling	 interactions	 were	 quantified	 from	 a	 number	 of	






Figure	 8.2.	 Stable	 and	 Unstable	Monocyte	 adhesion	 in	 the	 carotid	 artery	 of	 the	
ApoE	KO	mouse	
Monocytes	stained	with	Cell	Tracker	Orange	were	injected	in	the	mouse	circulation	and	
adhesive	 interactions	 onto	 the	mouse	 endothelium	 in	 the	 carotid	 artery	 were	 video-
recorded.	A	representative	monocyte	is	shown	here	exhibiting	mixed	adhesion	modes.	
The	 time	 passed	 post	 cell	 injection	 is	 shown	 on	 the	 top	 left	 corner.	 The	 blue	 arrow	
shows	 rolling	 adhesion	 and	 the	 green	 arrow	 shows	 stable	 adhesion.	 (A)	 Before	 an	






Figure	 8.3.	 Quantification	 of	 Monocyte	 Stable	 and	 Rolling	 interactions	 in	 the	
carotid	artery	of	the	ApoE	KO	mouse	
Total	 number	 of	 monocytes	 exhibiting	 stable	 or	 rolling	 adhesion	 onto	 mouse	
endothelium	when	monocytes	were	injected	alone	or	when	monocytes	were	decorated	
with	PEV	during	 the	 first	 six	minutes	post-cell	 injection.	Data	are	 shown	as	Mean	+/-	
SEM	of	2	independent	experiments.	Data	were	analysed	by	t-test.	*	indicates	P<	0.05.	
8.3.3. Stable	Interactions	
The	duration	of	 stable	 interactions	was	quantified	 (Fig.	 8.4).	When	monocytes	
carried	PEV	on	their	surface	their	stable	interactions	lasted	significantly	longer.	
The	majority	of	stable	 interactions	 took	place	 in	 the	 first	 three	minutes	passed	
post-cell	 introduction.	A	higher	percentage	of	 stable	 interactions	occurred	 in	 the	 first	
three	minutes	with	the	monocyte-PEV	aggregates	(>	75%)	than	when	monocytes	were	
perfused	alone	(<	75%),	whereas	a	higher	percentage	of	stable	interactions	occurred	in	





Duration	 of	 stable	 cell	 interactions	 when	 monocytes	 were	 injected	 alone	 or	 when	








alone	 or	when	monocytes	were	 decorated	with	 PEV.	 Data	 are	 shown	 as	 SEM	 from	 2	
independent	experiments.	Data	were	analysed	by	two-way	ANOVA.	
8.3.4. Rolling	Interactions	
The	 velocity	 of	 rolling	 interactions	 was	 quantified.	 No	 difference	 was	 noted	




post-cell	 introduction	 for	 the	 PEV	 sample,	 whereas	 an	 equal	 number	 of	 rolling	





Velocity	 of	 rolling	 cell	 interactions	 when	 monocytes	 were	 injected	 alone	 or	 when	













with	 established	 atherosclerosis	 and	 subsequent	 interactions	 with	 the	 inflamed	
endothelium	were	observed	at	the	athero-prone	“fork”	site	of	the	right	common	carotid	
artery.	 Another	 group	 investigated	 previously	 indirect	 PEV-mediated	 recruitment	 of	
monocytes	in	an	ex	vivo	setting	with	extracted	carotid	arteries	and	found	that	PEV	can	
deliver	 the	 chemokine	 RANTES	 to	 the	 athero-compromised	 endothelium,	 which	
enhanced	 subsequent	 monocyte	 arrest	 on	 the	 inflamed	 endothelium	 (Mause	 et	 al.,	
2005).	 However,	 our	 study	 is	 the	 first	 to	 date	 to	 investigate	 direct	 PEV-monocyte	
interactions	resulting	in	monocyte	recruitment	in	atherosclerosis	in	vivo.	
Due	 to	 higher	 availability,	 human	 monocytes	 were	 used	 instead	 of	 mouse	
monocytes	 (upon	 confirming	 that	 mouse	 PEV	 could	 also	 aggregate	 with	 human	
monocytes).	 Human	 and	 mouse	 monocytes	 exhibit	 extensive	 gene	 and	 protein	
homology	 (Ingersoll	 et	 al.,	 2010),	 which	 could	 translate	 into	 compatible	 human	
monocyte	–	mouse	PEV	adhesion	receptors.		Also	human	and	mouse	platelet	receptors	
share	 high	homology.	 Jesse	 et	 al.	 (2011)	 found	 that	 58%	of	 the	mRNAs	 expressed	by	
human	platelets	are	also	found	in	the	mouse	platelets.	
The	observed	“compatibility”	between	human	monocytes	and	murine	PEV	might	
be	 specifically	 owed	 to	 platelet	 P-selectin.	 P-selectin	 has	 been	 found	 to	mediate	 PEV-
monocyte	aggregation	(Chimen	et	al.,	under	review;	McEver	and	Cummings,	1997).	Liu	
et	 al.	 (2010)	made	 transgenic	mice	 that	 constitutively	 expressed	 human	 P-selectin	 in	
platelets	and	observed	that	 leukocytes	rolled	similarly	on	human	or	murine	P-selectin	
on	 activated	 murine	 platelets	 and	 in	 venules	 of	 the	 cremaster	 muscle	 upon	 trauma,	
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observed	high	affinity	of	human	monocytes	 for	murine	PEV.	 In	 these	experiments	we	
confirmed	 that	 human	monocytes	 can	 form	 heterotypic	 aggregates	with	murine	 PEV.	
However,	we	did	not	investigate	whether	human	monocytes	could	also	internalize	these	
vesicles.	 This	 aspect	 was	 beyond	 the	 scope	 of	 these	 experiments,	 as	 in	 these	
experiments	we	 just	wanted	 to	 test	 any	 direct	 adhesion	 benefit	 to	 the	monocytes	 i.e.	
from	utilizing	the	PEV	adhesion	receptors	on	the	surface	of	the	monocytes.	
Upon	infusing	the	monocytes	in	the	mouse	circulation	we	observed	two	modes	of	




Monocytes	 exhibited	 higher	 adhesion	 when	 pre-incubated	 with	 PEV.	 This	
observation	is	in	accordance	with	observations	made	by	Mause	and	colleagues	(2005),	







monocyte	 adoption	 of	 PEV-derived	 GPIb,	 as	 Mause	 and	 colleagues	 (2005)	 observed	
inhibition	 of	 monocyte	 adhesion	 with	 GPIb	 blocking.	 GPIb	 is	 the	 known	 platelet	
adhesion	partner	of	vWF	in	compromised	endothelium	and	this	interaction	is	known	to	
be	unstable	(Sakariassen	et	al.,	1986).	In	addition,	similar	studies	from	our	group	found	
that	 monocyte-bound	 PEV	 up-regulated	 adhesive	 interactions	 of	 monocytes	 with	 the	
endothelium	in	the	mouse	cremaster	muscle	microcirculation	in	a	GPIb-dependent	way	
as	well	in	a	model	of	induced	inflammation	(Chimen	et	al.;	under	review).	The	velocity	
of	 blood	 in	 the	 mouse	 carotid,	 which	 is	 typically	 500-600	 μm	 in	 diameter,	 ranges	
between	 2.5-18	 cm/s	 (Parzy	 et	 al.,	 2009).	 Based	 on	 these	measurements,	 the	 rolling	
monocytes	in	our	experiments	exhibited	30-200-fold	deceleration.	
Stable	 adhesion	 lasted	 longer	 for	 the	 monocytes	 that	 carried	 PEV	 on	 their	
surface.	This	 fact	 could	be	 the	result	of	monocyte	utilisation	of	another	PEV	receptor;	
GPIIb.	 GPIIb	 is	 the	 platelet	 receptor	 that	mediates	 stable	 adhesion	 between	 platelets	
and	 exposed	 ECM	 upon	 platelet	 activation	 (Savage	 et	 al.,	 1998;	 Jackson	 et	 al.,	 2003).	
Mause	and	colleagues	showed	that	GPIIb	blocking	also	decreases	monocyte	rolling	on	
atherosclerotic	endothelium.	
Apart	 from	monocyte	 adoption	 of	 PEV	 adhesion	molecules	 that	 remains	 to	 be	
explored	 in	 future	 experiments,	 another	 PEV-mediated	 mechanism	 of	 monocyte	
recruitment	to	the	vessel	wall	involves	PEV-mediated	activation	of	monocytes,	resulting	
in	 up-regulation	 of	 endogenous	 monocyte	 adhesion	 molecules	 on	 the	 surface	 of	
monocytes.	Montoro-Garcia	and	colleagues	(2014)	have	found	that	PEV	can	induce	up-
regulation	 of	 ICAM-1	 on	 the	monocyte	 surface.	 In	 addition,	 PEV	 have	 been	 shown	 to	
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promote	 monocyte	 adhesion	 indirectly	 via	 the	 deposition	 of	 RANTES	 to	 the	
endothelium	(Mause	et	al.,	2005).		
Atheromatous	 plaques	 are	 rich	 in	 various	 endothelial	 cell	 adhesion	molecules	
(CAMs)	such	as	P-selectin,	 ICAM-1	and	VCAM-1	(Patel	et	al.,	1998;	Poston	et	al.,	1992;	
Johnson-Tidey	 et	 al.,	 1994;	 O’Brien	 1993)	 that	 facilitate	monocyte	 recruitment.	 In	 an	
oscillatory	flow	study,	Hsiai	and	colleagues	(2003)	simulated	the	moving	and	unsteady	
separation	 point	 at	 the	 arterial	 bifurcation	with	 high	 spatial	 and	 temporal	 resolution	
and	 found	 that	 monocytes	 also	 underwent	 rolling,	 binding,	 dissociation	 and	 firm	
adhesion	on	EC.	 	Monocytes	also	exhibited	increased	rolling	in	the	carotid	artery	from	
ApoE	 KO	 mice	 ex	 vivo	 compared	 to	 wild	 type	 mice	 (Ramos	 et	 al.,	 1999).	 In	 these	
experiments,	 cell	 rolling	 was	 mediated	 by	 P-selectin	 and	 VCAM-1.	 Hence,	 an	

















with	 PEV	 in	 the	 circulation	 of	 a	mouse	with	 established	 atherosclerosis	 up-regulates	
monocyte	 adhesion	 to	 the	 carotid	 artery	 wall.	 Hence,	 we	 speculate	 that	 PEV	 might	
contribute	 to	 atherosclerosis	 progression	 by	 recruiting	 circulating	 monocytes	 to	 the	
inflamed	vessel	wall.	
In	order	to	investigate	the	potential	of	PEV	to	directly	affect	atherogenesis	there	
is	 need	 for	 an	 atherosclerosis	 animal	model	 that	 is	 free	 of	 platelets.	 This	 is	 required	
because	 PEV	 are	 capable	 of	 activating	 platelets	 and	 recruiting	 them	 to	 compromised	
endothelium	(Owens	et	al.,	1992;	Merten	et	al.,	1999).	Hence,	it	could	be	argued	that	any	
effect	 on	 atherogenesis	 upon	 PEV	 injection	 might	 have	 been	 caused	 by	 endogenous	
platelets	rather	than	PEV.	
An	 atherosclerosis	 animal	 model	 that	 is	 free	 of	 platelets	 did	 not	 exist	 to	 our	
knowledge,	 so	we	aimed	 to	 generate	one	by	breeding	 the	ApoE	KO	mouse,	which	 is	 a	
widely	 used	 mouse	 for	 atherosclerosis	 studies,	 with	 the	 transgenic	 mouse	 hiL-
4Rα/GPIbα-Tg	(Kanaji	et	al.,	2002).	
The	 ApoE	 KO	mouse	 lacks	 the	 apolipoprotein-E	 (ApoE)	 gene.	 ApoE	 mediates	
receptor	 recognition	 of	 intermediate-density	 lipoprotein	 and	 chylomicron	 remnant	 in	












In	 theory,	 this	 new	mouse	 ApoE	 KO-hiL4Rα/GPIbα-Tg	would	 be	 athero-prone	








ApoE-/-	 hiL4R/GPIbα-Τg	 mice	 were	 generated	 by	 crossing	 ApoE-/-	 with	
hiL4R/GPIbα-Τg	mice	to	first	generate	double	heterozygous	ApoE+/-	hiL4R/GPIbα-Τg+/-
mice.	 	 Heterozygous	 mice	 were	 crossed	 among	 themselves	 to	 generate	 different	
genotype	 combinations	 of	 which	 only	 the	 ApoE-/-	 hiL4R/GPIbα-Τg+/+	 and	 ApoE-/-	
hiL4R/GPIbα-Τg+/-	 mice	 were	 used	 in	 experiments.	 Presence	 of	 the	 ApoE	 gene	 was	






EDTA-anti-coagulated	 peripheral	 blood	 from	 10-week	 old	 ApoE	 KO	 hiL-
4Rα/GPIbα-Tg	mice	was	analysed	on	a	mouse	blood	haemocytometer	to	count	numbers	
and	measure	size.	The	blood	was	also	stained	with	anti-hiL4R	and	anti-GPIIb	antibodies	











































Anticoagulated	 peripheral	 blood	 was	 co-stained	 with	 anti-GPIIb	 and	 anti-hiL4Rα	
antibodies	 and	 analyzed	 by	 FACS.	 (A)	Representative	 forward	 vs	 side	 scatter	 plot,	 as	
gated	on	GPIIb+ve	events,	showing	platelets	and	PEV.	(B)	Overlay	histogram	of	hiL4Rα	
















































Figure	 9.7.	 Aortic	 Lesion	 characteristics	 in	 response,	 to	 a	 high	 fat	 diet	 for	 14	
weeks		
(A)	Mean	diameter	and	(B)	number	of	lesions	formed	in	aortas	of	ApoE	KO	or	ApoE	KO-





























The	 levels	 of	 the	 different	 lipids	 in	 the	 blood	were	measured	 before	 and	 after	
feeding	 the	 mice	 a	 high	 fat	 diet	 for	 14	 weeks.	 Total	 cholesterol	 levels	 increased	
significantly	 for	 both	 strains	 upon	 feeding	 a	 high	 fat	 diet	 for	 14	 weeks	 compared	 to	




upon	 feeding	 a	 high	 fat	 diet	 for	 14	 weeks	 compared	 to	 starting	 levels.	 However,	
triglyceride	 levels	 of	 ApoE	 KO-hiL4Rα/GPIbα-Tg	 mice	 were	 significantly	 higher	 than	
ApoE	triglyceride	levels	at	the	end	of	14	weeks	(Fig.	9.11B).	HDL	increased	significantly	
in	 the	ApoE	mouse	upon	 feeding	 the	high	 fat	diet,	 however	 the	HDL	of	 the	ApoE	KO-
hiL4Rα/GPIbα-Tg	 mouse	 was	 significantly	 lower	 than	 that	 of	 the	 ApoE	 mouse	 after	
feeding	on	the	high	fat	diet	(Fig.	9.11C).	LDL	increased	significantly	in	the	ApoE	mouse	















injected	 intravenously	with	 2.5	 μg/g	 of	 anti-hiL4Rα	 antibody.	 This	 caused	 circulating	





















(A)	Blood	platelet	 counts	and	(B)	platelet	 size	upon	 injection	of	2.5	μg/g	anti-hiL4Rα	
antibody	over	the	course	of	9	days	 in	the	ApoE	KO-hiL4Rα/GPIbα-Tg	mouse.	Data	are	
















We	 counted	 the	 number	 and	 size	 of	 circulating	 platelets	 in	 the	 new	 mouse.	
Previous	studies	had	indicated	that	the	platelets	 from	the	hiL4Rα	KI	mouse	are	 larger	
and	fewer	in	numbers	than	WT	platelets	(Kanaji	et	al.,	2002).	However,	these	deviations	
were	 not	 as	 dramatic	 as	 those	 seen	 in	 pathological	 thrombocytopenia	 disorders.	




hiL4Rα	KI	mouse	 in	 our	 experiments,	 exhibited	 larger	 and	 fewer	platelets	 than	 those	
derived	from	ApoE	KO	mice	of	10	weeks	of	age	on	a	normal	diet.	It	has	been	shown	that	
GPIb	 deficiency	 results	 in	 mild	 thrombocytopenia	 and	 circulation	 of	 ‘giant	 platelets’	
(Ware	 et	 al.,	 2000).	 However,	 the	 new	 mouse	 generated	 exhibited	 platelets	 of	 an	
intermediate	 phenotype.	 These	 platelets	 were	 smaller	 than	 those	 derived	 from	 the	
hiL4Rα	 KI	 mouse,	 but	 bigger	 than	 the	 ApoE	 KO	 platelets.	 These	 platelets	 were	 also	
higher	 in	 numbers	 than	 hiL4Rα	 KI	 platelets	 but	 not	 as	 high	 as	 ApoE	 KO	 platelets.	
Apolipoprotein	 E	 has	 been	 found	 to	 inhibit	 agonist-induced	 platelet	 aggregation	 and	
activation	in	vitro	(Nofer	et	al.,	2002;	Desai	et	al.,	1989;	Higashihara	et	al.,	1991;	Riddell	
et	al.,	1997).	Hence,	the	observed	differences	in	platelet	counts	and	size	in	the	ApoE	KO-
hiL4Rα/GPIbα-Tg	mouse	 compared	 to	 the	 hiL4Rα/GPIbα-Tg	mouse	might	 be	 directly	
attributed	to	the	absence	of	ApoE	protein.		
In	 addition,	 ApoE	 KO	 mice	 are	 characterized	 by	 hyperlipidemia.	
Hypercholesterolemia	 is	 suggested	 to	 promote	 platelet	 biogenesis,	 hence	 increases	
circulating	platelet	counts	(Wang	and	Tall,	2016;	Fessler	et	al.,	2013).	
Another	explanation	for	the	platelet	count	and	size	differences	could	be	that	the	
mice	 tested	were	 heterozygous	 for	 the	 hiL4Rα	 gene.	Unfortunately,	 because	 the	mice	
were	genotyped	by	FACS,	we	could	only	determine	whether	the	platelets	contained	the	
hiL4Rα	protein	or	not	but	we	could	not	distinguish	with	absolute	certainty	whether	the	





about	 the	 phenotype	 of	 hiL4Rα	 KI	 heterozygous	mice	 (Kanaji	 et	 al.,	 2002).	 However,	
GPIbα	 heterozygous	 expression	 results	 in	 intermediate	 platelet	 counts	 compared	 to	
platelets	from	WT	or	GPIbα	null	mice	(Ware	et	al.,	2000),	hence	this	could	hold	also	true	
for	 ApoE-/-	-hiL4Rα+/-	mice.	 This	 is	 consistent	with	 our	 observation	 that	 platelets	 and	
PEV	 from	ApoE	hiL4Rα	mice	 exhibit	 a	 little	 lower	amount	of	hiL4Rα	protein	on	 their	
surface	than	hiL4Rα.		
As	 expected,	 the	 hiL-4Rα/GPIbα-Tg	 mouse	 has	 adhesion	 problems	 due	 to	
inability	 to	 bind	 vWF.	 In	 this	 mouse	 model,	 platelets	 were	 incapable	 of	 binding	 to	
injured	 endothelium	 and	 forming	 thrombi	 (Boulaftali	 et	 al.,	 2013).	 In	 addition,	 these	






The	 main	 hypothesis	 of	 this	 PhD	 project	 is	 that	 PEV	 drive	 the	 progress	 of	
atherogenesis	 through	 interacting	 with	 monocytes.	 One	 way	 PEV	 could	 promote	 the	
inflammatory	activities	of	monocytes	in	atherosclerosis	is	through	facilitating	monocyte	
recruitment	 to	 the	 endothelium.	 Indeed,	 our	 group	 has	 shown	 that	 PEV	 increase	
adhesion	 of	 monocytes	 to	 immobilized	 stimulated	 vWF	 or	 to	 stimulated	 endothelial	
cells	 in	 in	 vitro	 flow	 assays.	 Our	 group	 also	 replicated	 this	 result	 in	 vivo	 in	 the	
microcirculation	 of	 a	 mouse	 model	 of	 induced	 inflammation	 (Chimen	 et	 al.;	 under	
review).	 In	 addition,	 in	 chapter	 8	 it	 was	 shown	 that	 injection	 of	 monocytes-PEV	
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aggregates	 in	 the	 circulation	 of	 mice	 with	 established	 atherosclerosis	 results	 in	
increased	adhesive	interactions	with	the	carotid	endothelium.	Injection	of	activated	WT	
platelets	 into	 ApoE	 KO	mice	 has	 been	 shown	 to	 increase	 atherosclerosis	 (Huo	 et	 al.,	









were	 used	 as	 a	 control.	 Since	 hiL-4Rα/GPIbα-Tg	 mice	 reportedly	 had	 adhesion	
complications	(Kanaji	et	al.,	2002;	Boulaftali	et	al.,	2013)	we	speculated	that	the	ApoE	
KO-hiL4Rα/GPIbα-Tg	 mice	might	 exhibit	 decreased	 levels	 of	 atherosclerosis,	 arising	
from	 decreased	 levels	 of	 PEV-mediated	monocyte	 recruitment.	 	 Our	 speculation	 was	
strengthened	 by	 the	 studies	 of	 Massberg	 and	 colleagues	 (2002),	 who	 found	 that	
inhibition	 of	 platelet	 (and	 PEV)	 adhesion	 by	 GPIbα-blocking	 antibodies	 significantly	
reduced	atheromatous	plaque	formation.		
Our	 ApoE	 KO-hiL4Rα/GPIbα-Tg	 mouse	 did	 not	 however	 exhibit	 decreased	
plaque	formation	in	the	aorta	compared	to	the	ApoE	mouse.	In	addition,	the	individual	
plaques	exhibited	the	same	characteristics	in	the	two	mouse	models.	This	result	agrees	
with	 the	 results	 by	 Koltsova	 and	 colleagues	 (2014),	 who	 performed	 similar	
atherosclerosis	 studies	 with	 the	 hiL-4Rα/GPIbα-Tg	 mouse	 using	 a	 different	
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atherosclerosis	mouse	model.	Ldlr-/-	mice	 lethally	 irradiated	and	 fed	on	a	high	 fat	diet	
reconstituted	 with	 GPIbα-/-	 bone	 marrow	 reported	 lower	 atherosclerosis	 than	 wt	
controls.	However,	 ldlr-/-	mice	 reconstituted	with	hiL-4Rα/GPIbα-Tg	bone	marrow	 that	
lacks	only	the	extracellular	domain	of	GPIbα,	exhibited	atherosclerotic	lesions	similar	to	
wt	mice.	Hence,	the	authors	concluded	that	the	decreased	atherosclerosis	seen	in	mice	




two	mice	 exhibited	 some	differences	 in	 lipid	metabolism.	Both	blood	 triglyceride	 and	
total	cholesterol	levels	rose	as	expected	upon	feeding	on	a	high	fat	diet	in	both	strains.	
However,	the	ApoE	KO-hiL4Rα/GPIbα-Tg	mice	had	lower	total	cholesterol	and	HDL	but	
higher	 triglyceride	 and	 LDL	 levels	 than	 the	 ApoE	 mouse.	 A	 combination	 of	 higher	
triglyceride	levels	(and	sometimes	lower	cholesterol	levels)	with	thrombocytopenia	or	
enlarged	platelets	 is	 also	 seen	 in	acute	hantavirus	 infections,	nephropathia	epidemica	
and	 subclinical	 hypothyroidism,	 even	 though	 the	 exact	 mechanism	 is	 unknown	
(Clement	et	al.,	2016;	Martynova	et	al.,	2016;	Yilmaz	et	al.,	2011).	Hence,	we	believe	that	
the	 differences	 observed	 in	 lipid	 metabolism	 parameters	 in	 the	 ApoE	 KO-




vivo.	 These	 antibodies	mimic	 the	mechanism	 of	 platelet	 auto-destruction	 seen	 in	 the	
bleeding	disease	autoimmune	 thrombocytopenic	purpura	 (ITP),	where	autoantibodies	
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target	 the	 individual’s	 own	 platelets,	 resulting	 in	 Fc-mediated	 platelet	 destruction	 by	
macrophages	in	the	reticuloendothelial	system	(RES)	(Semple	et	al.,	1998).	Monoclonal	
antibodies	 (mAbs)	 targeting	 mouse	 GPIIbIIIa,	 GPIIIa,	 GPIbα,	 GPIb-IX,	 GPV	 and	 CD31	
have	been	evaluated	(Nieswandt	et	al.,	2000).	
Intravenous	injection	of	anti-hiL4Rα	antibody	into	our	ApoE	KO-hiL4Rα/GPIbα-
Tg	 mice	 caused	 circulating	 platelet	 counts	 to	 drop	 dramatically	 as	 also	 shown	 by	
Boulaftali	 and	 colleagues	 (2013).	The	platelets	 stayed	as	 low	as	15%	of	 their	original	
counts	 for	 at	 least	 four	 days	 post-injection.	 Platelet	 counts	were	 restored	 seven	 days	







when	successive	 injections	of	 the	antibody	 (same	concentration)	were	attempted	at	a	
weekly	 frequency	 in	 order	 to	 prolong	 the	 platelet-free	 period,	 the	 mice	 exhibited	
anaphylaxis-like	 symptoms	 (mice	 extremely	 hypo-energetic	 on	 second	 injection,	
spasms	on	third	injection).		
Nieswandt	 and	 colleagues	 (2000)	 also	 reported	 an	 anaphylaxis-like	 reaction	
with	associated	hypothermia	and	a	decrease	in	hematocrit	due	to	internal	bleeding	with	
administration	 of	 anti-GPIIbIIIa	 antibodies	 (10μg).	 These	 side	 effects	 were	 PAF-
mediated	 and	 Fc-dependent.	 However,	 when	 Nieswandt	 et	 al.,	 (2000)	 gave	 repeated	










conclude	 that	 our	mice	 developed	 immune	 hypersensitivity	 that	 caused	 anaphylactic	
shock.	 	The	sensitizing	agent	in	the	antibody	most	likely	is	the	IgG2A	 .	IgG2A	,	as	well	as	
other	 IgG	 subclasses	 (IgG1	 and	 IgG2B),	 have	 been	 reported	 to	 induce	 systemic	
anaphylaxis	 in	 the	mouse	 (Khodoun	et	 al.,	 2013;	Miyajima	 et	 al.,	 1997;	 Jonsson	 et	 al.,	
2011).	 Hence,	 future	 approaches	 to	 prolong	 platelet-free	 period	 in	 ApoE	 KO-
hiL4Rα/GPIbα-Tg	mice	by	repeated	anti-	hiL4Rα	antibodies	should	try	alternative	anti-	
hiL4Rα	 antibodies,	 where	 the	 anti-	 hiL4Rα	 region	 is	 fused	 to	 non-immunogenic	
immunoglobulins.	
In	addition,	the	efficiency	of	anti-hiL4Rα	F(ab)2	fragments	could	be	evaluated	in	
causing	 thrombocytopenia	 in	 future	 investigations.	 Administration	 of	 anti-GPIbα	
antibodies	 caused	 virtually	 complete	 thrombocytopenia	 (without	 any	 associated	 side	
effects)	in	Fc-independent	mechanisms	in	mice	(Nieswandt	et	al.,	2000),	suggesting	that	
the	RES	was	not	involved	here.	Hence,	antibody-mediated	platelet	destruction	depends	
on	 the	 antigenic	 specificity	 of	 the	 injected	 antibody.	 If	 anti-hiL4Rα-mediated	 platelet	
destruction	does	not	involve	the	Fc	portion	of	the	antibody,	then	injecting	anti-hiL4Rα	
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F(ab)2	 fragments	 should	 achieve	 the	 same	 levels	 of	 thrombocytopenia	 without	 the	
observed	immunotoxic	effects.	
As	 it	 stands,	 we	 are	 currently	 unable	 to	 investigate	 the	 role	 of	 PEV	 in	
atherosclerosis	 independently	of	platelets	 in	 chronic	experiments	as	we	are	 currently	
unable	 to	maintain	 ApoE	 KO-hiL4Rα/GPIbα-Tg	mice	 free	 of	 endogenous	 platelets	 for	
prolonged	 periods	 of	 time	 (i.e.	 for	 6	 weeks	 which	 is	 the	 usual	 minimum	 time	 for	
observing	 differences	 in	 plaque	 formation	 in	 ApoE	 KO	 mice	 on	 a	 high	 fat	 diet)	 and	
constantly	 injecting	 PEV.	 However,	 our	 model	 allows	 the	 study	 of	 PEV	 in	 acute	




was	 a	 premature	 study	 and	 this	 result	 needs	 to	 be	 validated	 in	 further	 experiments.	
Intravenously	 injected	 HEK293T-derived	 EV	 in	 rodents	 have	 been	 found	 to	 localise	





differences	 are	 not	 dramatic).	 This	 mouse	 when	 fed	 a	 high	 fat	 diet	 develops	
atheromatous	plaques,	similar	to	those	exhibited	by	ApoE	KO	mice.	However,	this	new	
mouse	 exhibits	 some	 differences	 in	 lipid	 metabolism,	 with	 higher	 circulating	
triglycerides	(associated	with	a	little	higher	steatosis	and	higher	weight	gain	rate)	and	
lower	 circulating	 total	 cholesterol,	 most	 likely	 resulting	 from	 the	 quantitative	 and	
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qualitative	 differences	 in	 their	 platelets.	 This	 new	 mouse	 is	 also	 inducible	 of	
endogenous	 platelet	 clearance	 using	 anti-	 hiL4Rα	 antibodies.	 Hence	 it	 can	 serve	 as	 a	

















One	 of	 the	 hallmarks	 of	 atherosclerosis	 is	monocyte	 recruitment	 to	 the	 artery	
wall	 that	 involves	 direct	 interaction	 between	monocytes	 and	 endothelial	 cells,	 trans-
endothelial	 migration	 into	 the	 intima	 layer	 of	 the	 vessel	 wall,	 maturation	 into	
macrophages	and	uptake	of	fats,	becoming	foam	cells	(Libby	et	al.,	2011).		
In	 atherosclerosis,	 the	 endothelial	 cells	 express	 L-,	 P-	 and	 E-selectins	 and	
intercellular	 adhesion	molecules	 (ICAMs),	 such	as	 ICAM-1	 (Borregaard,	 2010;	Galkina	
and	Ley,	2007;	Johnson-Tidey	et	al.,	1994).	These	adhesion	molecules	are	recognised	by	
the	P-selectin	glycoprotein	ligand-1	(PSGL-1)	and	L-selectin	on	the	surface	of	leukocytes	
that	mediate	 capture	 from	 flow.	 Sequential	 formation	 and	 dissolution	 of	 these	 bonds	
under	 the	 shear	 forces	 generated	 by	 blood	 flow	 results	 in	 rolling	 adhesion	 along	 the	
luminal	 endothelial	 cells	 (Kansas	 1996;	 McEver	 and	 Cummings,	 1997).	 	 This	 initial	
interaction	results	in	the	activation	of	the	β2	integrins	lymphocyte	function-associated	







adhesion	 of	 monocytes	 to	 activated	 endothelial	 cells	 in	 vitro	 in	 a	 PEV-derived	
arachidonic	acid-	dependent	manner.	When	PMV	get	exposed	to	phospholipase	A2,	they	




al.,	 2000;	 Lukasik	 et	 al.,	 2013).	 The	 arachidonic	 acid	 also	 induces	 synthesis	 of	
cyclooxygenase-2	(COX-2)-derived	prostacyclin	(PGI2)	(Barry	et	al.,	1999;	Barry	et	al.,	
1997).	PEV	were	 found	 to	deliver	proinflammatory	mediators,	 such	as	 the	chemokine	
CXCR4	(Rozmyslowicz	et	al.,	2003),	IL-1	(Boilard	et	al.,	2010)	and	other	receptors	such	
as	PAR-1	to	cancer	cells	and	hematopoietic	stem-progenitor	cells.	As	a	result,	adhesion	
to	 endothelium	 or	 fibrinogen	 was	 enhanced	 (Janowska-Wieczorek	 et	 al.,	 2004;	
Janowska-Wieczorek	 et	 al.,	 2001).	 PEV	 can	 also	 activate	 cells	 through	 exposure	 of	
platelet	activating	factor	(Iwamoto	et	al.,	1996).	
In	 this	 thesis,	 it	 was	 found	 that	 released	 EV	 from	 activated	 platelets	 exhibit	
preferential	 affinity	 for	binding	monocytes	 in	 the	blood.	Leukocytes	acquired	 the	PEV	
receptors	 GPIb	 /	 GPIIb	 mostly	 in	 quanta	 that	 are	 significantly	 smaller	 than	 whole	
platelets	 at	 resting	 conditions.	 This	 suggested	 that	 leukocytes	 bound	 PEV,	 instead	 of	
whole	platelets.	Only	minimal	binding	of	whole	platelets	was	noted	to	the	leukocytes,	a	
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result	 that	 contradicts	 the	 observations	 of	 other	 groups	 (Nagasawa	 et	 al.,	 2013;	 Xiao	
and	Theroux,	2004;	Jensen	et	al.,	2001)	that	found	high	levels	of	whole	platelets	instead	
of	PEV	bound	to	leukocytes.	I	argue	that	their	contradictory	observation	is	most	likely	
an	 artefact	 arising	 from	 the	 fact	 that	 their	 experiments	were	 performed	 under	 static	
conditions.		
Upon	this	heterotypic	aggregate	formation,	I	observed	that	PEV	got	endocytosed	






is	mitochondria.	 From	 this	 project	 I	 found	 that	 released	 PEV	 from	 activated	 platelets	
may	contain	mitochondria	inside	them.	Contradictory	to	Laffont	et	al.	(2016),	I	did	not	
observe	 any	 “naked”	 mitochondria,	 i.e.	 without	 surrounding	 membrane	 being	 shed,	
which	 could	 be	 the	 result	 of	 different	 detection	 technique.	 Internalized	 PEV	
mitochondria	by	neutrophils	can	serve	as	a	substrate	for	phospholipase	A2	(PLA2	IIA)	
that	leads	to	the	formation	of	inflammatory	mediators	e.g.	 lysophospholipids	and	fatty	
acids	 from	 the	mitochondrial	membrane	 (Boudreau	 et	 al.,	 2014).	 Such	mediators	 are	
known	to	activate	leukocytes	and	promote	the	progression	of	atherosclerosis.	
PEV	were	also	found	to	transfer	various	miRNAs	affecting	recipient	cell	function	




cells	 contributes	 to	 foam	 cell	 formation	 (Schrijvers	 et	 al.,	 2007).	 In	 addition,	 PEV-
derived	 miR-24	 was	 found	 to	 target	 the	 mitochondrial	 gene	 mt-Nd2,	 causing	
mitochondrial	 dysfunction	 and	 cell	 apoptosis	 (Michael	 et	 al.,	 2016).	 	 Mitochondrial	
dysfunction	can	directly	promote	atherosclerosis	(Yu	and	Bennet,	2014).	
This	 interaction	between	monocytes	 and	PEV	 increased	monocyte	 recruitment	
to	 mouse	 atherosclerotic	 carotid	 endothelium	 in	 vivo	 in	 my	 experiments.	 Mause	 and	
colleagues	 (2005),	 studied	 indirect	 effect	 of	 PEV	 on	monocyte	 recruitment	 to	 carotid	
endothelium	 by	 ex	 vivo	 infusion	 of	 free	 PEV	 in	 the	 mouse	 circulation,	 followed	 by	
infusion	 of	 free	 monocytes.	 By	 using	 sttroboscopic	 epifluorescence	 illumination	
microscopy,	 they	 observed	 increased	 monocyte	 interactions	 with	 the	 atheromatous	
endothelium	with	 pre-perfusion	 of	 PEV.	 The	 underlying	mechanism	 in	 this	 case	 was	
PEV-mediated	 deposition	 of	 the	 chemokine	 RANTES	 (CCL5)	 to	 the	 inflamed	
endothelium	during	transient	PEV-endothelium	interactions.	
My	 study	however	was	 the	 first	 to	date	 in	our	knowledge	 to	 investigate	direct	
and	 in	 vivo	 PEV-mediated	 monocyte	 recruitment	 in	 atherosclerosis	 using	 intra-vital	
microscopy.	In	my	study	monocytes-PEV	aggregates	were	perfused	instead.	Though	the	
underlying	mechanism	was	not	investigated,	we	speculate	that	the	increased	monocyte	
recruitment	observed	was	due	 to	monocyte	adoption	of	PEV	adhesion	 receptors.	 PEV	
contain	 various	 adhesion	 receptors	 on	 their	 surface	 as	 stated	 previously,	 such	 as	
glycoproteins	Ia/Ib/IIa/IIb/IIIa/VI	(Aatonen	et	al.,	2014;	Garcia	et	al.,	2005),	which	are	
known	to	bind	to	the	subendothelium	(directly	or	indirectly	through	vWF)	(Sakariassen	
et	al.,	 1986;	Savage	et	al.	1998;	 Jackson	et	al.,	 2003).	 Indeed,	PEV	have	been	 found	 to	
promote	adhesion	of	monocytes	 to	activated	endothelial	 cells	 in	vitro	and	 in	vivo,	 in	a	
PEV-mediated		GPIb-dependent	manner	(Chimen	et	al.,	unpublished).		
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GPIbα	 particles	 inside	monocytes	 scattered	 around	 the	 cells’	 nucleus,	 independent	 of	
monocyte	lysosomes.	The	fact	that	PEV-derived	GPIbα	did	not	seem	to	get	targeted	for	
destruction	 in	 lysosomes,	 further	 suggests	 that	 it	may	 be	 recycled	 by	monocytes	 and	
exploited	to	enable	monocyte	adherence	to	the	endothelium.	Interestingly,	PEV-derived	
lipids	 appeared	 closer	 to	 the	 cell’s	 edges,	 away	 form	 the	 cell’s	 core.	 This	 differential	
localisation	 pattern	 suggests	 deconstruction	 of	 PEV	 and	 separation	 of	 the	 different	
components.	Other	EV	studies	have	also	reported	separation	of	EV	proteins	from	the	EV	

















the	 underlying	 mechanism(s)	 remain	 to	 be	 fully	 identified.	 Figure	 10.1.	 shows	 our	
proposed	 mechanism	 of	 PEV-mediated	 monocyte	 recruitment	 to	 atherosclerotic	
endothelium	 that	 remains	 to	 be	 fully	 investigated.	 If	 increased	 PEV-mediated	
recruitment	 translates	 into	 acceleration	 or	 exacerbation	 of	 atherosclerosis,	 then	 by	
blocking	 the	 interaction	 between	monocytes	 and	 PEV,	 we	 could	 potentially	 decrease	
monocyte	recruitment	 in	atherosclerosis,	ultimately	 leading	 to	deceleration	of	disease	
progression.	 The	 effect	 of	 chronically	 preventing	 monocytes	 and	 PEV	 from	 forming	
aggregates,	 with	 subsequent	 prohibition	 of	 PEV	 internalization	 by	 monocytes	 and	
associated	blocking	of	PEV	 transfer	of	 various	molecules	 (e.g.	 adhesion	 receptors	 and	
pro-inflammatory	mediators)	should	be	evaluated.	PEV	were	found	to	bind	leukocytes	






PEV	 preferentially	 bind	monocytes	 in	 the	 blood	 (1).	 Upon	 this	 heterotypic	 aggregate	
formation,	PEV	get	endocytosed	by	 the	monocytes	(2).	PEV	membrane	 lipids	separate	





of	 atherosclerosis	 and	 then	 check	 the	 effect	 on	 atherosclerosis	progression.	However,	
injecting	PEV	 in	a	mouse	 that	 already	contains	endogenous	PEV	might	not	 result	 in	a	
detectable	additional	effect	if	this	system	is	“saturated”	in	terms	of	PEV	numbers,	hence	
there	is	need	for	a	PEV-free	system.	Platelets	and	PEV	can	be	targeted	for	endogenous	
destruction	 by	 injecting	 antibodies	 against	 platelet/PEV	 surface	 proteins	 i.e.	
monoclonal	 antibodies	 (mAbs)	 targeting	mouse	GPIIbIIIa,	 GPIIIa,	 GPIbα,	 GPIb-IX,	GPV	
and	 CD31	 (Nieswandt	 et	 al.,	 2000).	 However,	 these	 antibodies	 also	 target	 exogenous	
PEV	 for	destruction.	Hence	 there	 is	need	 for	differentiation	between	endogenous	 and	
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exogenous	PEV.	During	 this	project,	 this	was	achieved	by	using	 the	hiL-4Rα/GPIbα-Tg	
mouse,	that	expresses	a	chimeric	protein	that	is	composed	of	the	extracellular	domain	
of	 the	 human	 IL4-R	 and	 the	 transmembrane	 and	 cytoplasmic	 sequences	 of	 human	
GPIbα	on	the	platelets	instead	of	the	murine	GPIbα	(Kanaji	et	al.,	2002).	Upon	injection	
with	 anti-human	 IL-4	 receptor	 α	 antibodies,	 the	 endogenous	 circulating	 platelets	 are	
temporarily	 effectively	 cleared	 from	 the	 circulation	 (Boulaftali	 et	 al.,	 2013).	 The	
antibodies	 only	 target	 endogenous	 platelets	 and	 PEV;	 hence	 it	 allows	 the	 adoptive	




the	 mice	 were	 effectively	 cleared	 from	 the	 circulation	 and	 recovered	 fully	 within	 a	
week.	However	when	repetitive	injections	with	the	antibody	were	given	to	the	mice	in	
order	 to	 prolong	 the	 PEV-free	 period,	 the	 mice	 developed	 anaphylaxis,	 hence	 the	
experiments	had	to	be	terminated.	To	our	knowledge,	this	was	the	first	study	to	assess	
effect	of	repetitive	dose	of	anti-hIL4Rα	antibody.	Hence,	we	conclude	that	caution	must	
be	 taken	when	 injecting	 anti-PEV/platelet	 antibodies	 in	 the	mouse	 circulation.	 Other	
strategies,	 such	 as	 using	 antibodies	 where	 the	 anti-	 hiL4Rα	 region	 is	 fused	 to	 non-
immunogenic	 immunoglobulins	 or	 injection	 of	 anti-hiL4Rα	 F(ab)2	 fragments	




enable	 infusion	 of	 platelets	 and/or	 PEV	with	 various	modifications	 and	 defects	 to	 be	
studied	in	vivo	in	different	chronic	diseases	and	conditions.		
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In	 conclusion,	 PEV	 are	 a	 rich	 source	 of	 biomolecules	 that	 may	 potentially	
contribute	 to	 atherosclerosis	 through	 their	 preferential	 interactions	 with	 monocytes.	
PEV	 up-regulate	 monocyte	 recruitment	 in	 atherosclerosis,	 though	 the	 underlying	
mechanism	remains	to	be	identified.	The	new	mouse	that	we	hope	to	generate	in	future	






lysosomes	 of	 foam	 cells	 (Jerome,	 2006),	 due	 to	 defects	 in	 the	 process	 of	 lysosomal	
hydrolysis.	 What	 causes	 this	 lysosomal	 dysfunction	 is	 unknown.	 Cell-internalized	 EV	
usually	end	up	in	lysosomes	for	degradation	(Tian	et	al.,	2013;	Tian	et	al.,	2010).	Hence,	
PEV	 or	 certain	 PEV	 components	 are	 expected	 to	 ultimately	 traffic	 into	 monocyte	
lysosomes	 upon	 internalization.	 Our	 experiments	 have	 found	minimal	 localization	 of	
PEV-derived	 GPIbα	 in	 monocyte	 lysosomes;	 however	 transfer	 of	 the	 rest	 PEV	
components	 into	 lysosomes	 has	 not	 been	 assessed.	 Since	 PEV	 have	 been	 found	 to	
contain	various	lysosomal	molecules	such	as	lysosomal-associated	membrane	protein-3	
(LAMP3)	(Perez-Pujol	et	al.,	2007),	we	speculate	that	 internalized	PEV	might	cause	or	
contribute	 to	 lysosomal	 dysfunction,	 ultimately	 contributing	 to	 atherosclerosis	
progression	by	transformation	into	foam	cells.		
The	differential	distribution	of	PEV-derived	GPIb	and	PEV	membrane	inside	the	
monocytes	 led	 us	 speculate	 that	 PEV	 get	 deconstructed	 and	 that	 the	 various	 PEV	
components	 lead	 a	 different	 post-internalization	 fate.	 It	 remains	 to	 determine	 which	
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components	 if	 any	 are	 transferred	 to	 monocyte	 lysosomes,	 endosomal	 vesicles,	 ER,	
monocyte	membrane	 or	 elsewhere	 and	whether	 they	 are	 recycled	 by	 the	monocytes	
intact	 or	 whether	 broken	 down	 in	 lysosomes.	 Live	 molecule	 tracking	 needs	 to	 be	
employed	to	achieve	this.	
Attempts	 to	 test	whether	 PEV	 can	 transfer	 their	mitochondria	 into	monocytes	
were	 unsuccessful	 because	 the	 MitoTracker	 dyes	 used,	 proved	 to	 be	 unsuitable	 for	
determining	mitochondrial	transfer	in	co-cultures	due	to	passive	diffusion	of	the	dye.	In	
order	to	overcome	these	issues,	two	future	approaches	are	proposed.	Firstly,	the	use	of	
fluorescent	 proteins	 such	 as	 GFP	 could	 be	 employed.	 Transgenic	mice	 that	 express	 a	
fluorescent	 protein	 coupled	 to	 their	 mitochondria	 such	 as	 the	 Gt(ROSA)26Sortm1(CAG-
mCherry/GFP)Ganl	mouse	(McWilliams	et	al.,	2016)	could	be	used	in	theory	to	generate	PEV	
with	 fluorescent	 mitochondria.	 PEV	 could	 be	 then	 incubated	 with	 wild	 type	 mouse	
monocytes	and	their	uptake	could	be	investigated	by	microscopy.		
Another	 approach	 involves	 the	 use	 of	 mitochondrial	 antibodies.	 However,	 the	
use	of	a	mitochondrial	antibody	pre-requires	that	the	cells/vesicles	are	permeabilized.	
Mitochondria	 cannot	 be	 stained	 with	 an	 antibody	 while	 in	 the	 platelet,	 because	
permeabilized	 platelets	may	 not	 be	 able	 to	 get	 stimulated	 and	 shed	 PEV.	Hence,	 PEV	









administration	 into	 the	mouse	 circulation	will	 have	 to	 be	 investigated.	 Intravenously	
injected	HEK293T-derived	EV	 in	 rodents	 localised	 predominantly	 in	 the	 liver,	 spleen,	
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Figure	12.1.	 Formation	of	 aggregates	between	CD16-ve	Monocytes	 in	blood	 and	
exogenously	provided	PEV	over	a	PEV	concentration	gradient		














Figure	 12.3.	 Formation	 of	 aggregates	 between	 Neutrophils	 in	 blood	 and	
exogenously	provided	PEV	over	a	PEV	concentration	gradient		
Representative	 FACS	 dotplots	 demonstrating	 percentage	 of	 Neutrophils	 positive	 for	





Figure	 12.4.	 Formation	 of	 aggregates	 between	 Lymphoocytes	 in	 blood	 and	
exogenously	provided	PEV	over	a	PEV	concentration	gradient		
Representative	 FACS	 dotplots	 demonstrating	 percentage	 of	 Lymphocytes	 positive	 for	





Figure	12.5.	 	GPIbα	expression	on	 leukocyte	 subsets	 in	whole	blood	over	a	PEV	
concentration	gradient		
Representative	FACS	overlay	histograms	demonstrating	GPIbα	expression	on	leukocyte	


















































Representative	 FACS	 dotplots	 demonstrating	 percentage	 of	 GPIbα+ve	 CD16+ve	
monocytes	over	time.		
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Figure	12.13.	Circulating	platelets	on	a	high	fat	diet	
(A)	Platelet	counts	and	(B)	mean	platelet	volume	in	the	ApoE	and	ApoE	KO-
hiL4Rα/GPIbα-Tg	over	the	course	of	14	weeks	on	the	high	fat	diet.	Data	are	shown	as	
Mean	+/-	SEM	of	8-10	mice.	Data	were	analyzed	by	two-way	ANOVA	test.		
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Figure	12.14.	Weight	of	livers	in	response	to	a	high	fat	diet	
The	weight	of	the	livers	of	the	ApoE	and	ApoE	KO-hiL4Rα/GPIbα-Tg	mouse	upon	14	
weeks	on	the	high	fat	diet.	Data	are	shown	as	Mean	+/-	SEM.	Data	were	analyzed	by	t-
test.		
	
	
	
	
